Preventing blood-borne infections among injection drug users by Academy for Educational Development & National Center for HIV, STD, and TB Prevention (U.S.) Division of HIV/AIDS Prevention.
ACADEMY FOR EDUCATIONAL DEV ELOPMENT 
WITH FU NDI NG PROVIDED B Y 
CE NTER S  F OR D ISEASE CONTROL & PREVENTION 
DIVISION OF HIV/AIDS PREVENTION 
DECEMBER 2 000 
PREVENTING BL OO D- B O R N E 
INFECTIONS AMONG 
INJEC TION DRUG USERS 
A Comprehensive 
Approach 
I D U  
H I  V 
P R E V E N T I O N 
This document was prepared by the 
Academy for Educational Development’s 
(AED) Center for Community-Based 
Health Strategies, under contract to the 
Centers for Disease Control and Prevention 
(Contract #200-97-0605, Task 018), to 
provide technical assistance to CDC-funded 
prevention partners to assist in reducing 
infection of HIV, sexually transmitted 
diseases, and blood-borne pathogens among 
injection drug users (IDUs), their sexual 
p a rtners, and their chi l d ren by promoting a 
comprehensive appro a ch to preve n t i o n . 
The Academy for Educational Development, 
founded in 1961, is an independent, non-
profit organization committed to solving 
critical social problems in the U.S. and 
throughout the world through education, 
social marketing, research, training, policy 
analysis, and innovative program design and 
management. Major areas of focus include 
health, education, youth development, and 
the environment. 
ii F O R E WO R D 
Foreword 
Injection drug users (IDUs) play a key role in the continuing epidemics of HIV and other blood-borne infections, 
primarily viral hepatitis. Addressing the role that IDUs play in these epidemics is a challenge because it necessitates 
coordinated action on two of our most complex public health problems —AIDS and drug addiction. 
In the past, prevention planners, public health agencies, community organizations, and providers tended to focus 
on one aspect or another of the problem: improving the quality of substance abuse treatment, encouraging HIV 
prevention education efforts, or helping IDUs who continue to inject to obtain sterile syringes. 
Preventing Blood-borne Infections Among Injection Drug Users: A Comprehensive Approach takes a 
different tack, one that many in the prevention arena recognize and are acting on. No one provider or approach can 
do it all. To help IDUs reduce their sexual and drug-use risks of transmission, communities and organizations 
must embrace a broad approach that incorporates a variety of pragmatic strategies addressing IDUs’ differing life 
circumstances, cultures and languages, behaviors, and readiness to change. This technical assistance document 
describes eight complementary strategies that, together, can make a real difference for HIV prevention for IDUs. 
Services and interventions for IDUs don’t take place in a vacuum, however. They are carried out within a complex, 
often contentious social, political, and legal environment. Potential partners in the effort to reduce infection among 
IDUs may not agree on everything, but they do need to find ways to work together so that a critical mass of IDUs 
can obtain sufficient, high-quality services. A Comprehensive Approach discusses this environment and lays out some 
principles that can help community groups, agencies, and providers begin — or continue— to collaborate. 
The challenges are substantial, but so are the rewards, for reducing infections among IDUs will translate into 
a substantial public health benefit for the whole community. We hope this document will help move the field in 
that direction by providing new ways of thinking about this problem and about IDUs and by encouraging dialogue, 
collaboration, and constructive action. 
Helene Gayle, MD, MPH 
Director 
National Center for HIV, STD, and TB Prevention 
Centers for Disease Control and Prevention 
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Introduction and Overview

Since 1981, 733,374 cases of AIDS have been reported to the Centers for Disease Control and Prevention 
(CDC). In 1999, 46,400 new cases were reported. It is estimated that 650,000 to 900,000 Americans are 
now living with HIV, and that approximately 40,000 new infections occur each year. Approximately 1 to 1.25 
million Americans are chronically infected with hepatitis B virus (HBV), and since 1995, approximately 
185,000 new infections have occurred each yea r. An estimated 2.7 million Americans are chronically infec t e d 
with hepatitis C (HCV). 
These bl o o d - b o rne infections are transmit­
ted primarily through two routes—sharing 
contaminated syringes, needles, and other 
drug injection equipment, and having unpro­
tected sex with infected individuals. Through 
both types of risk behaviors, injection drug 
users (IDUs) are an important factor in the 
continuing evolution of these epidemics. 
Women who become infected with HIV 
through sharing needles or having sex with 
an infected IDU can also transmit the virus 
to their babies before or during birth or 
through breastfeeding. 
To address this critical public health issue, 
program ma n a gers and staff, policy maker s , 
HIV prevention community planners, and 
others in the public health community must 
focus attention on ways in which they can 
m o re effec t ive ly rea ch and influence IDUs 
and must intensify efforts to develop and 
carry out prevention and treatment strategies 
directed to IDUs and their sex partners and 
children. This technical assistance document 
is designed to help staff, planners, and 
policy makers accomplish this goal. It first 
describes the complex problems facing pro-
grams and professionals who work with the 
issue of p reventing blo o d - b o rne infe c t i o n s 
in IDUs and then proposes a comprehensive 
approach to ameliorating these problems. 
We recognize that other drugs besides 
injection drugs are also important in the 
transmission o f bl o o d - b o rne infe c t i o n s . 
However, we focus on injection drugs in 
this document because of the key role they 
play in the intersection of addiction and 
infection and because of the myriad ways in 
which communities and providers can work 
with injection drug users to reduce their risk 
and burden of infection. 
The core of the comprehensive approach is 
a group of pragmatic strategies. These 
strategies recognize that services and inter­
ventions for IDUs must be organized so 
that prevention and behavior change mes­
sages can be delivered and reinforced across 
various settings, populations, life circum­
stances, patterns of drug use, and stages of 
behavior change. Though many kinds of 
services and interventions can be directed 
toward IDUs and the issues of drug use 
and disease, eight strategies are included 
here. They are: 
• substance abuse tre a t m e n t ; 
• community outreach; 
• interventions to increase access to sterile 
syringes; 
• interventions in the criminal justice system; 
• strategies to prevent sexual transmission; 
• counseling and testing, partner counseling 
and referral services, and prevention case 
management; 
• coordinated services for IDUs living with 
HIV/AIDS; and 
• primary drug preve n t i o n . 
These eight strategies are supported by 
four cross-cutting principles: 
• Ensure coordination and collaboration. 
A coordinated and collaborative approach 
to serving IDUs, their sex partners, and 
their children is essential because no one 
provider or institution can or does deliver 
all req u i red services. The comprehensive 
approach outlined in this document 
requires action by many sectors. Providers 
must work toge t h e r, sharing their var i o u s 
exp e rtises and outlooks, recognizing and 
overcoming their philosophical differences, 
building on existing relationships, and 
reaching out to groups with whom they 
m ay not have wor ked before. 
• Ensure coverage, access, and quality. 
Programs and interventions will not be 
e ffe c t ive if they do not rea ch a critical 
mass of people who can be helped, if 
IDUs cannot or will not use them, or if 
they are of poor quality. If they hope to 
truly reach and help IDUs, agencies and 
providers must consider ways to effectively 
deal with these issues as they plan, deliver, 
and monitor programs and services. 
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• Recognize and overcome stigma. Many 
people fear and disapprove of injection 
drug use and consider IDUs to be bad 
or weak people whose addiction results 
from moral failure. IDUs live in an envi­
ronment of high risk and are frequently 
ostracized. Many, though not all, are poor 
and live on the margins of society. If 
IDUs are to be successfully engaged in 
prevention efforts and if public policy is 
to move forward, these negative attitudes 
and misconceptions must be recognized 
and addressed. Addiction is now known 
to be a treatable, chronic brain disease. 
Making this understanding of addiction 
more generally known and accepted is 
key to overcoming stigma. 
• Tailor services and programs. IDUs are 
tremendously diverse. They have different 
l a n g u a ges, cultures, sexual orientations, 
l i fe circumstances, behaviors, and require­
ments for services. In planning and deliv­
ering interventions, programs and 
providers must take into account the fac­
tors that characterize IDUs—who they 
a re, whe re they are, what they do, wha t 
motivates them, and with whom they 
socialize. Tailoring services and pro gr a m s 
and involving IDUs in their planning, 
implementation, and monitoring will 
m a ke them more effec t ive . 
This document describes in more detail 
the need for and characteristics of the 
comprehensive approach. It is divided into 
t h ree ch a p t e r s : 
Chapter 1: Injection Drug Users Play a 
Key Role in the Transmission of HIV 
and Other Blood-borne Infections. Thi s 
chapter provides epidemiologic detail on 
the importance of injection drug use in 
the epidemics of HIV and other blood-
borne infections and describes the drug 
use and sexual behaviors that place IDUs 
at risk of infection. 
Chapter 2: The Legal, Social, and Policy 
Climate Limits Prevention Options for 
IDUs. This chapter describes the context 
within which prevention programs with 
IDUs must work—the existing stigmas and 
biases that characterize ma ny public and 
provider attitudes toward IDUs, even in the 
face of current knowledge about the nature 
of addiction, and the policy, legal, and 
service provision climate that has emerged 
f rom these attitudes. 
Chapter 3: A Comprehensive Approach 
is a More Effective Approach. This chap­
ter briefly describes the component strate­
gies and principles of the comprehensive 
approach. Vignettes about selected programs 
are included throughout this chapter to 
illustrate the ways in which the strategies 
and principles are being applied in diverse 
communities and settings. 
This document also includes two 
Appendixes. Appendix A provides greater 
detail on each of the eight key strategies, 
including findings from programs and 
research and discussions of issues and 
barriers faced by agencies and providers 
in each of these areas. Appendix B is a 
matrix of the many research studies and 
reports cited in Appendix A, organized by 
strategy so that readers have easy access to 
this rich literature. 
More effective and comprehensive prevention 
approaches for IDUs will clearly benefit 
injection drug-using men and women and 
their partners and chi l d ren. The benefit s 
have important implications for society as a 
whole as well, for reducing the transmission 
of HIV and other blood-borne infections in 
this population means reducing transmission 
in the broader population. The results will 
be a smaller impact on and costs for health 
and social services, reduced crime, and a 
m o re pro d u c t ive society. Many indiv i d u a l s , 
o rganizations, and agencies have rec o g n i z e d 
the importance of the issue of HIV and 
other blo o d - b o rne infections among IDUs 
and are acting in innovative ways to address 
them. We hope this document provides the 
vision and impetus for other program staff 
and policy makers to take the steps neces­
s a ry to effec t ive ly address the preve n t i o n 
and care needs of injection drug users. 
More effective and 
comprehensive prevention 
and treatment approaches 
will cle a rly benefit IDUs, 
their part n e rs and children, 
and society as a whole. 
The comprehensive 
approach consists of 
8 pragmatic strategies 
supported by 4 cross-
cutting principles. 
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Of the 46,400 new cases of AIDS 
reported in 1999, almost 14,000 were 
IDU-associated: 
• 7,207, or 52 percent of these IDU-
associated cases, were heterosexual 
male IDUs; 
• 2,931, or 21 percent, were female IDUs; 
• 1,806, or 13 percent, were men who have 
sex with men and were IDUs; 
• 1,790, or 13 percent, were heterosexual 
sex partners of IDUs; and 
• 99, or less than 1 percent, were children 
whose mothers were IDUs or the sex 
p a rtners of IDUs. 
These numbers for IDU-associated AIDS 
cases in 1999 are minimum estimates, as 
11,209 of the 46,400 cases (24 percent) 
were cl a s s i fied as “other/risk not reported 
or identifie d .” Some of these cases were 
I D U - a s s o c i a t e d . 
Data from prevalence surveys and case 
surveillance continue to demonstrate the 
heavy impact of the HIV/AIDS epidemic 
on racial and ethnic minority populations 
and on women, youth, and children. The 
data suggest three inter related issues play a 
role in this—disparities in socioeconomic 
status, the nation’s inability to substantially 
reduce substance abuse, and the intersec -
tion of substance abuse and the epidemics 
of HIV and other STDs. There is no 
question that drug use plays a major role 
in the spread of the epidemic of HIV and 
other blood-borne infections among 
African Americans and Hispanics, both 
through the direct impact of injection drug 
use and indirectly through sex with an 
IDU or through the exchange of sex for 
drugs or money (CDC, 1999a; CDC, 
1999b). In 1998, IDU-associated AIDS 
cases represented almost 40 percent of all 
cases among African Americans and 43 
percent of all cases among Hispanics 
(CDC, 1999b). In 1998, the IDU-associ­
ated infection rate was five times higher 
among Hispanics than among whites and 
more than ten times higher among African 
Americans than among whites (CDC, 1999c). 
Within these continuing high numbers, 
however, there appear to be some promising 
trends. Partly because of prevention efforts 
targeting those at highest risk, the epidemic 
has slowed considerably since its earliest 
days (CDC, 1999b). HIV seroincidence in 
injection drug users has declined over the 
past several years in the largest drug-using 
communities, including New York, northern 
New Jersey, and Los Angeles (Des Jarlais et 
al., 2000; H o l m b e rg, 1996). These decli n e s 
can be attributed to changes in IDUs’ risk 
behaviors, including greater use of sterile 
Since 1981, 733,374 cases of AIDS have been reported to the CDC (CDC, 1999a). At least 430,441 
of these Americans have died. It is estimated that 650,000 to 900,000 Americans are now living with HIV, 
and that approximately 40,000 new infections occur each year (CDC, 1999b). HIV infection and AIDS 
is concentrated in large urban areas, primarily along the East and West Coasts, in the south, and in Puerto 
Rico. In the late 1980s and early 1990s, AIDS incidence increased in all regions of the country, with the 
most dramatic increases in the South. Since then, incidence has declined in all regions except the South, where it 
has remained stable (CDC, 1999b). CDC surveillance data show that injection drug use is directly or indi­
rectly associated with about one-third of all AIDS cases (CDC, 1999a). 
Injection Drug Users Play a Key Role 
in the Transmission of HIV and 
Other Blood-borne Infections 
I D  U 
H I  V 
P R E V E N T I O N 
Injection drug use 
is a major force in 
HIV/AIDS: 
• about 1⁄3 of 
adult AIDS cases 
are related to 
injection drug use 
C H A P  T E R  O N E  
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needles, more disinfection of drug prepa­
ration equipment, shifts from injection to 
snorting, and stopping using drugs. 
The shift from injecting to snorting drugs 
is documented by information on drug use 
t rends gat h e red by the National Institute 
on Drug Abuse’s (NIDA) Community 
Epidemiology Work Group (CEWG, 
1998). CEWG contributors report that 
although heroin use indicators continue to 
increase in 12 cities monitored by CEWG, 
in those cities in which high-purity white 
powder heroin is available, heroin snorting 
has become much more prevalent and is 
spreading to new and younger users. 
However, this may be a short-lived trend, 
as many of these snorters may shift to 
injecting if the purity of available heroin 
drops. It is also known that many drug users 
who begin by snorting heroin eventually 
move to injecting it (Irwin et al., 1996). 
The findings on declining serop reval e n c e 
have been supported by other recent work, 
including an examination of temporal trends 
in HIV seroprevalence in New York from 
1991 to 1996 (Des Jarlais et al., 1998). 
New York has between 170,000 to over 
200,000 IDUs and almost 50,000 cases 
of diagnosed AIDS among IDUs and their 
p a rtners and chi l d ren (Des Jarlais et al., 
1998). New York City accounts for almost 
one-fourth of the IDU AIDS cases in the 
U.S. and almost one-tenth of all AIDS cases 
in the U.S. During the first half of the 
1990s, the city saw a steady decline in HIV 
seroprevalence. The authors attribute the 
decline in number of seropositive IDUs to 
two major factors. The first is the death of 
many HIV-positive IDUs who became 
infected early in the epidemic. Others may 
have become too ill to engage in the activities 
needed to obtain and use drugs. The second 
factor is the adoption of risk reduction 
behaviors as a result of community out-
reach efforts, syringe exchange programs, 
and other contributing factors. 
The transmission of other blo o d - b o rn e 
diseases, primarily hepatitis B and hep a t i t i s 
C, through unsafe sex and sharing needles, 
s y r i n ges, and drug preparation equipment, 
such as filters, water, and cookers, is another 
important concern for public health agencies 
and service providers. App rox i m a t e ly 1 to 
1.25 million Americans are chronically 
infected with hepatitis B virus (HBV), and 
since 1995, approxi m a t e ly 185,000 new 
infections have occured each year. The CDC 
reports that the incidence of HBV infec­
tion increased through the mid-1980s, then 
declined through 1994. A small portion of 
this decline is attributed to the wider use 
of vaccine among healthcare workers. It is 
hypothesized that a significant portion of 
this decline was the result of reduced high-
risk practices following the introduction of 
HIV prevention messages. 
An estimated 2.7 million Americans are 
chronically infected with hepatitis C. Most 
are unaware of their infection because some 
i n d ividuals experience no symptoms for 
20-30 years after infection (Alter et al., 
1999). However, hepatitis C is a major 
cause of cirrhosis and liver cancer, and 
HCV-related end stage liver disease is the 
leading reason for liver transplantation in 
the U.S. The estimated annual incidence of 
hepatitis C remained relatively stable through 
m u ch of the 1980s. Howeve r, based on 
sentinel surveillance for acute viral hepatitis 
conducted in four U.S. counties, the CDC 
estimates that the ave r a ge number of n e w ly 
a c q u i red HCV infections has decli n e d 
from 180,000 in 1984 to 40,000 in 1998 
(Alter and Moyer 1998, CDC unpubl i s h e d 
data). The risk of exp o s u re to HCV fro m 
transfused blood has declined dramatically in 
recent years with improvements in screening 
blood donations. In contrast, ille gal drug 
use currently accounts for about 60 per -
cent of HCV transmission, while sexual 
exposures account for 20 percent (Alter, 
1999). Studies have consistently shown 
that injection drug use is the single most 
important risk factor for hepatitis C virus 
infection (Alter et al., 1999; Alter and 
Moyer, 1998; Garfein et al., 1998; Thomas 
et al., 1995). Among IDUs, hepatitis C 
v i rus infection is ext re m e ly preva l e nt — in 
studies conducted worldwide, from 50 to 
95 percent of IDUs are infected (Garfein et 
al., 1998). This high prevalence persists even 
in populations in which the prevalence of 
HIV is relatively low (van Beek et al., 1998). 
This may be because HCV has a higher 
ave r a ge transmission effic i e n cy than doe s 
HIV (Coutinho, 1998; Crofts et al., 2000). 
In addition, HIV may be transmitted on 
equipment such as swabs, spoons, and rinse 
water that may be commonly shared by 
IDUs even if they do not share syringes1 
( C o u t i n h o, 1998; Crofts et al., 2000). 
Another reason why HCV is of p a rt i c u l a r 
c o n c e rn is that infection appears to be 
a c q u i red rel a t ive ly soon after drug injecting 
is initiated (one study reported that 50 to 
80 percent of new IDUs became infected 
within 6 to 12 months of first injecting 
[ G a r fein et al., 1996]). Howeve r, more 
recent studies are suggesting that IDUs are 
getting infected at a slower rate (Garfein et 
1The term “syringe” is used throughout this document to refer to the needle and all other parts of the syringe. 
IDUs are also 
important in 
the hepatitis C 
epidemic: 
• illegal drug use and 
high-risk sex are the 
factors most strongly 
associated with 
hepatitis C infection 
among those 17-59 
years old 
• 1⁄2 of hepatitis C cases 
in the U.S. are directly 
or indirectly linked to 
illegal drug use 
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al., 2000). There is however a very large 
reservoir of potentially infectious indiv i d u­
als, whi ch provides multiple opportunities 
for transmission to occur (Alter and 
M oye r, 1998). 
Risk Behaviors Associated 
with Infection by HIV and Other 
Blood-borne Infections 
D RU G P R A C T I C E S 
The process of preparing and injecting 
d rugs and the various items of e q u i p m e n t 
used provide many opportunities for con­
tamination with and transmission of HIV 
or other blood-borne viruses (AED, 1997). 
To be injected, drugs such as heroin must 
be dissolved in water. Heat is sometimes 
used to speed the process. This is typically 
done in a spoon or a bottle cap, called a 
“cooker.” The drug and water solution is 
then drawn into a syringe through a filter 
or a “cotton,” which prevents small particles 
in the solution from clogging the narrow 
gau ge needle. 
Before injecting intravenously, an IDU must 
d e t e rmine whether the needle is in a vei n . 
To do so, he or she pulls back the syringe 
plunger to see if blood enters the syringe. 
This is called “ reg i s t e r i n g.” If blood reg i s­
ters, the needle is in a vein. Reg i s t e r i n g 
contaminates the entire syringe with blo o d : 
needle, hub, barrel, and plunger (Koester, 
1998; Normand et al., 1995). 
Once the user registers that the needle is in 
a suitable vein, the drug is injected directly. 
To ensure that all the drug is injected, the 
IDU may pull the plunger back several 
times, drawing blood into the syringe eac h 
time, and then re-injecting it. This technique, 
called “booting ,” increases the presence of 
residual blood in the syringe (Koester, 1998; 
Normand et al., 1995). 
HIV survives in the residual blood in used 
s y r i n ges, even if it has been rinsed with 
water. A recent study showed that HIV in 
used syringes remained viable and infectious 
at room temperature for more than 4 weeks 
(Abdala, 1999). 
After injecting the drug, the IDU rinses the 
syringe with water to prevent any remaining 
blood from cl o t t i n g. This contaminates the 
rinse water. Drug injection may take place 
in locations with little access to water, so 
rinse water may be reused and therefore 
become increasingly contaminated. In many 
cases, this water is used for dissolving drugs 
to be injected as well as for rinsing. In the 
absence of a sufficient supply of new sterile 
s y r i n ges, IDUs must reuse their syringe s . 
D i s i n fecting used syringes with ble a ch is 
recommended as a risk reduction measure, 
but even if done correctly, it is not as safe 
as using a new, sterile syringe. In reality, the 
multiple steps invol ved in the ble a ch i n g 
procedure and the difficulty of a d e q u a t e ly 
cleaning the hard-to-reach internal spaces 
of a syringe mean that many IDUs are 
u n a ble to pro p e rly disinfect their used 
s y r i n ges. (Gershon, 1998; Glegh o rn et al., 
1994; McCoy et al., 1994). 
The patterns of cocaine and heroin use 
present particular viral transmission risks 
(Koester et al., 1996). The desire and need 
for cocaine mean that users of this drug 
inject fre q u e n t ly, multiplying the opport u­
nities for transmission of blo o d - b o rn e 
v i ruses. Heroin injectors make fewer injec­
tions per day, but their risks are multiplied 
because of their overwhelming physical and 
emotional need to avoid the withdrawal 
syndrome. Their objective is to inject as 
soon as possible after obtaining the drug, 
whi ch means they may use wha t ever syringe 
or equipment is closest to hand, whether 
or not that presents viral infection trans-
mission risks (Koester et al., 1996). 
Transmission of HIV and other blood-
borne viruses can occur through either 
d i rect or indirect sharing of c o n t a m i n a t e d 
equipment. Direct sharing involves injecting 
drugs with a syringe already used by another 
injector. Indirect sharing occurs when injec­
tors prepare their own drugs but use injection 
paraphernalia, such as water, cookers, cottons, 
and spoons, that others have used, or when 
injectors jointly prepare and share drugs 
( Koester and Hoffer, 1994). This occurs, 
for example, when several IDUs pool their 
money to purchase drugs toge t h e r. Th e 
e n t i re amount of d rug is dissolved during 
a shared preparation process. The preparer 
draws all the drug and water solution into 
a syringe through the cotton. Using the 
calibrations on the syringe, the preparer 
then transfers individual doses of the drug 
into the syringes of the other users. After 
injecting the drug, users rinse their syringes 
with water. Though syringes themselves are 
not used by more than one person in indirect 
s h a r i n g, they still become contaminated 
with blood because of contact with con­
taminated ancillary paraphernalia. 
Other practices associated with indirect 
sharing can also transmit infection, including 
( Koester and Hoffer, 1994): 
• S q u i rting the drug solution from a prev i­
ously blood-contaminated syringe into the 
cooker or spoon and then drawing it into 
another syringe. 
• Using the plunger from a previously 
blood-contaminated syringe to mix the 
d rug with wat e r. 
• Returning the drug solution from a 
p rev i o u s ly blood-contaminated syringe to 
the shared cooker or directly to another 
s y r i n ge. This occurs when the user draw s 
up more than his or her allotted share of 
the drug. 
• “ B e a t i n g,” or pre s s i n g, a used cotton 
(or several cottons) to ret r i eve any dru g 
remaining in the cotton from a previous 
injecting session. 
• “Kicking out a taste” by putting a part of 
the drug/water solution from a previously 
blood-contaminated syringe back into the 
cooker or into another IDU’s syringe so 
that another or several other IDUs can 
get some of the drug. 
• Drawing up the water for dissolving the 
drug by using another injector’s used and 
i n a d e q u a t e ly disinfected syringe . 
Another attribute of drug use that con-
tributes to the risk of viral transmission is 
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the use of more than one drug. For example, 
IDUs often use alcohol, cigarettes, and 
marijuana in addition to the drug they inject 
( A E D, 1997). “ S p e e d b a l l ,” a combination 
o f he roin and cocaine is favo red by some 
injectors, and has been highly correlated 
with HIV infection (Battjes et al., 1994). 
Common reasons for this polydrug use 
include the need to counteract the effects 
of one drug with another, the desire to 
experience the effects of more than one 
drug, and the need to substitute when the 
drug of choice is too difficult or costly to 
obtain. Polydrug use can increase the risk 
o f HIV and other blo o d - b o rne disease 
transmission in several ways. For exa m p l e , 
the situations and people with whom an 
IDU uses drugs may vary depending on 
the drug. These differing contexts may 
expose the individual to a variety of high-
risk situations. Furt h e rm o re, intox i c a t i o n 
with one drug may lessen an indiv i d u a l ’s 
ability or desire to reduce risks associated 
with the use of another drug. 
S E X U A L B E H AV I O R S 
High-risk drug use behaviors and high-risk 
sexual behaviors are often linked, further 
increasing the risk of HIV and other blood-
borne diseases being transmitted from one 
person to another (Chu et al., 1998). These 
risky sexual behaviors include unprot e c t e d 
anal, vaginal, or oral sex; multiple partners; 
and lack of treatment of sexually transmitted 
diseases (STDs), especially those with 
ulcerative lesions. These high-risk drug and 
sexual behaviors intersect in a variety of ways 
to increase risk. For example, sex partners 
o f HIV-infected IDUs may begin injecting 
drugs themselves (Ouellet et al., 1998). 
D rug injectors who also fre q u e n t ly smoke 
crack cocaine tend to spend time in crack 
houses or other places with other drug-
injecting cocaine users (Friedman et al., 
1995). Crack use is associated with high-
risk sexual activities, possibly because of the 
disinhibiting effect of the drug or because 
of the addicted person’s need to obtain the 
d ru g, whi ch leads to excha n ges of s ex for 
crack or for money to buy crack (Edlin et al., 
1994). Many IDUs, both men and women, 
trade sex for drugs or money to buy drugs 
or engage in commercial sex or hustling to 
generate income for their habits and this 
i n c reases their transmission risks (AED, 
1997; Kail et al., 1995; Rietmeijer et al., 
1998; Schilling et al., 1992). 
The Context of High-risk Drug and 
Sexual Practices 
The degree of risk associated with injecting 
drugs is determined in part by the physical 
setting in which it takes place and the people 
with whom a user injects. An understanding 
of the contexts in which drug use occurs is 
particularly important because they help to 
explain the ways drug use takes place and 
they help define individual users and the 
other people with whom they spend time, 
buy drugs, inject drugs, and have sex. This 
knowledge, in turn, illuminates the ways in 
which infection is transmitted from on e 
individual to another, as well as from small 
high-seroprevalence groups to the larger 
community (Des Jarlais et al., 1993; 
Friedman et al., 1995; Friedman et al., 1997; 
Needle et al., 1995). Armed with these 
insights, policy makers and service providers 
can develop prevention interventions that 
are tailored to the characteristics and needs 
o f sp e c i fic groups of injection drug users 
(AED, 1997; Bourgois, 1998; IOM, 1995). 
The following sections discuss several key 
social contexts for drug use. 
D  RU G  U S E S E T T I N  G S  
Drug use takes place in a variety of locations 
that allow people to inject by themselves 
or in small groups. These locations include 
apartments or homes, bars, massage parlors, 
social clubs, residential hotels, abandoned 
buildings, public bathrooms, and “shooting 
gal l e r i e s ” (A E D, 1997; Des Jarlais et al., 
1993; IOM, 1995; Latkin et al., 1996a). 
In some settings, users rent out needles and 
other equipment for a small fee or a portion 
of the user’s drug, which is paid to the dealer 
operating the gallery. The needles are then 
returned and used by the next injector. In 
other settings, sharing drugs or equipment 
occurs without payment of drugs or money. 
Key components of this context are the 
number of drug users in the setting and the 
riskiness of the behaviors. When a setting 
brings together multiple individuals who 
prepare and inject drugs in risky ways (with 
few syringes and widespread direct and 
i n d i rect sharing) or who have high-risk sex, 
transmission of HIV and other blood-born 
v i ruses can spread rapidly and effic i e n t ly 
from one user to others (Latkin et al., 1994). 
S O C  I A L  N E T  W O R K S  
These are groups of users linked by various 
relationships and bonds. Networks differ 
based on the number of members and how 
stable the relationships are, the types of 
relationships among members, the degree 
to whi ch the group is open to incl u d i n g 
new members, the kind of social activity 
that occurs within it, and the types of drug 
used and how they are used (Friedman et al., 
1997; Needle et al., 1995). In addition, net-
works may be defined by race or ethnicity, 
gender, sexual orientation, social class, and 
the presence of kinship among members. 
The nature of the relationships among 
members and the interpersonal and group 
dynamics of the network dire c t ly affects a 
member’s drug-use and sexual behaviors and 
therefore are highly influential in determining 
that person’s risk of infection (Friedman 
High-risk drug use 
behaviors and high-risk 
sexual behaviors 
are often linked, 
further increasing 
risk of transmission. 
7I D U S A N D T R A N S M I S S I O N O F H I V 
et al., 1997; Latkin et al., 1996b; Needle et 
al., 1995). For example, some networks are 
small, consisting of a close group of drug-
using or sex partners. These individuals may 
have increased risk because they may be less 
likely to use condoms or sterile syringes, 
which may conflict with the intimacy and 
trust developed in the relationships. Ot h e r 
types of networks are characterized by a 
l a rge r, more open membership, and the 
level of risky behavior engaged in by mem­
bers is influenced by the settings in which 
drug use takes place and the closeness of the 
ties that bind members (Trotter, 1995). A 
member who has close links with other 
drug injectors in the network is more likely 
to engage in high-risk practices, such as 
sharing syringes or injecting in shooting 
galleries, than are drug injectors who are 
only peripherally connected to other network 
members (Friedman et al., 1997). Further-
more, those members with the most material 
res o u rces are at the top of the netwo r k ’s 
h i e r a rchy. When sharing drugs, they will 
shoot first, which may make it more likely 
that they will use a sterile syringe and 
equipment. In contrast, the newest members 
of the network or those with the fewest 
material and other res o u rces command the 
least respect and exist on the margins of 
the network. They often must engage in 
the riskiest drug and equipment sharing 
practices, such as collecting used cottons 
to extract any drug remaining in them 
( B o u rgois, 1998; Bourgois, unpublished). 
Social networks are a critically important 
c o n t ext for understanding drug use and its 
intersection with the transmission of HIV 
and other blood-borne pathogens because of 
their role in maintaining an epidemic within 
the group and in providing a starting po i n t 
for rapid transmission beyond the group 
(Friedman et al., 1997). They are also a 
c r i t i c a l ly important context when consider­
ing prevention efforts because these same 
dynamics also may be used to introduce and 
reinforce norms that support risk reduction 
and to develop effec t ive channels of c o m­
munication with members (Latkin, 1995). 
M E  M B  E R S H I P  I N  G R O  U  P  S 
W I  T H  E S P E C I  A L  LY 
H I G  H  R I S K S  
Certain groups of injection drug users 
warrant particular attention because their 
occupations or behaviors lead to drug- and 
sexually-related transmission risks that 
appear to be higher than they are for other 
populations. They can experience consid­
erable societal stigma to begin with because 
of these occupations and behaviors, and 
their drug use compounds this problem and 
contributes to their higher transmission risk. 
For example, many IDUs have c oex i s t i n g 
problems, such as mental illness, phy s i c a l 
illness, homelessness, and incarc e r a t i o n . 
As many as 30 percent of homeless adults 
may be substance abusers. (NIDA, 1990; 
Schutt et al., 1992). Overall, homeless 
adults have higher HIV rates than do the 
general population, particularly in high 
prevalence areas. A recent survey of home-
less adults using a storefront medical clinic 
found that more than two - t h i rds were at 
risk of HIV infection from various sources, 
including unprotected sex with multiple 
partners, injection drug use, sex with an 
IDU partner, or exchanges of sex for money 
or drugs (St. Lawrence and Brasfield, 1995). 
Some homeless also have mental illness 
and violent and unstable living situations, 
and because of this they find it dif ficult to 
form the safe, intimate relationships that 
could help them reduce their risk. Limited 
availability of or access to mental health 
services increases this problem. 
Men and women in prisons and jails also 
suffer disproportionately high rates of 
drug abuse as well as of HIV infection. 
Recent data from the National Center on 
Addiction and Substance Abuse (CASA) 
show a direct or indirect connection between 
substance abuse and the incarceration of 
nearly 80 percent of those in federal, state, 
and local prisons and jails (Belenko, 1998); 
60-80 percent of inmates have serious 
substance abuse problems (Leshner, 1999). 
Another recent report, published by the 
National Institute of Justice, CDC, and 
the Bureau of Justice Statistics shows that 
in 1996, 24,881 inmates in state and fed­
eral prisons were kn own to be infe c t e d 
with HIV (Hammett et al., 1999). HIV-
positive inmates comprised 2.4 percent of 
the state prison population in 1996 and 
1.0 perce n t of the federal prison popula­
tion. Between 1991 and 1996, the number 
of HIV-positive inmates grew at about the 
same rate as the overall prison population 
(both increased by about 42 percent). 
Female sex workers and female IDUs who 
have sex with other women are particularly 
vulnerable to infection because many are 
poor and homeless and addicted to alcohol 
as well as drugs. Female IDUs who trade 
sex for money or drugs are more likely to 
share needles than are female injectors 
who do not engage in sex trading, and are 
less likely to use new needles or to clean 
old ones (Kail et al., 1995). Female drug-
injecting partners of male IDUs may be 
more likely to inject after the man and 
therefore be exposed to greater risk. 
Regardless of the origin of their risks, these 
wom e n often exist in a subordinate and 
physically dependent relationship to the 
men with whom they interact, and these 
power imbalances make it dif ficult for 
them to change their behaviors in ways 
that might reduce risk (AED, 1997; 
Bourgois, unpublished). 
Key contexts of 
high-risk behaviors: 
• drug use settings 
• social networks 
• membership in groups 
with high risk 
• geography 
• income and social factors 
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Young injection drug users are another 
group who require increased attention 
because the contexts in which they inject 
frequently increase their risk of transmission. 
Young IDUs may be runaways or peripheral 
members of drug-using social networks. 
If they lack money to buy drugs, they may 
be forced to trade sex for drugs or money. 
Men who have sex with men (MSM) and 
inject drugs also face increased risks of 
transmission. For example, recent evidence 
from CEWG shows that methamphetamine 
use, once largely restricted to the West, is 
now spreading into other parts of the 
country and gaining in popularity among 
MSM. Methamphetamines can be admin­
istered in several ways but the injection 
route appears to be increasingly common. 
This method of administration incre a s e s 
a user’s chances for engaging in high-risk 
sexual and non-sexual behaviors, thus 
increasing the risk of acquiring or trans­
mitting infection (NIDA, 2000). 
G E O G R A P H I C 
D I  F F  E R  E N C E S 
Location often influences the types of 
drugs available, and this in turn dictates the 
method of administration (e.g., injected, 
smoked) and the level of risk experienced 
by users (Sullivan et al., 1998). For example, 
the two major sources of heroin in the 
United States today are South America and 
Mexico. South American heroin is distributed 
primarily to cities on the East Coast and 
is a high purity, white powder form of the 
drug. Because of this high purity (60-70 
percent), an increasing number of users are 
resorting to snorting the drug rather than 
injecting it (CEWG, 1998). In contrast, 
the major forms of heroin available on the 
West Coast, Texas, and some Midwestern 
cities, such as Chicago and St. Louis, are 
Mexican black tar and brown powdered 
heroin. Mexican black tar heroin also has 
recently reappeared in Atlanta (CEWG, 
1998). Black tar heroin is less pure than 
the white powder form (39 percent) and 
has a consistency somewhere between tar 
and wax. Its difficult texture makes it hard 
to snort and users are therefore more likely 
to inject it, which exposes them to the 
potential transmission risks associated with 
injection practices. The combination of the 
texture and the drug’s cost (in San Francisco, 
it is commonly sold in $20 units about 
the size of pencil eraser) also increases the 
chances that IDUs who are short of money 
will share the drug. This involves dissolving 
the drug and dividing it into portions 
equivalent to the money each person 
contributed to the purchase of the drug. 
This procedure increases the risk of infection 
through shared needles and ancillary para­
phernalia (Bourgois, unpublished; Koester 
and Hoffer, 1994). 
I N  C O  M E  A N D  
S O  C I  A L  F A C T O R S 
Many IDUs have jobs and health insurance 
(Eisenhandler and Drucker, 1993; SAMH­
SA, 1999). Others are less involved in the 
m a i n s t ream economy and must res o rt to a 
variety of tactics to support their habits, 
including panhandling, scavenging, day labor, 
sex work, and petty theft. As noted already, 
the relative social status of IDUs has a direct 
i n fluence on the degree of risky behavi o r 
necessary for survival. Those who begin with 
higher social status and more secure income, 
housing, and support networks may be more 
a ble to control their risks of t r a n s m i s s i o n . 
Poorer IDUs, those with concomitant health 
or mental problems, and those with unstable 
living and social circumstances may have 
difficulty obtaining sterile syringes or be 
more susceptible to legal penalties for syringe 
possession, and thus may be more likely 
to pursue risky behaviors, such as sharing 
injection equipment (Bluthenthal et al., 
1999a; Bluthenthal et al., 1999b; Case et 
al., 1998). For these IDUs, any cha n ge in 
financial or social circumstances can have a 
significant impact on their risk profile. A 
case in point is the 1997 federal decision to 
cease Supplemental Security Income (SSI) 
benefit payments to individuals whose drug 
or alcohol addiction is considered a con­
tributing factor to their disability. Data 
from a 1995 study of IDUs living in six 
San Francisco area communities showed 
that benefits for SSI recipients contributed 
to the overall stability of their lives and to 
a lower risk of acquiring or transmitting 
infection because they were less likely to be 
homeless, were less reliant on illegal income, 
used drugs less often, and shared syringes 
less often than did IDUs who did not 
receive benefits (Lorvick et al., 1997). A 
follow-up study showed that those who 
lost SSI benefits as a result of the ruling 
were more likely to participate in ille gal 
activities, more likely to share syringes, 
and injected drugs more often than did 
those who retained benefits (Bluthenthal 
et al., 1999b). 
Conclusion 
Tod ay, a major force behind the ep i d e m i c 
o f HIV and other blo o d - b o rne illnesses is 
i n fections among IDUs, their sex partn e r s , 
and their ch i l d ren. IDUs engage in a 
number of drug-use and sexual practices 
that signifi c a n t ly increase their risk of c o n­
tracting HIV and hepatitis and of p a s s i n g 
them on to others. The next chapter of this 
document fu rther describes the pro bl e m 
facing programs and professionals as they 
a d d ress the complex prevention needs of 
IDUs: the env i ronment of stigma and 
b i as — the “ j u n k i ep h o b i a” — in whi ch 
m a ny IDUs live and the policy, legal, and 
service provision climate that has emerged 
from these attitudes. 
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Negative Attitudes and Stigma 
Toward IDUs Persist Despite a 
New Understanding of Addiction 
Negative attitudes and biases about addiction 
and drug users are pervasive and derive 
from experience and deeply felt moral and 
philosophical beliefs. These attitudes, 
w i d e s p read among the general public and 
many policy makers, are prevalent even 
among service providers and health profes­
sionals (Cole and Slocumb, 1993; 
McGrory et al., 1990; Wal l a ck, 1991; 
Yedidia et al., 1993; Yedidia et al., 1996). 
IDUs are stigmatized, seen as less valuable 
citizens than others in the population. 
Many IDUs are marginalized, without full 
participation in the economic, social, or 
cultural life of their community. For those 
IDUs who are infected with HIV or other 
blood-borne illnesses or who have associated 
mental illness or other conditions, the 
stigmatization and marginalization are 
further increased (Des Jarlais et al., 1993). 
In the eyes of many, IDUs, at best, ar e 
seen as victims of their addiction. At worst, 
they are viewed as criminals or as weak and 
bad people whose chaotic lives and inability 
to overcome addiction result from moral 
failure rather than from a legitimate medical 
condition or a lack of access to adequate, 
comprehensive treatment (Des Jarlais et al., 
1993; Leshner, 1997). They are regarded 
somehow as alien figures, as one of “them,” 
not one of “us.” Their addiction or result­
ing infection with HIV or hepatitis is “their 
fault.” IDUs are incor rectly perceived to 
be unwilling to change their behaviors or 
unable to respond to education, outreach, 
or treatment interventions (Jones and 
Anderson, 1999). These negative and 
dehumanizing attitudes toward IDUs even 
extend to the providers and programs that 
work with them. These professionals and 
organizations are also seen as having lower 
The AIDS epidemic and the public health importance of other blood-borne illnesses, primarily hepatitis B and 
hepatitis C, have introduced a new dimension to the issue of injection drug use and increased the urgency of 
finding effec t ive and appro p r i ate interventions for IDUs. Numerous studies have examined issues related to the 
nature of addiction, the reasons why individuals begin and continue to use addictive drugs, and the factors that 
help them change their behaviors so as to stop using drugs. Despite this growing body of s c i e n t i fic knowledge, 
many myths, negative stereotypes, and biases persist about drug users and their lives, the health and safety risks 
they take, and their ability to overcome addiction. These stereotypes and beliefs profoundly influence the service, 
policy, and legal environment affecting IDUs and the scope and quality of health and social services provided 
to them (Friedman, 1998). They also constrain efforts to reduce the spread of blood-borne pathogens among 
IDUs and ach i eve the nat i o n’s ultimate goal, whi ch is to substantially reduce or even eliminate drug use. To 
design and deliver effective interventions for IDUs, prevention providers, program staff, and policy makers must 
better understand the lives and issues faced by IDUs, address the biases they and society have toward this pop­
ulation, and work to ameliorate the stigma caused by such biases. They must also explore ways to surmount the 
profound differences in philosophy and approach that exist among various types of providers and that all too 
often hinder collaboration and limit effective solutions. 
The Legal, Social, and Policy 
Climate Limits Prevention 
Options for IDUs 
I D  U 
H I  V 
P R E V E N T I O N 
C H A P T E R  T  W O 
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social value than those working with 
mainstream populations and are often 
stigmatized for serving IDUs (AED, 
1999; Friedman, 1998). 
“Junkiephobia” is a term that has been used 
to encapsulate this complex of stereotypes, 
stigma, and negative attitudes toward IDUs 
(Jones and Anderson, 1999). Like “racism” 
and “homophobia,” “ j u n k i ep h o b i a ”c overs 
a number of social and individual factors 
underlying these attitudes. For example, a 
lack of knowledge about addiction and 
ignorance of the lives and cultures of IDUs 
is a factor leading to stereotyping and 
stigmatization. Fear of the addictive capacity 
of drugs and of addicts themselves is 
another factor. Reluctance to support 
policies that might appear to promote or 
condone drug use, such as syringe exchange, 
is a third powerful factor. Lack of specific 
provider training and education also hamper 
those in service agencies from providing 
empathetic, responsive, and appropriate 
services and education to IDUs. 
These attitudes persist among the public, 
policy makers, and service providers 
despite advances in the neurosciences and 
the behavioral sciences that have transformed 
the understanding of drug abuse and 
addiction. It is now known that the roots 
of addiction lie in a series of complex 
biochemical changes that occur in the 
brain over time, causing alterations in 
brain function. The result is a chro n i c 
and relapsing, but treatable, disease with 
intertwined biological, behavioral, and 
social components. 
Studies over the last 20 years have revealed 
that all drugs have the same effects on a 
single pathway deep inside the brain, the 
mesolimbic dopamine system (Childress 
et al., 1999; Koo b, 1996; Koo b, 1992; 
N I DA/Hospital Practice, 1997; Vol kow 
et al., 1993). When activated in response to 
natural rewards, such as food, water, sex, and 
nurturing, this pathway provides pleasurable 
feelings. These pleasurable feelings cause the 
individual to repeat the behavior to reactivate 
the reward pathway. All addictive drugs, 
including heroin, cocaine, marijuana, alcohol, 
and nicotine, also activate this reward system 
by causing an extra release of dopamine 
into the pathway. Initially, an individual 
uses a drug because of the pleasurable 
effects on mood, perception, and psycho-
logical state. Prolonged drug use, however, 
causes fundamental and long-lasting 
changes in the brain. At some point, these 
changes throw a metaphorical “switch” in 
the brain. Once the swi t ch is thrown , the 
individual moves from a state of voluntary 
drug use to a state of addiction in which 
drug seeking and use are uncontrol l a bl e 
and compulsive. In the addicted state, the 
pleasurable effects of the drug may be 
minimized or absent altogether. 
The compulsion to use some drugs, like 
heroin, is partly driven by the need to ward 
o ff the withdrawal syndrome, which occurs 
when use is stopped or reduced. This syn­
drome is characterized by nausea and 
vomiting, muscle cramps, sweating, agitation, 
and depression. Because these symptoms 
can be managed with medications and 
because not all addictive drugs result in 
this syndrome (cocaine, for example, does 
not), addiction is no longer defined so much 
by the element of physical dependence, 
but is increasingly described as compulsive 
drug seeking and use that come to dominate 
a drug addict’s life, even in the face of terrible 
physical and social consequences (Leshner, 
1997; NIH, 1997). 
Another concept that is key to the current 
understanding of drug addiction is that it 
is not an acute illness, but rather a chronic, 
relapsing condition that is treatable. Like 
other chronic illnesses, such as diabetes, 
asthma, or hypertension, appropriate treat­
ment must be focused more on effective 
management over the long term rather 
than on a permanent cure (Leshner, 1997). 
Treatment compliance and relapse rates in 
drug addiction are about the same as in 
these other chronic medical conditions 
(O’Brien and McLellan, 1996). 
Negative Attitudes Toward 
IDUs Affect Public Policy and 
Treatment Approaches 
Public and provider attitudes and perce p­
tions about drug use and users color 
attitudes toward appropriate responses 
to the problem of injection drug use. 
The substantial investment in prisons and 
criminal justice institutions, the relatively 
limited public support for substance abuse 
treatment, and laws and regulations limiting 
sterile syringe sales and syringe exchange 
programs appear to reflect a national incli­
nation to respond to drug users in a punitive 
and dehumanizing fashion. For example, 
active drug users are disqualified from the 
federal Supplemental Security Income 
program if their addiction is considered to 
be a contributing factor to their disability 
(Bluthenthal et al., 1999; Lorvick et al., 
1999), and welfare recipients are tested for 
Addiction is no longer 
defined so much by 
the element of physical 
dependence, but is 
increasingly described as 
compulsive drug seeking 
and use that come to 
dominate a drug addict’s 
life, even in the face of 
terrible physical and 
social consequences. 
Overall, treatment for 
addiction is as successful 
as treatment of other 
chronic conditions, 
such as asthma, diabetes, 
and hypertension. 
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drug use and may lose their benefits if the 
test is positive (though in some areas they 
may retain food and rent vouchers) 
(Friedman, 1998). Pregnant drug-using 
women still face barriers in obtaining treat­
ment and, should they be incarcerated, in 
obtaining prenatal care and retaining custody 
of their child after delivery (Breitbart et 
al., 1994; GAO, 1999). 
The impact of these public and personal 
attitudes on current laws, regulations, and 
policies can be seen in several ways: 
◆ Emphasis on criminal penalties rather 
than treatment. With several notable 
exceptions (alcohol and tobacco use by 
adults), the use of addictive drugs is illegal 
and users are subject to arrest and incar­
ceration. Punitive laws for drug possession 
and dealing channel users and IDUs into 
prison rather than substance abuse treatment. 
This, combined with the criminal activities 
that many IDUs pursue to maintain their 
addictions, means that they are frequently 
a rre s t e d and imprisoned. This tends to 
reinforce the public’s perception of them as 
“bad” people and of drug use as a crime 
rather than a medical and behavioral problem. 
◆ Funding priorities. The federal govern­
ment currently spends nearly twice as much 
on programs to stop drugs from entering 
the U.S. as on programs to reduce the 
demand for drugs. In 1998, two-thirds of 
the $16.18 billion federal drug control 
budget was allocated for “supply reduction” 
activities, such as border control efforts, and 
one-third for “demand red u c t i o n ”a c t iv i t i e s , 
such as prevention and treatment programs 
(ONDCP, 1999 in Amaro, 1999). The 
drug control budget for fiscal year 2000 is 
expected to increase by over $1.6 billion, 
but the proportion dedicated to demand 
reduction will be only slightly augmented 
( A m a ro, 1999). 
◆ Limited substance abuse treatment 
services. It is clear that the people who 
need substance abuse treatment far out-
number the people who are able to receive 
it. For example, data from the Substance 
Abuse and Mental Health Services 
Administration’s (SAMHSA) National 
Household Survey on Drug Abuse 
(NHSDA) show that in 1996, more than 
5.3 million people with severe substance 
abuse problems needed treatment services. 
However, only 37 percent received such 
treatment (Epstein and Gfroerer, 1998). 
Of the estimated 600,000 opiate-dependent 
individuals in the U.S., only about 
115,000 (19.2 percent) are in methadone 
maintenance treatment (NIH, 1997). Par t 
of this results from a lack of funding. 
Other contributing issues include a shortage 
of physicians and other health care profes­
sionals who are trained and able to provide 
treatment; complex federal regulations that 
limit the flexibility and responsiveness of 
treatment programs; limitations in health 
insurance coverage for treatment; and an 
existing patchwork of federal, state, and 
local regulations and funding mecha nisms 
that limit prov i d e r s ’ ability to provide the 
continuum of services necessary to meet the 
complex substance abuse treatment, medical, 
and social service needs of injection drug 
users (AED, 1999; NIH, 1997). 
Community resistance to substance abuse 
treatment facilities and programs— the 
“not-in-my-backyard” (NIMBY) factor — 
also plays an important role in limiting the 
availability of t reatment and other serv i c e s 
for IDUs. Common objections to these 
facilities are that they contribute to an 
increase in crime in the area, attract unde­
sirable groups of people, and import the 
drug culture. As a result, treatment facilities 
are often located in industrial or run-down 
parts of town to avoid the presence of 
residential neighbors and diminish the 
possibility of community res i s t a n c e . 
Treatment program counselors also may 
routinely patrol the area around their facility 
to ensure that clients do not loiter and 
cause problems with neighbors. 
During 1999, a number of prominent voices 
spoke out on these issues and in favor of 
major increases in the funding and attention 
d evoted to substance abuse tre a t m e n t : 
• General Barry McCaffrey, Director of the 
Office of National Drug Control Policy 
(ONDCP), proposed a new strate gy of 
integrating drug testing and substance 
abuse treatment into almost every phase 
of the criminal justice process, from 
arrest to the return to community after 
prison. Gen. McCaffrey outlined this 
strategy at a “National Assembly on 
Drugs, Alcohol Abuse and the Criminal 
Offender,” which was sponsored by the 
O N D C P, the Dep a rtment of Justice, and 
the Department of Health and Human 
Services to bring together 900 law enforce­
ment, prison, and public health specialists 
from around the country to discuss ways 
to break the seemingly unbreakable link 
between substance abuse and crime. The 
assembly advocated better collaboration 
between substance abuse, public health, and 
Legal and public 
policy results 
of attitudes 
and stigma: 
• emphasis on 
criminal punishment 
over treatment 
• differences in 
funding priorities 
• limited drug 
treatment services 
• restrictive syringe 
prescription and 
paraphernalia laws 
and regulations 
• a fragmented and 
polarized atmosphere 
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criminal justice, much greater reliance on 
substance abuse treatment to address the 
cause of most involvement with criminal 
justice, and better programs to ease inmates’ 
return to their home communities after 
prison (Wren, 1999). 
• Dr. Alan Leshner, Director of the National 
Institute on Drug Abuse (NIDA), made 
the case that as a society we should no 
longer focus on unanswerable questions 
about the morality of treating versus 
punishing those addicted to drugs, but 
instead should focus on the practical 
benefits to individuals and society as a 
whole of treating drug addiction. “If we 
are ever going to significantly reduce the 
tremendous price that drug addiction 
exacts from every aspect of our society, 
drug treatment for all who need it must be 
a core element of our society’s strategies” 
(Leshner, 1999). 
• Dr. Hortensia Amaro of Boston University 
School of Medicine argued that limited 
funding for substance abuse treatment is 
an exp e n s ive long-term policy. She noted 
that the federal govern m e n t ’s policy of 
spending nearly twice as much on reducing 
the supply of drugs as on reducing the 
demand for them through prevention and 
treatment programs is “ p e rp l ex i n g ”g iven 
that treatment has been shown to be more 
effective than law enforcement and incar -
ceration in reducing the demand for illegal 
drugs. “Providing treatment to all in 
need could save more than $150 billion 
over the next 15 years, at a price tag of just 
$21 billion in treatment costs. Funding 
treatment for persons addicted to drugs 
is prudent fiscal policy: every dollar 
invested in drug treatment generates $7 in 
savings of future costs” (Amaro, 1999; 
California Department of Alcohol and 
Drug Programs, 1994; Rydell and 
Everingham, 1994). 
◆ Restrictive syringe prescription and 
paraphernalia laws and regulations. In the 
i n t e rest of limiting drug use, a number of 
laws restrict the purchase and possession of 
equipment used to prepare and administer 
injection drugs. They fall into several 
major catego r i e s : 
• Drug paraphernalia laws in many states 
make it illegal to distribute or possess 
any equipment intended for injecting, 
smoking, or otherwise consuming ille gal 
substances (AED, 1997; Case et al., 
1998; Gostin, 1998; Koester, 1994). 
Currently, 44 states have such laws. 
• Prescription laws require that a person 
wishing to buy syringes have a valid medical 
prescription for syringes. In addition, some 
states require that syringe purchasers show 
identification and provide their name, 
address, and other identifying information 
(AED, 1997). Until recently, eight states 
had prescription statutes (Gostin, 1998). 
In 2000, New York, Rhode Island, and 
New Hampshire partially or completely 
removed their prescription laws. In the 
states in which these laws are in effect, 
p hysicians are allowed to pre s c r i b e 
hypodermic equipment only for medical 
purposes (AED, 1997). 
• P h a rmacy re g u l ations or practice guidelines in 23 
jurisdictions restrain pharmacists from 
selling sterile syringes or impose addi­
tional requirements on customers for 
their purchases. In addition, some drug 
stores have corporate or individual policies 
that limit over-the-counter sales of 
syringes (Jones and Taussig, 1999). 
Other related laws and restrictions include 
the Mail Order Drug Paraphernalia Act, 
which permits federal enforcement against 
individuals who knowingly sell or distribute 
syringes to IDUs, and a Congressional 
prohibition against federal funding for 
syringe exchange programs (SEPs) 
(Gostin, 1998). 
◆ A fragmented and polarized atmosphere. 
C u rrent public policies and res t r i c t ive law s 
and regulations are an important fac t o r 
constraining efforts to develop compre­
hensive and effective interventions for IDUs. 
Another critical factor is the profound 
differences in training, experience, attitude, 
and approach among the various profes­
sionals who provide services to IDUs (for 
example, those working in infectious disease 
p revention, substance abuse tre a t m e n t , 
mental health, criminal justice, and primary 
care). These philosophical and practical 
gulfs foster an atmosphere of p o l a r i z a t i o n , 
work against a coordinated, collaborative 
a p p ro a ch, and hinder system-wide efforts 
to reach IDUs. The gulfs emerge from lack 
o f knowledge about issues outside of one’s 
own expertise, specific training and education 
p e r s p e c t ives, attitudes held toward users, 
personal experience with addiction and 
recovery, and experience working with IDUs. 
One example of these differences is the 
debate over the relative merits of various 
substance abuse treatment approaches. 
Recovery from addiction is a day-by-da y, 
minute-by-minute, sometimes precarious 
balancing act in which the user makes 
repeated, sequential decisions not to use. 
Relapse can be common. Traditional 
Differences 
among providers 
of services 
to IDUs are 
caused by: 
• lack of knowledge 
about issues beyond 
one’s expertise 
• specific training 
and educational 
perspectives 
• attitudes toward users 
• personal experience 
with addiction and 
recovery 
• experience working 
with IDUs 
17T H E L E G A L ,  S  O C I A L, A N D P O L I C Y C L I M AT E 
substance abuse treatment models have 
focused exclusively on abstinence as the 
only acceptable short- and long-term out-
come. A person or program that appears 
to tolerate any use of drugs is seen as 
enabling the user to continue his or her 
addiction. Treatment approaches that 
focus on abstinence from alcohol and 
drug use include detoxification programs, 
inpatient and outpatient programs, and 
peer-based residential treatment settings 
(called therapeutic communities). These 
approaches are usually complemented by 
self-help or “12-Step” programs, such 
as Alcoholics Anonymous, Narcotics 
Anonymous, or Cocaine Anonymous 
(AED, 1997). All have the ultimate goal 
of helping an individual achieve and main­
tain a drug-free recovery (to become 
“clean and sober”). 
Another appro a ch, methadone maintenance 
treatment, has been used for more than 
30 years to treat tens of thousands of 
individuals addicted to opiates. Consistent 
participation in methadone maintenance 
programs over time diminishes and often 
eliminates use of other opiates, with con-
sequent benefits of reduced transmission 
of HIV and other blood-borne infections 
and reduced criminal activity (NIH, 1997). 
The effectiveness of this approach is 
dependent on a number of issues, including 
adequate dosage, the length and continuity 
of treatment, and the presence of associated 
psychosocial support services. Though 
considerable research supports the effec­
tiveness of methadone maintenance treatment 
and it is a legally sanctioned treatment in 
most states, its use is very highly regulated by 
federal and state agencies, it is still contro­
versial, and less than 20 percent of o p i a t e -
d ependent indiv i d u a l s have access to it 
(NIH, 1997). 
Another perspective on working with IDUs, 
called risk reduction or harm red u c t i o n , 
sees the fundamental problem as the adverse 
consequences of continued drug use (Des 
Jarlais et al., 1993). This approach is based 
on a recognition that many IDUs and other 
drug users are initially unwilling or unable 
to stop drug use and that many things can 
be done to help protect them, their families, 
and society from the harmful consequences 
of the drug use until they are able to stop 
using. Because HIV, hepatitis B, and hepatitis 
C infections are transmitted through shared 
injection equipment, it is possible for active 
users to reduce the risk of or prevent 
infection (Des Jarlais et al., 1993). Primary 
HIV-related risk red u c t i o n approaches 
include a range of interventions, such as 
substance abuse treatment to reduce or 
stop drug use; referrals to HIV-antibody 
testing and medical care services; referrals 
to social s u p p o rt services; education about 
ways for IDUs to increase control over 
whe n , how often, whe re, and with whom 
they inject; and ef forts to encourage active 
users to switch to non-injection forms of 
drug use. For those IDUs who are unable or 
unwilling to stop injecting, risk reduction 
interventions also focus specifically on 
injection practices — providing access to 
sterile syringes through exchange programs 
or over-the-counter sales from pharmacies; 
emphasizing the need to never share syringes, 
water, or drug preparation equipment; 
emphasizing bleach disinfection for IDUs 
who do not have sterile syringes; and pro­
viding alcohol swabs to clean injection sites 
to help prevent abscesses and other infections. 
A recent analysis of the laws in the 50 
states, the District of Columbia, and 
Puerto Rico found that physicians in 
nearly all of these jurisdictions may legally 
prescribe sterile syringe equipment to prevent 
disease transmission and that pharmacists 
in most states have a clear or reasonable 
legal basis for filling the prescription. While 
physician prescription will likely not result 
in widespread access to sterile syringes, it 
may have an important beneficial impact 
among individual IDUs who cannot or 
will not stop injecting (Burris et al., 2000). 
Traditional 
substance abuse 
treatment 
approaches: 
• detoxification 
• inpatient/outpatient 
programs 
• methadone maintenance 
• peer-based residential 
treatment settings 
• self-help programs 
Risk reduction 
approaches: 
• substance abuse 
treatment 
• referrals to HIV-
antibody testing, 
medical care, and 
social services 
• providing education 
about ways to manage 
drug use and gain 
control over daily 
life issues 
• reduction in risky 
injection practices 
• access to sterile 
syringes 
• working with injectors 
who choose to attempt 
abstinence 
• focusing on “treatment 
readiness” 
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All of these approaches have strong 
advocates as well as fierce opponents. 
D e fenders of a b s t i n e n c e - o n ly interve n t i o n s 
argue that tolerating any drug use is unac­
ceptable because it allows users to continue 
their self-destructive behavior and prevents 
them from achieving a “drug-free” status. 
Specifically, they express concerns that 
promoting syringe exchange programs and 
safer injection practices ser ve to encourage 
continued drug use, that methadone main­
tenance programs merely substitute one 
addicting drug for another, and that support 
for risk reduction approaches is an opening 
wedge for the eventual legalization of drugs. 
Many advocates of abstinence-based sub-
stance abuse treatment are former drug 
users for whom this approach was essential 
to recovery. Their experience is the foun­
dation of their conviction that abstinence 
is the only valid strategy for helping IDUs 
to stop using drugs. 
Defenders of methadone maintenance 
treatment cite its effectiveness in reducing 
dependence on illegal drugs and in helping 
users become productive members of society. 
Defenders of risk reduction cite as com­
pelling reasons for pursuing their approach 
the limited number of substance abuse 
treatment slots available, the fact that many 
users are unable or unwilling to permanently 
and completely stop their drug use, the 
importance of injection drug use in the 
HIV and hepatitis epidemics, and the 
i m p o rtance of injection drug use in other 
health problems such as abscesses and 
e n d o c a rditis. Another strength, they say, is 
risk red u c t i o n’s underlying principle of 
beginning any efforts with users at the 
place whe re they are, wh i ch then allow s 
providers to help them move to a new and 
better place whe re risk is red u c e d . 
A 1998 U. S. House of Rep re s e n t a t ive s 
d ebate on legislation to prohibit fed e r a l 
funding for syringe exchange pro gr a m s 
highlights the polemics involved in the 
debate over approaches to working with 
IDUs and illustrates some of the attitudinal 
and philosophical perspectives described 
earlier in this chapter (U.S. House of 
Representatives, 1998): 
“Mr. Goodlatte. Not only are needle exchange pro-
grams inconsistent with federal law, the results of 
community-based needle exchange program have been 
disastrous. Needle exchange programs have resulted 
in communities with higher crime, communities 
that are littered with used drug paraphernalia, and 
communities that are magnets for drug addicts and 
the high-risk behavior that accompany them….I urge 
my colleagues to support this legislation, oppose the 
use of needle exchange programs, and make sure 
that we continue the fight on drugs in a sensible 
way by cracking down on drug traffickers and 
educating people in the country about the dangers 
of using illegal drugs. 
Ms. Woolsey. Maintaining the ban [on federal 
funding for needle exchange programs] will not help 
s ave our ch i l d ren or anyone else. In fact, the ban on 
needle excha n ge actually thre atens lives….In 1995, 
needle excha n ge pro g rams were found to reduce the 
spread of AIDS and not to lead to increased drug use. 
This bill would ignore the science by denying public 
health experts a tool in the fight against AIDS, a 
tool that has been proven to slow the spread of this 
deadly disease. And those of my colleagues who are 
worried that free needles increase drug usage have 
to stop and think. We have to be reassured that 
knowing that the positive step by a drug user to 
choose clean needles is actually a first step in a very 
positive way towards their recovery. Just think about 
it. This is an opportunity to begin the healing process.” 
Conclusion 
As seen in this chapter, the social, legal, 
and public policy climate surrounding drug 
use creates structural and environmental 
barriers that limit the ability of IDUs to 
stop their drug use and reduce their risks of 
acquiring or transmitting infection. For 
example, IDUs are advised to enter substance 
abuse treatment and, if they continue to 
inject, to use only sterile syringes. 
However, insufficient substance abuse 
treatment capacity and syringe laws that 
make it illegal to obtain or possess sterile 
injection equipment often make it dif ficult 
or impossible to car ry out this public 
health advice. 
This climate presents a multi-layered 
challenge for program staff, policy makers, 
and others in the public health community. 
Many types of services and inter ventions 
currently exist to serve the complex drug-
related, medical, and social circumstances 
of IDUs and their families. More of these 
services and interventions are clearly needed, 
but if they are to be successful, public health 
program staff, service providers, and policy 
leaders need to design them with this exist­
ing social, legal, and policy climate in mind. 
This is because the social attitudes and 
structural factors described here often sub­
s t a n t i a l ly limit pro gram activities and con-
tribute to a fragmented service delivery 
system that does not ensure the availability 
of a full range of high-quality services that 
IDUs can easily obtain. Services and pro-
grams need to be or ganized and delivered 
in such a way that prevention messages and 
public health strategies can be reinforced 
across IDUs’ various circumstances, patterns 
of drug use, stages of change of risk 
behaviors, and across the many community 
and institutional settings where they ar e 
found. At the same time, individual services 
need to be supported by a philosophical 
framework that moves beyond the stigma 
surrounding IDUs, reduces the cur rent 
polarization among different approaches to 
working with IDUs, and ensures that col­
laboration is integral to the provision of 
services. The next chapter provides further 
detail on this vision o f a compreh e n s ive 
approach to preventing HIV and other 
blood-borne pathogens among IDUs. 
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Though many services and interve n t i o n s 
can be used to help IDUs, this approach 
focuses on eight specific strategies and fou r 
u n d e rlying principles. Figure 1 i l l u s t r a t e s 
the compre h e n s ive appro a ch and shows 
how its components are linked. The eight 
s t r a t egies, clu s t e red around the concept of 
HIV prevention for IDUs, are supported 
and framed by the cross-cutting principles of 
collaboration, tailoring, overcoming stigma, 
and ensuring coverage, access, and quality. 
A range of strategies are included because 
a single type of service or program (sub-
stance abuse treatment, HIV prevention 
education, access to sterile syringes) is not 
enough. Multiple services and programs 
delivered in multiple settings are needed. 
The supporting principles are included 
because if the strategies are to succeed, 
the providers, health departments, and 
community organizations who plan, deliver, 
and monitor them must consciously focus 
not only on “what” to pursue but also on 
“why” and “how” they will be pursued. 
Each principle contains the seeds of positive 
action that will allow communities, agen­
cies, and providers to come together and 
act more effe c t ive ly. 
The remainder of this chapter defines and 
describes the four supporting principles 
and the eight key strategies for preventing 
blood-borne diseases among IDUs. 
Accompanying these descriptions are 
vignettes about selected programs around 
the country that are working with IDUs. 
Although many of these programs provide 
similar types of services and all employ 
multiple components of the compreh e n s ive 
approach, the vignettes are intended to high-
light one or another strategy or principle 
and show the way in which each program’s 
unique approach, content, or philosophy 
brings that particular principle or strategy 
to life. Many other exemplary programs 
throughout the country are in c o rp o r a t i n g 
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Figure 1 
P revention planners, pro g ram staff, policy makers, community-based organizations, and others who work with 
IDUs must deal with several significant and interrelated problems: 
• the high risk of infection with HIV and other blood-borne pathogens, particularly hepatitis B and C; 
• a ran ge of s ex and drug use behav i o rs that maintain the epidemics and facilitate their transmission to 
n o n - i n fected IDUs as well as to the larger population of s ex part n e rs, ch i l d ren, and other adults who 
do not inject drugs; 
• attitudes of bias and stigma that margi n a l i ze and dehumanize IDUs and that limit options for prevention 
through their negative influence on laws, regulations, social policies, and access to services; and 
• profound and deeply held differences of philosophy and orientation among providers and organizations, 
whi ch cause polarization and fra g m e n t ation, hinder cooperative wo rking re l at i o n s h i p s, and ultimat e l y, 
limit the effectiveness of services and interventions for IDUs. 
These pro blems are hard to solve. Their complex i t y, interc o n n e c t e d n e s s, and deep - rooted nat u re re q u i re a 
comprehensive and multifaceted approach. This chapter proposes and describes such a comprehensive approach. 
C H A P T E R  T H R E E  
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In 1996, the Georgia Department of Health received funding from 
the Center for Substance Abuse Treatment (CSAT) of the federal 
Substance Abuse and Mental Health Services Administration 
(SAMHSA) to develop and deliver a series of workshops to bring 
together staff from the state’s public health and substance abuse 
treatment agencies. CDC also participated by providing technical 
assistance and oversight. The genesis of this project was the fact 
that the shift of the epidemic toward IDUs and disadvantaged and 
minority populations meant, increasingly, that providers were 
working with clients who had multiple problems. Having providers 
focus only on a client’s substance abuse problem, or STD, or high-
risk sexual behaviors was clearly not adequate. But significant barriers 
prevented these professionals from providing more comprehensive 
services. Staff from public health or substance abuse treatment 
didn’t know what questions to ask to assess a client’s problems in the 
other arena, or felt it wasn’t appropriate to ask those questions. 
Federal confidentiality protections precluded substance abuse 
treatment and public health staff from discussing a client who 
was being seen at both types of facilities. Longstanding patterns 
of limited communication between the different agencies created 
an additional barrier. 
Clearly, something was needed to help break down these barriers 
and foster collaboration. Staff needed an opportunity to learn about 
each other’s subject areas, client assessment procedures, and treat­
ment options. More than that, they also needed an opportunity to 
make personal connections across agency disciplines, cultures, and 
bureaucracies — connections that would allow them to develop 
mutual respect and a common vocabulary, foster a willingness to 
hear each other’s point of view, and understand the realities of 
each agency’s funding and policy requirements. The desired out-
come? Collaborative working relationships, strong channels of regular 
communication, and ultimately, system-wide positive change. 
Over a 7-month period in 1997, 24 2-day workshops were held 
across the state. About 1,100 nurses, counselors, social workers, 
clinicians, and epidemiologists participated. The first part of each 
workshop focused on one of the biggest difficulties — lack of knowl­
edge. The trainers provided the public health participants with a 
“Substance Abuse 101”; the substance abuse treatment participants 
received the same for STDs. The entire group received an update on 
the HIV/AIDS and TB epidemics. The remainder of the workshop 
emphasized skills-building so that participants could conduct more 
comprehensive prescreening, risk assessment, and counseling with 
clients. Throughout the workshop, participants were encouraged to 
talk with each other, share experiences, and learn about the day-
to-day realities and challenges faced by others. 
An essential element in the success of the workshops was including 
all the involved parties in planning and implementation. Before the 
workshops, high-level administrators and front-line staff from the 
public health and substance abuse treatment agencies met to discuss 
existing barriers to collaboration, needed tools and skills, and goals 
and objectives for the workshops. They also discussed Qualified 
Service Organization Agreements (QSOA), which would allow 
substance abuse treatment and public health provider agencies to 
share limited information about clients within the legal constraints 
of federal confidentiality protections. 
The response to the workshops was immediate, powerful, and posi­
tive. They changed attitudes, altered the way that many participants 
worked with clients, created collaborations, and led to requests for 
further trainings. Since then, several other series of cross-training 
workshops in Georgia have helped participants develop new 
approaches to dealing with issues such as substance abuse treatment 
planning, harm reduction, and confidentiality. 
In 1998, CSAT, CDC, and the Health Resources and Services 
Administration (HRSA) developed an interagency agreement to 
expand the cross-training concept. This initiative, called “HIV/AIDS, 
TB and Infectious Diseases: The Alcohol and Other Drug Abuse 
Connection,” provides training and technical assistance to state 
infectious disease and substance abuse health care delivery systems 
so that they can more effectively serve individuals who have or are at 
high risk of having concurrent conditions. During FY99 alone, 13 
cross-training workshops were held in 6 states. In addition, trainers 
have responded to 40 requests for cross-training information and 
technical assistance from states and federal agencies. 
Many components and principles of the early cross-training experi­
ences have been applied in the current initiative: 
• Reflect the diversity of the epidemic. Because success in one 
area is dependent on addressing others, the workshop now covers 
prevention, treatment, and care issues for the various substance 
abuse and infectious disease topics (HIV, STDs, TB, hepatitis). 
Workshop planners and participants include representatives from 
mental health and criminal justice as well as from infectious diseases 
and substance abuse. Planners report that this greater diversity 
in the cross-training helps participants more easily appreciate and 
understand other points of view and approaches than does a 
workshop with more restricted representation or content. 
• Tailor to the local community. Before a workshop is held, 
planners research the disease issues in the community to ensure 
that topics and skills building exercises reflect and are tailored to 
the needs, cultures, and languages of the community. Participant 
lists reflect the particular needs and existing service delivery sys­
tems of the community. Planners also select workshop trainers 
with this principle in mind. 
• Build local commitment and capacity. Although a request 
for a cross-training workshop may come from one agency or 
organization, all the potential partners must agree to support and 
participate in the training. They are also part of the planning group, 
select the participants, and identify local co-trainers. All of these 
activities help to build local capacity for further training and 
encourage widespread institutional commitment to improving 
prevention, treatment, and care systems. 
• Follow up. An essential element of the initiative is long-term 
follow up to track changes that result from workshops (Are 
trainings being replicated? How many QSOAs have been signed? 
Have other types of collaborative activities developed?) and to 
provide necessary technical assistance to states. 
For more information: HIV/AIDS, TB and Infectious Diseases Cross-
Training: The Alcohol and Other Drug Abuse Connection. 
www.treatment.org/Topics/infectious.html 
Cross-Training for HIV/AIDS, Infectious Diseases, and Substance Abuse Providers: 
A Novel Idea Becomes a Nationwide Trend 
C R O S S - T R A I N I N G 
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these same approaches and philosophies 
in their work with IDUs. Readers also are 
encouraged to read Appendix A, which pro­
vides expanded discussions of the eight key 
s t r a t egies, including findings from res e a rch 
and programs and descriptions of issues 
and barriers facing providers and agencies 
as they seek to accomplish their goals. 
Guiding Principles 
E N S U R  E C O O R D  I N A T  I  O  N 
A N D  C O L L A B O R A  T  I  O  N 
Current medical care, social service, and 
HIV and drug use prevention and treatment 
systems are complex and governed by a 
patchwork of federal, state, and local 
funding arrangements and regulatory envi­
ronments (AED, 1999). Service providers 
report frustrations with the barriers these 
multiple systems create and the ways in 
which they limit providers’ ability to provide a 
continuum of services to meet the complex 
needs of injection drug users (AED, 1999). 
If interventions with IDUs are to succeed, 
agencies and providers must find ways to 
work within these systems to coordinate 
their efforts. 
This principle also embodies another 
idea — collaboration. The profound and 
often conflicting differences in approach 
and orientation espoused by various organi­
zations, philosophies, and providers, and 
the resulting reluctance of agencies and 
providers to work together for IDUs con-
tributes to the fragmented service delivery 
system and leads to policies, laws, and 
regulations that can be inconsistent, contra­
dictory, and sometimes at cross-purposes. 
Providers, agencies, and policy makers must 
collaborate, sharing their various skills, per­
spectives, and experiences, building on prior 
relationships, and reaching out to groups 
with whom they may not have worked 
before. Partners in this effort need not 
agree on everything, but they do need to find 
ways to cooperate so as to achieve the larger 
goals of reducing HIV and viral hepatitis 
infection in injection drug users and reducing 
substance abuse. 
E N S U R E C O V E R AG E , 
A C C E S S , A N D Q U A L I T Y 
P ro grams and interve ntions will not be 
effective if they do not reach a critical m a s s 
of people who need them, if IDUs cannot 
or will not use them, or if they are of poor 
quality. The first of these elements, coverage, 
c o n c e rns whether services or interve n t i o n s 
a re rea ching a sufficient number of IDUs 
to make a real difference. For example, it is 
estimated that only a small percentage of 
those needing substance abuse tre a t m e n t 
a c t u a l ly rec e ive those services (Epstein and 
G f roerer, 1998). Similarly, pharmacies and 
s y r i n ge exch a n ge pro grams help a growi n g 
number of IDUs who continue to inject to 
obtain sterile syringes. However, these pro-
grams often fall short of reaching all those 
who desire to reduce their transmission 
risks by obtaining and using sterile syringes 
(Lurie et al., 1998; Remis et al., 1998). 
The Statewide Partnership for HIV Education in Recovery 
Environments (SPHERE) develops and delivers training to substance 
abuse treatment providers, AIDS service organizations, and com­
munity-based health centers in HIV/AIDS prevention and substance 
abuse issues and related topics such as capacity building, policy 
development, organizational development, and coordination and 
collaboration. Increasingly, programs are calling SPHERE for help 
in developing long-term training and development plans and this 
contributes to system-wide positive change. 
Funded by the Massachusetts Department of Health’s AIDS bureau 
and its substance abuse treatment bureau, SPHERE’s primary goal is 
to foster and support interdisciplinary collaboration across the many 
groups that work with substance abusing populations and those at 
risk of or infected with HIV and other blood-borne pathogens. By 
holding cross-trainings and educational workshops and conducting 
outreach to HIV/AIDS, substance abuse, syringe exchange, mental 
health, primary care, and other providers, SPHERE hopes to create 
a synergy among providers so that they can learn with and from each 
other, share best practices, and overcome philosophical barriers. 
In addition to its trainings and efforts to foster collaboration, SPHERE 
has developed a number of tools and forms that have been adopted 
by many organizations and service providers in the state. Among 
these are new standardized intake and record release forms and a 
comprehensive HIV risk assessment tool and a program satisfaction 
and evaluation tool. 
For more information: SPHERE, Brockton, MA, 800/530-2770. 
One-stop Shopping to Help Programs Work Better 
S P H E R E 
A comprehensive 
approach rests on 
4 basic principles 
• ensure coverage, access, 
and quality 
• ensure coordination 
and collaboration 
• overcome stigma 
• tailor services and 
programs 
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The second concern, access, relates to issues 
such as the number and location of pre­
vention and care services and programs, 
whether they are free or not, whether IDUs 
need a referral to use them, and whether 
IDUs know about their availability. 
Problems with access stem from the very 
nature of IDUs’ lives as well as from the 
way in which the services and programs 
are organized and delivered. IDUs may not 
k n ow what services are ava i l a ble to them, 
how to get to them, or how to use them. 
Frequently, their lives are so dominated 
by the demands of their addiction that 
p a rticipation in organized interventions 
is beyond their capability. Further, when 
IDUs do attempt to use care systems or 
programs, they report that some procedures 
and staff are insensitive and demeaning, 
confidentiality is not protected, and agency 
policies effe c t ive ly pose barri e r s to care 
(NYHRE, 1998; Rogers et al., 1998; 
Thaca, 1997). This creates powerful feelings 
of mistrust and alienation and a strong 
reluctance to seek out or participate in 
programs and services. 
The third issue, quality of care provided 
to IDUs, covers a host of issues such as 
the training and competency of service 
providers, the adequacy of medications 
prescribed (for example, are IDUs receiving 
a more effective dose of 80-100 mg of 
methadone per day [Strain et al., 1999] or 
only 30 mg per day?), and the provision 
of all necessary services (for example, are 
substance abuse treatment services accom­
panied by needed primary medical care or 
psychosocial services?). The ability of IDUs 
to comply with treatment regimens, main­
tain or improve their health, and reduce 
their risks of acquiring or transmitting 
HIV and other blood-borne pathogens is 
directly related to the quality of the preven­
tion and care services they receive. 
If agencies and providers hope to truly help 
IDUs, they must consider ways to effectively 
deal with these key issues of coverage, access, 
and quality as they plan, deliver, and monitor 
programs and services. 
R E C O G N I Z E  A N D  
O V  E  RC O M E  S T I G M A  
If IDUs are to be successfully engaged in 
p revention effo rts and if p u blic policy is 
to move forward, the nega t ive attitudes, 
stereotypes, and stigma attached to injection 
drug users and their addiction must be 
recognized and overcome. It is all too easy 
for IDUs to be dehumanized, to become 
“ t h e m ,” not “ u s .” In fact, IDUs are “ u s” 
— they are fam i ly members, neighbors, 
friends, colleagues, patients. A willingness 
to put a human face on the problem, to 
attempt to understand the disease of drug 
addiction, and to consider IDUs as full 
human beings is a critical step to moving 
NYHRE is the largest harm reduction program in New York State. 
Now in its ninth year, its services also include outreach, HIV/AIDS 
prevention education, psychotherapy, treatment advocacy, referrals to 
health care, syringe exchange, and training for service providers. The 
ways in which it plans and provides its services and programs provide 
a useful perspective on the issues of coverage, access, and quality. 
About 35,000 people are enrolled in NYHRE programs and the staff 
sees about 8,000 individuals each year. In the last three years, NYHRE 
has doubled in size and budget and the number of staff has tripled. 
Reaching a critical mass of those who need help is a long-term and 
often difficult process, particularly in a city like New York, which has 
an extremely large IDU population. However, NYHRE’s philosophy 
of reaching as many users as possible “where they are,” providing 
as many different types of services as possible, and creating linkages 
among a myriad of services and service providers are good ways to 
address existing gaps in coverage. 
“We understand that there are reasons why people use drugs and 
good reasons why they are not connected to services. We take that 
as our point of departure,” says Terry Ruefli, NYHRE’s executive 
director, in describing the ways in which NYHRE helps IDUs break 
down barriers to obtaining services. For example, says Ruefli, 
NYHRE provides traditional services in a nontraditional way. “We 
have a psychotherapist, but he doesn’t sit in his office and wait for 
patients to come to him. He sets up two chairs on the sidewalk, 
and hangs his diploma on one of them. We do all our services on 
the street. Everything. Whatever need you have, you can get it met 
in this program in one way or another.” 
As part of its efforts to improve service quality and increase coor­
dination among providers, NYHRE conducts harm reduction training 
programs. These workshops increase participants’ awareness of 
the difficulties that IDUs face in obtaining high-quality services and 
provide training in the principles and practices of harm reduction. 
These trainings help providers learn to respect the ethnic and street 
cultures from which their clients come, which, in turn, helps them 
understand drug users, what makes sense to them, how they inter­
pret the world, how they expect to be treated, and what kinds of 
interventions will be most effective. 
Located in one of the poorest urban communities in the nation — the 
Hunts Point section of the Bron x — NYHRE has worked hard to 
collaborate with others on a variety of projects whose needs are 
defined by the community itself. Ruefli explains that NYHRE is “part 
of the process by which IDUs see that there’s light at the end of the 
tunnel. They’re not condemned to die of AIDS, to be homeless, to 
be mentally ill. We are one of the ways in which people can climb 
out of that.” 
For more information: New York Harm Reduction Educators, Inc., 
Bronx, NY, 718/842-6050. 
Focusing on Coverage, Access, and Quality 
N E W  Y O R K  H A  R M  R E D U  C T I  O N  E D U C A T O R S  ( N  Y H  R E )  
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Stigma toward IDUs and other drug users results from individual 
experiences with drug use or drug users, but it is also generated 
in large measure from broader societal attitudes toward drug use. 
Changing social attitudes is one way to affect change on an individual 
level. The National Institute on Drug Abuse (NIDA), a component of 
the National Institutes of Health (NIH), supports over 85 percent of 
the world’s research on the health aspects of substance abuse and 
addiction and it is working on a number of fronts to disseminate 
the results of its research. This dissemination effort is helping to 
improve the nation’s understanding of addiction and, as a result, 
change attitudes about drug addiction and people who use drugs. 
These various activities include: 
• Being clear on the terminology. NIDA carefully crafts the 
language it uses to talk about addiction and individuals who use 
drugs so that it reflects current scientific knowledge and is clearly 
understandable. These words and phrase s — “addiction is a brain 
disease,” for example — are used repeatedly and in multiple 
contexts so that, eventually, they can become a permanent part 
of the way that society talks about this issue. 
• Fostering dialogue with communities. Since 1996, NIDA has 
hosted a series of 1-day Town Meetings in communities across the 
country to help bridge “the great disconnect”— the dichotomy 
between the public’s perception of drug addiction and the scientific 
facts. These meetings, which are tailored to meet local interests 
and needs, give NIDA the chance to provide communities with 
the latest findings from drug abuse prevention and treatment 
research. They also give communities — local civic leaders, health 
care providers, parents, teachers, concerned citizens — a chance 
to tell NIDA what kind of information they need to better deal 
with drug problems in their community. 
• Taking information to the people. If research findings and 
scientific facts are to have an impact and be useful, they need to 
be used. A big focus of NIDA’s information dissemination effort, 
therefore, is creating a wide range of publications and other mate-
rials that are appealing, user-friendly, and pragmatic. For example, 
NIDA’s recent publication, Principles of Drug Abuse Treatment: 
A Research-based Guide synthesizes 25 years of research into a 
series of practical principles that communities can use to develop 
effective substance abuse treatment programs. NIDA has also 
produced numerous educational booklets, slide shows, and other 
materials for parents, youth, and teachers. 
• Harnessing the power of partnerships. NIDA has developed 
collaborative relationships with many different organizations and 
agencies, from Hollywood’s Entertainment Industries Council, to 
the American Medical Association and other professional associa­
tions, to other federal agencies such as the Department of Justice 
and the Office of National Drug Control Policy (ONDCP), to 
community coalitions such as Join Together and Community 
Anti-Drug Coalitions of America (CADCA). NIDA works through 
these partnerships to promote wide distribution of information, 
ensure that depictions of drug use and addiction are accurate, and 
create a better and more thorough understanding of drugs and 
their effects on the brain and body. 
For more information: National Institute on Drug Abuse (NIDA), 
Bethesda, MD, www.nida.nih/gov. 
Working to Change Attitudes on a National Scale 
N I D A 
The ARRIVE Program of Exponents, Inc. is designed to improve the 
quality of life of traditionally underserved minorities affected by 
drugs, HIV/AIDS, incarceration, and poverty. Serving clients from the 
entire New York City area, Exponents’ programs intervene with 
detainees, recently released inmates, people living with HIV/AIDS, 
and substance users and their families. The ARRIVE curriculum covers 
harm reduction, relapse issues, HIV care and prevention strategies, 
health education, infection control, and nutrition. HIV counseling, 
referrals to much-needed services, and peer-led support groups 
reinforce classroom information and help clients amplify their 
strengths and resources to meet their health and social challenges. 
Communications and presentation classes help clients transform 
personal experience into marketable skills. 
ARRIVE is based on a “corporate social work model,” says deputy 
executive director, Maria (Sam) Josepher. “It was begun by people 
who were corporately aware as well as people who had been in 
the substance abuse field for more than 30 years. We used a lot of 
what we learned from the business world to teach addicts — the 
importance of information, communication skills, respect, cleanliness — 
all of this is given to the client. On the social work side, the clients 
receive a lot of therapeutic peer support. We acknowledge the 
incremental steps that people make. We notice when people are 
dressing better, acting better, making more out of their lives.” 
Started in 1988, ARRIVE now trains over 900 substance users a year, 
60 percent of whom are HIV-positive. It has maintained an 83 percent 
retention rate over the last decade. As Ms. Josepher explains, the 
program is based on the premise that investing in human capital not 
only works, but is cost-effective. “We see people go through a trans-
formation within 2 months,” she says. ARRIVE costs about $1,000 
per person for more than 60 hours of education, support groups, and 
counseling. For $1,000 you have a person who is literally transformed, 
motivated, and renewed.” 
Ms. Josepher illustrates this with the following story: “One of my 
staff is a woman who was in and out of prison for prostitution, for 
drugs, for burglary. She would get off drugs but couldn’t stay off. 
She didn’t have that ability. She was a heroin IDU for 20 years and 
on methadone for two. She came into the ARRIVE program. She 
saw people like herself training, counseling, and becoming part of the 
solution. Then we put her on a computer. She just started soaking 
it up like a sponge. She became a volunteer, our first part-time 
employee. She never went back to drugs. The last time she was in 
prison was about 9 years ago. Two years ago she bought a house. 
When she announced this at a staff meeting, there wasn’t a dry eye 
in the place.” 
For more information: The ARRIVE Program of Exponents, Inc., 
New York, NY, 212/243-3434 www.exponents.org. 
Overcoming Stigma Through Investing in Human Capital 
A R R I V E 
26 A  C  O M P R E H E N S I V E A P P RO A C H 
beyond the stigma. Overcoming stigma is 
also, fundamentally, a pragmatic necessity, 
for without it, the job of helping IDUs 
overcome their addiction and prevent dis­
ease will not be accomplished. 
T A  I  LO R S E  RV I C  E S 
A N D P RO G R A M S 
IDUs have diverse languages, cultures, sexual 
orientations, life circumstances, behaviors, 
and requirements for services. One size does 
not fit all. In planning and delivering inter­
ven t i o n s , providers must take into account 
the factors that differentiate IDUs— who 
they are, where they are, what they do, 
what motivates them, who they socialize 
with. Programs and pr oviders must also 
account for the fact that the behaviors or 
occupations of certain groups of IDUs, 
such as the mentally ill, the homeless, 
commercial sex workers, and those in prisons 
and jails, put them at particularly high risk 
of acquiring and transmitting infection. 
Tailoring interventions to the particular 
characteristics and service needs of recipients 
will increase their effectiveness. Involving 
IDUs in planning, delivering, and evaluating 
services and interventions is one important 
way to make sure that they are appropri­
ately tailored. 
Key Strategies 
S  U  B  S  T A N C E  A B  U S E 
T R E AT M E N T 
Drug addiction is a chronic illness charac­
terized by compulsive, uncontrollable 
drug craving, seeking, and use, even in the 
face of enormous ne gative consequences. 
Though nearly all addicts believe initially 
that they can stop on their own, most of 
their attempts fail to achieve long-term 
abstinence (NIDA, 1999). Substance abuse 
treatment provides the medical, psychological, 
and behavioral support necessary for 
i n d ividuals to stop using drugs and to 
allow their brain processes to ret u rn to 
pre-addiction functioning (see Chapter 2 
for more detail on the changes in brain 
function that occur during addiction). 
Well-Being Institute is a drop-in day treatment center located in 
Detroit’s inner city. It works primarily with HIV-infected, substance-
abusing women who are mentally ill. These women tend to fall 
between the cracks of the existing health care delivery system, which 
is not well suited for creating and maintaining long-term relationships 
with such a high-risk population. The program locates eligible women 
through street outreach, nursing staff contacts with case managers 
in Detroit’s HIV care network, and referrals. Through its own model 
of individualized nursing care, Well-Being staff help clients achieve 
three primary objectives: access — overcoming barriers to obtain­
ing care for their HIV disease, substance abuse problem, or mental 
illness; retention — maintaining relationships with care providers 
over the long-term; and adherenc e — sticking with treatment 
regimens over time. 
To illustrate the specific and broader pay-offs of tailoring interventions 
to the needs and circumstances of particular IDUs, Geoffrey Smereck, 
Well Being’s director, tells the story of a mentally ill woman who 
was also homeless, an IDU, a victim of domestic violence, and had 
an HIV-related cancer: 
“In the course of 9 months, we got her housing, got her primary 
health care needs met, and made sure she kept going to her health 
care appointments. We got her into a substance abuse treatment 
program so she was getting herself off drugs. We made sure she took 
her HIV meds and her meds to reduce her mental illness symptoms. 
I ran into her 3-4 months ago and she looked great. For public policy 
purposes, notice how she is no longer really an infection risk to any 
other person. She is a thousand-fold less drain on public resources. 
No one will have to pick her body out of an alley somewhere. Simply 
getting her to take her meds and getting her to show up for regular 
health care appointments is a far more cost-effective way of dealing 
with her health problems than her showing up in an ER somewhere 
with her problems like an out-of-control train wreck. The kind of 
interventions that can prevent the train wrecks can save the public 
health care systems enormous amounts of money, not to mention 
preventing a lot of human suffering. When I talked to her, the client 
wanted to get into community college and into the workplace. If 
we can get someone to stop soaking up resources, let alone to 
start contributing….” 
For more information: The Well-Being Institute, Detroit, MI, 
734/913-4300. 
Tailoring Interventions for a Specific Population of IDUs 
W E L L - B  E I N  G  I N  S T I  T U T  E 
Substance abuse 
treatment—why 
include it? 
• it helps users stop 
using drugs 
• it helps prevent 
transmission because 
users reduce drug-
and sex-related 
risk behaviors 
• it has major positive 
effects on a user’s life 
• it’s cost effective 
• it’s a good way to 
reach IDUs with 
other messages 
and interventions 
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River Region Human Services AIDS Outreach Program, located in 
Jacksonville, Florida, focuses on providing substance abuse treatment 
services to high-risk IDUs. Additional services include HIV, STD, and 
TB testing; group support meetings; referrals to mental health and 
substance abuse treatment services; sexual risk reduction education 
and condom distribution; and counseling and education. Over time, 
it has developed links and collaborative relationships with a variety 
of other agencies that provide substance abuse treatment, case 
management, and medical services. River Region recently assumed 
management of a 40-bed supportive housing facility. 
River Region is unusual in that outreach is an integral component of 
its services. River Region goes out into the community to find IDUs 
and offer them substance abuse treatment, HIV testing, and other 
services. By working in the neighborhoods with IDUs, they’ve been 
able to develop trust and credibility. “We’ve been doing it so long, 
we are recognized and have a good rep,” says director Marc 
Gross. “Once you get one good one with all the connections, they 
will work with you and get their buddies into treatment.” 
Persistence and patience are key elements. “You have to address the 
substance abuse problems first,” says Gross. “The other issues can 
come later. If the person isn’t interested in treatment, don’t give up. 
Keep after them, eventually they will come. It’s not a fast process.” 
In addition to working in the community, River Region is the sub-
stance abuse treatment provider for the Jacksonville jail, and has 
recently added an HIV testing and education component to these 
services. Its numerous links with community-based agencies and 
service providers ensure continuity and consistency for inmates 
once they return to the community. 
For more information: River Region Human Services AIDS Outreach 
Program, Jacksonville FL, 904/359-6088. www.rrhs.com 
In Substance Abuse Treatment, Be Persistent and Accept Small Victories 
R I V E  R R E  G I O  N H U M A N  S E R  V  I  C  E  S 
Often, because of the complexity of the 
disease and the frequency of relapse to drug 
use, treatment requires multiple episodes 
over a long period of time. 
For injection drug users, substance abuse 
treatment is a powerful disease prevention 
strategy. Drug injectors who do not enter 
treatment are up to six times more likely to 
become infected with HIV than are injectors 
who enter and remain in treatment 
(NIDA, 1999). Because substance abuse 
treatment helps users reduce or eliminate 
the number of drug injections, it lowers 
the risk of infection with HIV or hepatitis 
that might occur through unsafe injection 
practices, such as multi-person use of 
syringes or sharing of drug injection 
equipment (Thiede et al., 2000). It also 
prevents or reduces other harmful conse­
quences of drug use, such as abscesses and 
endocarditis (inflammation of the lining 
of the heart). Further, because drug use 
impairs rational decision making, which 
can lead to high-risk behavior, substance 
abuse treatment can reduce the risk of 
HIV and hepatitis infection that can 
occur through high-risk, unprotected sex. 
In the last decade, the effectiveness of 
substance abuse treatment and its broader 
social benefits have been emphatically 
demonstrated (Gerstein and Harwood, 
1990; Hubbard et al., 1989; Metzger et 
al., 1998; NIDA, 1999; NIH, 1997a; 
Pickens et al., 1991). Successful treatment 
can have a major positive impact on many 
areas of a person’s life, helping him or her 
improve family life, employment and 
health, and decrease involvement with 
crime. Overall, treatment for addiction is 
as successful as treatment of other chronic 
conditions, such as asthma, diabetes, and 
hypertension (NIDA, 1999; O’Brien and 
McLellan, 1996). 
Substance abuse treatment makes financial 
sense as well. Every $1 invested in substance 
abuse treatment reduces the costs of drug-
related crime, criminal justice costs, and 
theft by $4 to $7. The average cost of 1 
year of methadone maintenance treatment 
is $4,700 per person. The cost of 1 year 
of imprisonment per person is about 
$18,400. When health care savings are 
added in, total savings can exceed costs by 
a ratio of 12 to 1 (NIDA, 1999). 
Substance abuse treatment programs also 
reach drug users and their partners with 
other HIV prevention messages and inter­
ventions. Participation in these interventions 
offered in the treatment setting is associated 
with reduced drug- and sex-related risk 
behaviors (Calsyn et al., 1992; El-Bassel 
and Schilling, 1992; Malow et al., 1994; 
McCusker et al., 1993). 
C O M M U  N I T Y  O U T R E A  C H 
Many IDUs are not engaged by conven­
tional service systems that provide treatment 
and prevention services or medical, mental 
health, or social welfare services. This is due 
partly to funding and capacity limitations 
on the part of the service systems. It is 
also due to IDUs’ own attitudes and life 
c i rcumstances. The ove r whelming priorities 
of obtaining and using drugs often prevent 
IDUs from seeking out services, such as HIV 
prevention, that may seem abstract or 
Overall, treatment for 
addiction is as successful 
as treatment of other 
chronic conditions, 
such as asthma, diabetes, 
and hypertension. 
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unimportant in comparison. In addition, the 
stigma and nega t ive attitudes exp e r i e n c e d 
by many IDUs when they have worked 
with service providers leads them to mistrust 
gove rnment agencies and conve n t i o n a l 
service systems and be reluctant to obtain 
s e rvices. Thus, to effec t ive ly provide pre­
vention, treatment, and care services to IDUs, 
it is essential to bring the services to IDUs in 
the settings in which they live and socialize. 
Community outreach programs can make 
a valuable contribution to preventing 
blood-borne infections (Wiebel et al., 1996). 
These practical and relatively low-cost 
approaches are designed to reach high-risk 
IDUs and present and reinforce preve n t i o n 
messages in a community setting . They 
can be the first step in developing a rela­
tionship with drug users and ultimately 
linking them with services. Because they are 
both an individual- and community-level 
intervention, they help create a culture of 
risk reduction among drug users, their 
families, friends, and neighbors. This culture 
of risk reduction also helps to support 
recovering drug users returning from 
substance abuse treatment and those 
returning to the community after time 
spent in prison or jail. 
Community outreach is typically carried out 
in settings where drug users gather — on 
the street, in homes, in shooting galleries 
and crack houses, and in housing projects, 
emergency rooms, laundromats, and parks. 
Ideally, the messages and services are delivered 
by people with whom the drug user is 
familiar and likely to trust, such as peers 
who live in the community. Many commu­
nity outreach workers are recovering IDUs 
themselves. A typical outreach encounter 
i nvo l ves fac e - t o - face communication that is 
intended to assist IDUs in changing their 
high-risk drug use and sexual behaviors. 
Outreach workers may give out literature 
on HIV and how to prevent it or provide 
information on ava i l a ble services. They also 
distribute condoms and bleach kits for 
decontaminating injection equipment and 
they help IDUs obtain other services in 
the community, such as housing assistance 
Located in the heart of Detroit’s Empowerment Zone, Taking It 
to the Streets’ target population is low-income, underserved, at-
risk and HIV-infected African American substance users. It provides 
health education, HIV risk reduction counseling and testing, and 
syringe exchange services, and collaborates closely with six of the 
area’s largest chemical dependency treatment centers. 
Taking It to the Streets was based in part on a National AIDS 
Demonstration Research Project supported by NIDA that looked at 
effective outreach to injecting drug users. The program has pioneered 
the indigenous leader outreach approach. It operates on the diffusion 
model, which focuses on the spread of ideas and practices throughout 
a social system from person to person. Harry Simpson, former 
executive director of the Community Health Awareness Group that 
oversees the program, describes the staff as “individuals who share 
the demographic characteristics as well as the life experiences” of 
the people they serve. “They walk the walk, and they talk the talk. 
Because they are often in recovery themselves, they are seen as 
credible role models.” Simpson says also that community involve­
ment is the “central theme in our program’s design, development and 
implementation, and monitoring and evaluation.” 
Taking It to the Streets is research-based, incorporating approaches 
and specific strategies that have been shown to work. For example, 
it was one of the first programs in the state to use OraSure for HIV 
testing, a quick, relatively noninvasive technology with proven reliable 
results. Project Respect is the counseling model employed by the 
program because, according to Simpson, “The results of their 
research showed that people who had gone through a two-session 
contact had pretty much the same outcome as those in longer sessions. 
After we implemented the Project Respect Model, our return rate 
increased from 40 percent to more than 80 percent.” 
Simpson stresses that the mobility of the program is also key to its 
success. His staff work out of specially outfitted vans that some have 
called “prevention on wheels.” Simpson says, “These vans let us 
take the service to those who need it most, rather than waiting for 
them to come to us.” 
For more information: Taking It to the Streets, Detroit, MI, 
313/872-2424 
A Science-based Community Outreach Program 
T A K I N G  I T  T O T H  E  S  T R E E T  S 
Community 
outreach— why 
include it? 
• it reaches IDUs 
who don’t use or are 
missed by conv e n t i o n a l 
service systems 
• it provides services 
in settings that are 
familiar to IDUs 
• it helps create a cul­
ture of risk reduction 
in the community 
• it uses peers who 
are likely to be trusted 
by IDUs 
• it’s relatively low cost 
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or mental health treatment. Outreach also 
involves working with drug users’ social and 
drug-using networks to diffuse prevention 
messages and build risk reduction skills. 
O u t re a ch can also be used to rec ruit dru g 
users to other activities, such as confidential 
risk assessments, HIV testing and counsel­
ing, and substance abuse treatment, and to 
distribute sharps containers for safe disposal 
o f used syringes. 
I  N  T  E  RV E N  T I O N S  T O 
I N C R E A S  E I D U S  ’ A C  C  E  S  S 
T O  S T E R I L E  S Y  R I N G E S 
C l e a rly, the best solution for injecting dru g 
users is to stop injecting and enter substance 
abuse treatment. However, many drug users 
either cannot get into substance abuse 
treatment programs or will not stop inject­
ing drugs. Even those injectors who are in 
treatment may relapse to injecting drugs. 
Given these realities, several governmental 
bodies and institutions1 h ave rec o m m e n d e d 
consistent, one-time-only use of s t e r i l e 
syringes as a central strategy in the effort 
to reduce the transmission of HIV and 
other blo o d - b o rne pathogens among those 
individuals who continue to inject drugs. 
Most states restrict the sale, distribut i o n , 
and possession of sterile syringes: 44 states 
have drug paraphernalia statutes, 5 states 
have syringe prescription statutes, and 23 
states have pharmacy regulations or prac­
tice guidelines. These restrictions present 
s i g n i ficant barriers to the sale of syringes to 
IDUs by pharmacists, the prescription of 
sterile syringes to IDUs by physicians, the 
operation of syringe exch a n ge pro gr a m s , 
the safe disposal of blo o d - c o n t a m i n a t e d 
used syringes, and ultimately, to the efforts 
by IDUs to reduce their risks of a c q u i r i n g 
or transmitting blo o d - b o rne pathogen s 
(Gostin, 1998). 
Three types of interrelated interventions are 
now being pursued in the U.S. to increase 
IDUs’ access to sterile syringes. Several 
states and municipalities are working on 
policy efforts to allow increased pharmacy 
sales of syringes, remove criminal penalties 
for syringe possession, and include language 
in laws stating that preventing HIV and 
other blood-borne pathogens is a “legitimate 
medical purpo s e ” for prescribing sterile 
s y r i n ges to IDUs who cannot or will not 
stop injecting drugs. Many jurisdictions are 
pursuing efforts to sustain and expand syringe 
exch a n ge programs, which provide IDUs with 
free sterile syringes and a way to safely 
dispose of blood-contaminated used 
s y r i n ges. Many of these syringe excha n ge 
programs also provide additional servi c e s , 
such as education and counseling, primary 
medical services, and referrals to substance 
a buse treatment and social servi c e s . 
I n i t i at ives with pharm a c i s t s p rovide education 
about the role of sterile syringes in reducing 
the transmission of blo o d - b o rne pathoge n s 
such as HIV and viral hepatitis, address 
pharmacist concerns and questions about 
s y r i n ge sales and disposal, and encourage 
cha n ges in pharmacy policy and practice. 
An individual IDU makes approximately 
1,000 injections each year, which even in 
a moderate-size city adds up to millions 
of syringes and millions of injections a 
year (Lurie et al., 1998). Given this fact, 
a ch i eving the recommendation of the 
one-time-only use of sterile syringes will 
require the coordination of all of these 
interventions so that every IDU who cannot 
or will not stop injecting will be able to 
In 1992, in response to a growing AIDS epidemic largely fueled by 
injection drug use, Connecticut modified its syringe laws to partially 
remove the legal barriers to pharmacy sales of syringes to IDUs. 
These changes included repealing the state prescription law to allow 
the purchase of up to 10 syringes without a prescription and modi­
fying the paraphernalia law to allow possession of up to 10 syringes 
without drug residue. 
An evaluation of the effect of changing Connecticut’s syringe laws 
revealed substantial increases in pharmacy sales of syringes in high 
injection drug use areas compared with areas of minimal injection 
drug use. Furthermore, a large number of IDUs reported that they 
had shifted their primary source of syringes from “the street” to 
“the pharmacy” and reported substantially reduced rates of syringe 
sharing after the new laws went into effect. 
Connecticut was able to successfully change the state syringe laws 
because of collaborative efforts between the state health department 
and the Department of Consumer Affairs, the state’s pharmacy regu­
latory body. Since 1992, there have been several collaborative efforts 
between the health department and pharmacy schools and organi­
zations to educate pharmacists about the changes in the law and the 
important role pharmacists can play in helping active IDUs obtain 
sterile syringes, and to encourage pharmacists to sell syringes to 
IDUs to help prevent transmission of HIV and other blood-borne 
pathogens. Other states, including Maine, Minnesota, and Washington, 
and very recently New York, Rhode Island, and New Hampshire, 
have used Connecticut’s experience as a model in their efforts to 
change laws and regulations restricting syringe sales. 
For more information: Groseclose et al., 1995; Valleroy et al., 1995. 
Changing Connecticut’s Syringe Laws Results in Increased Pharmacy Sales of Syringes to IDUs 
I N C R E A  S I N G  I D  U S  ’ A C C E S S T O  S T E  R I L E  S Y  R I  N G  E S  
1This includes the U.S. Public Health Service, the Institute of Medicine of the National Academy of Sciences, and the U.S. Prevention Services Task Force. 
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obtain and safely dispose of a sufficient 
number of sterile syringes to prevent the 
acquisition or transmission of blo o d -
b o rne pathogen s . 
In October 1999, the American Medical 
Association (AMA), the American 
Pharmaceutical Association (APhA), the 
Association of State and Territorial Health 
Officials (ASTHO), the National 
Association of Boards of Pharmacy 
(NABP), and the National Alliance of State 
and Territorial AIDS Directors (NASTAD) 
issued a joint statement urging state leaders 
in medicine, pharmac y, and public health 
to coordinate action to improve IDUs’ access 
to sterile syringes through pharmacy sales. 
They encouraged public health leaders to 
work to reduce legal and regulatory barriers 
that restrict access, expand availability of 
substance abuse treatment, and improve 
options for safe disposal of syringes 
(NASTAD, 1999). This statement builds 
on previous similar policies adopted by the 
APhA in 1999, the AMA and NASTAD 
in 1997, and ASTHO in 1995. 
I  N  T  E  RV E N T I O  N S I N 
T H E  C R  I M I N  A L  J U S T I C E  
S YS T E M 
Because injection drugs are illegal and drug 
users often resort to crime to support 
their drug addiction, IDUs are frequentl y 
arrested and imprisoned. A recent study 
on substance abuse and prisoners found 
that 81 percent of state inmates, 80 percent 
o f federal inmates, and 77 percent of l o c a l 
jail inmates had some type of drug abuse 
problem (Belenko, 1998). In 1996, an esti­
mated 250,000 state prison inmates had 
injected drugs, including 120,000 who had 
shared needles. Some 14,000 federal prison 
inmates had injected drugs, including 6,000 
who shared needles (Belenko, 1998). 
At the same time, inmates in prisons and 
jails have disproportionately high rates of 
HIV infection and other STDs, hepatitis, 
and other health problems. At the end of 
1996, 2.3 percent of male and 3.5 percent 
of female state and federal prison inmates 
were known to be infected with the HIV 
virus (Hammett et al., 1999). AIDS was 
Since the early 1990s, 400 jurisdictions have established drug courts 
with the idea that a different approach was needed. In the drug 
court model, the emphasis shifts from incarceration with occasional 
treatment, to treatment with (hopefully) only occasional incarcera­
tion. In most drug courts, substance abusing defendants who have 
been charged with nonviolent offenses are screened for eligibility. If 
eligible, the defendant will be offered a deferred prosecution or the 
opportunity to plead guilty to the charges with the promise that if he 
or she complies with court-mandated substance abuse treatment, 
the court will vacate the plea and dismiss the charges. If the defendant 
refuses treatment or fails to fully comply, the case will be prosecuted 
in the usual fashion. Defendants who choose treatment regularly 
report back to the court on their progress. A central component of 
the model is monitoring of drug use through frequent drug tests. The 
court uses escalating sanctions for drug use and rewards for 
progress to create incentives for the defendant’s recovery. 
The Brooklyn Treatment Court (BTC) has taken this model a few 
steps further. What it has tried to do is recognize the myriad needs 
and situations of substance abusing individuals who come into the 
criminal justice system. These men and women are not just addict­
ed to drugs. They have serious health problems as well as employ­
ment, housing, and social service needs. Women drug users have par­
ticularly complex situations; many have experienced physical or sex­
ual abuse and many have child custody issues. 
To accommodate these needs, the BTC has developed a broad 
network of on-site and off-site collaborative services. For example, 
the New York City Department of Health provides screening, testing, 
and education for HIV, TB, STDs, and pregnancy. The NYU Division 
of Nursing, in collaboration with the Brooklyn Hospital, provides 
primary health care services. The Human Resources Administration 
provides assistance with welfare, food stamps, and Medicaid. The 
BTC also provides acupuncture and short-term drug education and 
intervention through its Treatment Readiness Program. The BTC’s 
Project Connection has relationships with many local organizations, 
which helps clients return to their communities after treatment and 
promotes enhanced court-community relations. BTC also works 
with attorneys to advocate for women involved in child custody 
cases and collaborates with the Family Court and the Administration 
for Children’s Services to coordinate case management of women 
who are involved in the criminal justice and Family Court systems. 
In describing BTC’s approach and philosophy, Valerie Raine, BTC’s 
project director, says, “What we have tried to do here is bring as 
many services on site to the courthouse, so this population is not 
tossed around and referred out. You lose them the minute you refer 
them even across the street. A lot of what we’re trying to do is to 
integrate services. Because, especially in New York, services are so 
frequently fragmented in a way that doesn’t effectively meet the needs 
of the population. If you only meet one need and not the others, they 
are probably going to fail — to recidivate, to start using again.” 
The Brooklyn Treatment Court has been in operation since 1996. 
It has placed more than 1,525 people in treatment; more than 500 
are still in treatment and about 374 have “graduated.” It enjoys a 
high retention rate — about 60 percent. 
For more information: Brooklyn Treatment Court, Brooklyn, NY, 
718/243-2639. www.drugcourttech.org 
An Innovative Approach to Working with IDUs Within the Court System 
B R O O K L Y N T R E A T M E N T C O U R T 
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diagnosed in 0.5 percent of all inmates, 
a rate six times higher than that of the 
U.S. population. The high-risk behaviors 
responsible for the transmission of HIV 
and other blood-borne illnesses among 
inmates include high-risk sexual activity, 
sharing of needles and other drug injection 
equipment, and tattooing with impr ovised 
tools and materials (Calzavara et al., 1997; 
Dolan et al., 1996; Mahon, 1996; 
Struckman-Johnson et al., 1996). 
In light of the many IDUs who are in the 
criminal justice system and the large numbers 
of at-risk and infected individuals, this 
setting is a crucial venue for HIV- and 
h ep a t i t i s - related interventions and servi c e s . 
P roviding a range of health and preve n t i o n 
education interventions to inmates not only 
benefits them and their overall health but 
can also improve the health of the commu­
nities to which the vast majority of inmates 
return (Hammett et al., 1999). 
One of the most important types of inter­
ventions in prisons and jails is education 
and prevention efforts led by inmates them-
selves. These programs can be cost-effective 
and they have a credibility that programs 
led by outsiders cannot match. Peer-led 
programs also provide significant benefits 
to the peer educators themselves. Thro u g h 
p a rticipating in the pro grams, peer leaders 
can develop a positive focus in their lives, 
regain a sense of purpose and empowerment, 
and realize that they are able to influence 
others in ways they never believed possible 
(Hammett et al., 1999). 
Prevention services cur rently offered to 
inmates vary widely across state, county, 
and city jails and prisons. They include 
instructor-led and/or peer-led HIV 
education, pre- and post-test counseling , 
multi-session prevention counseling, the 
use of audiovisual materials, and the 
distribution of written materials. Most 
correctional systems provide HIV antibody 
testing, although testing policies differ 
widely. Few systems routinely screen inmates 
for STDs and only limited viral hepatitis 
prevention and treatment services are a vail­
able. A very few systems make condoms 
available to inmates. 
Currently, the number of AIDS cases are increasing faster among 
women than among men; heterosexual transmission is responsible 
for a growing percentage of these cases (38 percent of cases among 
women in 1997, as compared with 14 percent in 1987). Using a 
condom is the principal way to prevent heterosexual transmission, 
but its use is relatively low among the male partners of women at 
risk and is partner-specific, meaning that rates of use are lower 
with main partners than with other partners. 
The Prevention of HIV in Women and Infants Demonstration Projects 
(WIDP) was a 5-year, multi-site intervention designed to increase 
positive attitudes, behaviors, and community norms around condom 
use among women at risk of HIV infection. Using the stages of 
change theory, social learning theory, and the diffusion-of-innovation 
theory, the WIDP built on strategies previously applied in CDC’s 
AIDS Community Demonstration Projects to see whether a variety 
of HIV prevention activities focusing on the need to use condoms 
with main and other partners would increase the use of condoms. 
This 1991-1996 intervention took place in two public housing commu­
nities in Pittsburgh, a low-income neighborhood in West Philadelphia, 
and a group of inner-city neighborhoods in Portland, Oregon. 
Several other communities served as a comparison group. 
The centerpiece of the intervention consisted of a series of culturally 
specific role-model stories that were developed for use in each 
community. In each story, the main character moved from one 
stage in the stages-of-change theoretical model to the next. In each 
community, 33 to 48 stories, each of which were based on inter-
views with women in the community, were developed and widely 
distributed as fliers, brochures, posters, and newsletters. 
Several other activities supported these stories — a peer network of 
volunteers was formed to provide HIV prevention information and 
distribute the stories and condoms; small businesses and neighbor-
hood organizations and agencies were recruited as distribution sites 
for the stories and other HIV prevention information and as sites for 
workshops or other activities; each intervention city also hired four 
full-time outreach workers to provide individualized HIV prevention 
information and condoms to women in the community. 
The WIDP reached large numbers of at-risk women with HIV pre­
vention messages and it was well received by community leaders, 
businesses, and residents. It was also effective in encouraging 
women to talk with their main partners about using condoms and 
to begin using them. There was a similar, though not statistically 
significant, positive change in condom use with other partners as 
well. One final and notable finding was that intervention effects 
began to appear only after the WIDP had been active for 2 years. 
In combination with the other findings, this suggests that to be 
effective in low-income, higher-risk neighborhoods, interventions 
need to address the particular social, economic, and cultural issues 
that affect the target population and they need to be sustained 
over the long term. 
For more information: Lauby et al., 2000. 
Preventing the Sexual Transmission of HIV at the Community Level 
T H  E W O M E N A N D I N F A N T S D E M O  N S  T R  A T I O N  P R  O  J  E  C  T  S 
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New antiviral and combination therapies 
a re widely ava i l a ble in correctional fac i l i t i e s 
(Hammett et al., 1999). However, a number 
of factors, including the high cost of the 
regimens, inmate reluctance to seek testing 
and treatment, uneven clinical quality of 
services, and a lack of uniform treatment 
standards means that the availability of 
comprehensive care for infected inmates 
that involves case management, psychosocial 
treatment in conjunction with medical 
services, hospice care, substance abuse treat­
ment, and continuity of services between 
prison and the community, may be limited 
(Hammett et al., 1999). 
S  T  R  A T E G  I E S T O  P R  E V  E N T 
S  E  X  U A L T R  A N S  M I S  S I  O N 
S exual transmission of HIV and hep a t i t i s 
involving IDUs is an important factor in 
the continuing epidemics of these diseases 
in the U.S. In 1997, 11 percent of the new 
AIDS cases reported that year were among 
men and women whose sex partners were 
IDUs. Twe l ve percent were among male 
IDUs who also reported having sex with 
other men (CDC, 1998a). High-risk sexual 
b e h avior is also stro n gly associated with 
hepatitis B transmission (CDC, 1999). 
As described in Chapter 1, high-risk drug 
behaviors and high-risk sexual behaviors are 
often linked (Chu et al., 1998). For example, 
a large portion of IDUs use alcohol and/or 
c r a ck cocaine, wh i ch are often associated 
with increased frequencies of u n s a fe sex u a l 
behavior (Edlin et al., 1994) and number 
of sex partners (Corby et al., 1988). Some 
IDUs support their drug habits by exchang­
ing sex for money or drugs. Therefore, the 
extent to wh i ch IDUs ch a n ge their sex u a l 
behaviors in response to these diseases is 
critical. This is parti c u l a rly true in light of 
the fact that although IDUs will make large 
cha n ges in their injection risk behavior in 
response to concerns about AIDS, changes 
in sexual behavior are generally more modest 
(Des Jarlais, 1995; Friedman et al., 1993). 
In addition, it appears that IDUs are more 
likely to reduce sexual risk behaviors with 
casual sexual relationships than with their 
p r i m a ry sexual partners (CDC/AC D P, 
1999; Friedman et al., 1994; Friedman et 
al., 1999) or with sexual partners who do 
not inject illicit drugs (Friedman et al., 
1994; Friedman et al., 1999; Vanichseni et 
al., 1993). The reluctance to use condoms 
with main partners may be due to concerns 
that doing so violates the intimacy and trust 
d eveloped in the rel a t i o n s h i p. 
To date, distributing condoms and infor­
mation has commonly been used to help 
IDUs reduce their risk of sexual transmis­
sion. These materials are given out for free 
by most outre a ch wor kers, syringe excha n ge 
and other risk reduction programs, drug 
u s e r s ’ organizations, and some substance 
abuse treatment programs. One-on-one 
sexual risk reduction counseling and group 
interventions are also conducted by peers to 
address skills building and rehearsal, inter-
personal communication, problem-solving, 
situational analysis, and self-manage m e n t 
s t r a t egies. Strategies for female drug users 
and sexual partners of drug users have 
stressed the importance of building 
self-esteem, social supports, and sexual 
negotiation skills to encourage safer sex 
practices with partners. 
In developing strategies to reduce sexual 
transmission among IDUs, agencies and 
organizations should design them with 
s p e c i fic target groups (for example, in-
treatment versus out-of-treatment drug 
users) and specific goals (for example, pre-
venting acquisition of infection in unin­
fected IDUs and preventing transmission 
from infected IDUs to others) in mind. 
These strategies should also take into 
c o nsideration the determinants of sexual 
transmission, including the consistency of 
condom use, the presence of c o n c u rre n t 
STDs, the presence of concurrent injection 
drug and crack use, and the extent of sexual 
a c t ivity while high. Interventions designed 
for the sexual partners of IDUs are an 
important complementary element of 
ove rall strategies for reducing sex u a l 
t r a n smission among IDUs. 
H I  V  C O  U N S  E L I N G  
A N D T E S T I N G , P A RT N E R 
C O U N S E  L I N G  A N D  
R E F E R R  A L  S E RV  I  C  E  S , 
A N D  P R E V  E N T I O N  C A S E  
M A NA G E M E N T 
A compreh e n s ive appro a ch to preve n t i n g 
HIV and other blood-borne infections must 
include the opportunity for individuals to 
discover whether they are infected, and if 
they are, to help them inform their partners. 
If they are not infected but engage in high-
risk practices, the approach can also help 
IDUs begin or sustain behavior changes 
that will reduce their risk of acquiring or 
transmitting the infection. Three interrelated 
services are designed to meet these objectives: 
• HIV prevention counseling and testing; 
• partner counseling and referral services; and 
• prevention case management. 
Because these services are one-on-one and 
focused around the needs of the client, they 
have the potential to address the complex 
lives and circumstances of IDUs and more 
effectively influence their risk behaviors than 
can more limited and diffuse interventions. 
In addition, partner counseling and refe rr a l 
s e rvices and prevention case manage m e n t 
have the potential to provide the continuity 
of care that is so important to successful 
outcomes with IDUs. 
HIV counseling and testing (C&T) is a prevention 
intervention that provides HIV antibody 
testing and individual client-centered 
counseling. The counseling is focused on 
working with the client to identify his or 
her risk behaviors and then to develop an 
individualized risk reduction plan. It pro­
vides a private and confidential way for 
i n d ividuals to learn their HIV sero s t a t u s 
and get further help, whatever the results of 
the testing. A number of C&T approaches 
h ave been developed that are well suited to 
IDUs, including new, rapid HIV antibody 
tests that allow a person to be tested and 
receive their results in one visit (CDC, 
1998b), other new tests that allow testing 
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Despite the benefits of HIV testing, many people find it difficult to 
complete the process because of worries related to being possibly 
infected. Fear of partner retaliation; stigma; and future health, employ­
ment, and insurance problems all may prevent a person from discov­
ering his or her HIV infection status and disclosing it to others. 
IDUs face all these concerns and more. For example, the formality 
and perceived hostility of the health care system discourage IDUs 
from seeking testing. If they do get tested and find they are infected, 
finding and notifying partners may be difficult. Users may not know 
the names of their partners, know only street names, or lack adequate 
locating information. IDUs may be involved in illegal activities with 
partners and that makes them reluctant to reveal names. Given these 
realities, alternative models of providing counseling, testing, and 
partner notification services clearly are needed. 
One such model is the Outreach-Assisted Model of Partner 
Notification, an intervention of the Partners in Community Health 
Project, located on Chicago’s west side. This model expands tradi­
tional community outreach activities to include counseling and testing 
and partner notification. As part of their regular HIV/AIDS prevention 
and education responsibilities, trained indigenous outreach workers, 
who are already familiar figures in the community, talk to high-risk 
IDUs and their drug-using and sex partners about the benefits of 
voluntary HIV testing and partner notification. Confidential testing 
is offered at the intervention’s neighborhood storefront office. An 
HIV counselor provides pre- and post-test counseling to IDUs who 
come in for testing and works with infected individuals to determine 
how partners will be notified. If an infected IDU prefers to notify 
partners, the counselor will help prepare the person for these 
conversations. The IDU can also request that the outreach workers 
notify the partners. In this case, the counselor provides the locating 
and identifying information to the outreach workers; the outreach 
workers do not know the identity of the infected IDU. In the course 
of their regular duties, the outreach workers will locate partners 
and inform them of their possible exposure. 
This model has a number of benefits. For one thing, it offers 
community-based testing and counseling in a non-threatening and 
familiar environment by counselors and outreach workers who 
are trusted by and can communicate with those who live in the 
neighborhood. The outreach workers’ thorough knowledge of the 
neighborhood and its social networks makes it possible for more 
partners to be located and informed than if outsiders were to do it. 
In addition, because the outreach workers are in the neighborhood 
all the time and often talking with individuals, their presence does 
not automatically indicate that they are there for partner notification. 
Thus, it provides a measure of privacy and protection for partners 
who are notified. 
This model was tested on Chicago’s west side over the course 
of a year. During this time, the project recruited 386 IDUs. Almost 
all — 376 — returned to get their results and of these, 60 IDUs tested 
positive. All but one were willing to identify their partners to the HIV 
counselor. Rather than seeing notification by others as intrusive or 
unwanted, the majority — 82 percent — welcomed the help and 
asked that the outreach staff notify one or more partners. One con­
cern that is often expressed about HIV testing and partner notification 
is that notification can lead to violence, but fortunately this did not 
occur. Moreover, recruitment for testing continues successfully 
in neighborhoods where notification has occurred. These results 
suggest that expanding traditional community outreach to include 
counseling, testing, and partner notification is a viable HIV prevention 
strategy among IDUs. 
For more information: Levy and Fox, 1998. 
Helping HIV+ IDUs Tell Their Partners 
O  U  T  R  E  A C H - A S S I S T  E D  M O  D E L  O F P A  R T N E R  N O  T  I  F  I  C  A T  I  O  N 
In 1988, Austin’s Community AIDS Resources and Education (C.A.R.E.) 
Program first began offering services to IDUs and their drug-using and 
sex partners. The program offers four major types of services — 
counseling, testing, and partner notification; early intervention services; 
street and community outreach; and case management. In addition, 
C.A.R.E. offers TB screening, client advocacy, acu-detox (a 15-point 
acupuncture procedure for stress reduction and relapse prevention), 
and a Journey program (outpatient substance abuse treatment 
designed specifically for individuals living with HIV). 
C.A.R.E. provides free, no-appointment-needed confidential and 
anonymous counseling and testing at its clinic, at two Travis County 
correctional facilities, and at each of the publicly funded drug treatment 
programs. These services are the “entry point” for 85 percent of 
C.A.R.E.’s clients and they lead directly into the program’s other 
highly integrated services. C.A.R.E.’s work with jail inmates shows 
how this operates. Individuals who test positive for HIV while in jail 
are linked immediately with a C.A.R.E. community outreach worker. 
This worker stays in touch with the inmate, works with the cor­
rectional facility medical staff to ensure that the inmate receives 
medical care, and develops a case management plan for that person 
that includes provisions for continuity of care and HIV medications 
once the inmate is released. This worker also makes sure that the 
street outreach team is aware of any inmates who may be released 
from jail earlier than expected, which helps to ensure that the per-
son stays linked to the help he or she needs. C.A.R.E. also provides 
education and early intervention services to all inmates at correctional 
facilities. In 1999, the program educated 3,443 men and women in 
jails about HIV and STD prevention, safer sex practices, hepatitis C 
prevention, and harm reduction. 
C.A.R.E. receives its funding from a variety of sources, including the 
Texas Department of Health, the Texas Commission on Alcohol and 
Drug Abuse, Ryan White Title III, and the City of Austin. 
For more information: C.A.R.E., Austin, TX, 512/473-2273 x 108. 
Using C&T, PCRS, and Case Management as an Entry Point to Reach IDUs with Multiple Services 
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to be conducted with oral fluids rather 
than blood, and C&T settings designed to 
attract IDUs (CDC, 1989). 
Partner counseling and referral services (PCRS), 
formerly known as “ p a rtner notifi c a t i o n ,” 
begin when a person seeks HIV counseling 
and testing. If the test is positive for HIV, 
he or she is given the opportunity to receive 
PCRS at the earliest appropriate time. 
During the initial PCRS interview, the 
counselor will discuss with the client his or 
her responsibilities to sex and drug-use part­
ners and available options for notifying them 
o f the cli e n t ’s infection. The HIV-infected 
client is encouraged to voluntarily and 
confidentially disclose identifying, locating, 
and exposure information for each partner. 
The PCRS provider and client together 
formulate a plan and set priorities for 
n o t ifying partners. 
PCRS can have important benefits for 
individuals and communities in that they 
provide an opportunity for agencies to notify 
the part n e r s of infected individuals of their 
exposure to HIV and, potentially to viral 
hepatitis also. If already infected, the part­
ners’ prognosis can be improved through 
earlier diagnosis and treatment. If not 
infected, the partners can be assisted in 
changing their risk behavior, thus reducing 
the likelihood of acquiring the virus. From 
an epidemiological standpoint, following the 
chains of transmission from one infected 
individual to another within and across 
social networks permits public health inves­
tigators to chart the course of the epidemic 
and reach individuals at very high risk. 
Prevention case management (PCM) is an intensive, 
ongoing, client-centered HIV prevention 
activity designed to help individuals with 
complex lives and circumstances adopt and 
maintain HIV risk-reduction behaviors. It 
provides counseling, support, and help 
with services to address the relationship 
between HIV risk and other issues such 
as substance abuse, STDs, mental health 
problems, and social and cultural factors. 
Because it has the potential to address a 
wide range of social problems and risk 
behaviors, PCM is particularly suited for 
individuals like IDUs, who have or are likely 
to have difficulty initiating or sustaining 
practices that reduce or prevent HIV 
transmission and acquisition. PCM strives 
to develop an ongoing relationship with 
each client to provide an environment of 
trust and understanding within which 
prevention counseling can take place. 
C  O  O  R  D  I  N A T E D  S E RV  I  C  E  S 
F O R I D  U S L I  V I  N G W  I  T  H 
H I V / A I D S 
Because HIV disease is a chronic and com­
p l ex condition with fre q u e n t ly ch a n g i n g 
recommendations for treatment reg i m e n s , 
i n fected IDUs and their families req u i re 
close monitoring and a constantly cha n g i n g 
array of services in their homes, in the 
Working in upper Manhattan and the South Bronx, Health Bridge’s 
goal is to engage, link, and provide continuous care to HIV-infected 
men and women who have fallen through the cracks and are lost 
to follow-up within the traditional medical care delivery system. 
According to Debbie Indyk, director of Health Bridge, the key is to 
“identify strategic sites for reaching people who are not reached 
elsewhere, and engage them for whatever they need to be engaged 
for. We have lots of people with HIV who know their status but aren’t 
in care and lots of people who don’t even know their status. But we 
can reach these people if we think strategically about where to find 
them and establish linkages and infrastructure. Through outreach 
you find crises, but subsequently, you can also deal with stabilization 
and growth and development.” 
Working closely with the Mount Sinai Jack Martin Fund Clinic and 
other New York City programs for IDUs, Health Bridge staff provide 
holistic care to HIV-infected individuals who live in single room occu­
pancy (SRO) hotels. Through their “home visiting” approach and 
consistent presence in the hotels, Health Bridge staff are able to 
successfully engage clients and provide various services, including 
wound care, urgent care, entry into substance abuse treatment, and 
stage-based links to primary care. For those clients who are not ready 
to come into the clinic for care, a Health Bridge team consisting of a 
physician assistant, a part-time attending physician, a medical assistant, 
and two case managers provide care, support, and referrals to 
housing, case management, and other services at the SRO hotels. 
A fundamental element of the Health Bridge model is recognizing 
that disenfranchised individuals, such as HIV-infected IDUs, need 
support through various phases of engagement and retention in care. 
For example, clients may be willing to meet with Health Bridge staff 
but not come to the clinic for care; they may be ready to take AZT 
to reduce the risk of perinatal transmission, but not want to begin 
treatment for their own HIV disease. Through a model derived from 
the stages of change theory and using sustained outreach to reach 
individuals “where they are,” Health Bridge staff have built a safety 
net that can quickly identify people in crisis as well as those ready 
to be engaged in medical care, substance abuse treatment, and other 
care and support services. 
Since its inception in 1998, Health Bridge has reached well over 100 
people living in three SRO hotels. Over one-half are African American 
and about two-thirds are men. Recognizing the very great need in 
this part of New York, Health Bridge is actively trying to expand its 
capacity and linkages so that it can serve increased numbers of 
infected and at-risk individuals. 
For more information: Health Bridge, New York, NY 212/241-7863. 
Coordinated Services Improve the Health and Quality of Life of IDUs Living with HIV 
H  E  A  L T H B R I D G E  
35A  C  O M P R E H E N S I V E A P P RO A C H 
hospital or health care fac i l i t y, and in the 
community (Keenan, 1990). With appro­
priate and high-quality services and med­
ications, IDUs living with HIV can lead 
fulfilling, pro d u c t ive lives. 
Many IDUs continue to engage in high-risk 
b e h aviors after they learn they are infec t e d 
with HIV and, thus, place others at risk of 
HIV infection and themselves at risk for 
collateral health problems (CDC, 1996; 
HRSA, 1994; Kwi a t kowski et al., 1998; 
M e t s ch et al., 1998). When HIV-infected 
IDUs are actively engaged in health care, 
h oweve r, they can be fo l l owed to identify 
renewed high-risk sex or drug use and 
counseled about the effects of these behaviors 
on themselves and others. HIV-infected 
drug users who are in substance abuse 
t reatment and are rec e iving other health 
services are more likely to comply with 
HIV/AIDS drug treatment regimens and 
to reduce their sex and drug risk-related 
behaviors (Booth et al., 1999). 
As a marginalized population, IDUs can be 
less connected to the AIDS service delivery 
system than are other infected indivi d u a l s . 
Like non-IDU consumers, many IDUs do 
not know where to go to obtain services or 
what services are appropriate for different 
people at different stages of the disease. 
The service delivery system can be too 
complex and fragmented for them to navigate 
and often too remote geographically, socially, 
and culturally. Some pro grams pro h i b i t 
s e rvices to active drug users, whi ch pre s e n t s 
form i d a ble barriers for IDUs. Nega t ive 
attitudes by staff toward IDUs’ behaviors 
and life circumstances further exa c e r b a t e 
the situation. IDUs living with HIV/AIDS 
therefore need a full complement of services, 
delivered in a setting geared to attract IDUs 
from the community and retain them. Case 
m a n a gers and prevention case managers 
should offer risk reduction counseling and 
prevention services to these individuals and 
assist them with managing their chronic and 
acute health care needs, including taking 
Over the last 25 years, many community groups and coalitions have 
sprung up to respond to a variety of social problems in the U.S. 
Among the most powerful are coalitions that have worked to prevent 
alcohol and drug use among youth and to achieve drug-free com­
munities. These coalitions recognize that primary prevention is not 
so much a specific program – though those are important — but a 
process over time in which a variety of individuals and groups come 
together to study and then address the problem of drug abuse and 
related issues (Rusche, 1995). The results include strengthened 
organizations, more consistent policies, shared understanding of 
different viewpoints, changed social attitudes, and reduced drug 
use. Three good examples of community coalitions are: 
• Join Together founded in 1991, which supports community-
based efforts to reduce, prevent, and treat substance abuse across 
the nation. In 1996, Join Together broadened its scope to include 
gun violence prevention because of its belief that communities 
need to employ comprehensive strategies that respond to the 
harms related to substance abuse. Join Together produces reports, 
newsletters, and community action kits; supports a National 
Leadership Fellows program; sponsors public policy panels that 
examine and recommend changes in public policies and practices 
related to substance abuse; provides technical assistance designed 
to link people nationwide so that they can share information and 
resources; and conducts surveys to measure and define the 
community movement against substance abuse. Join Together is 
funded by a grant from The Robert Wood Johnson Foundation 
to the Boston University School of Public Health. 
• Community Anti-Drug Coalitions of American (CADCA), 
which creates and strengthens the capacity of new and existing 
coalitions to build safe, healthy, and drug-free communities. 
CADCA supports its 4,300 members with technical assistance 
and training, public policy initiatives, media strategies and marketing 
programs, and conferences and special events. The President’s 
Drug Advisory Council founded CADCA in 1992 and it is currently 
funded by The Robert Wood Johnson Foundation, the Knight 
Foundation, the Samuel Newhouse Foundation, the Annie E. 
Casey Foundation, and the K-Mart Corporation. 
• The Miami Coalition, which is a broadly-based community 
organization dedicated to reducing the problems of drug abuse, 
addiction, and directly related social issues. The Coalition serves 
as a convener and facilitator, bringing together diverse local insti­
tutions and organizations to determine how Miami-Dade County 
can collectively tackle this major criminal justice and health crisis. 
These groups have included law enforcement, medicine, education, 
business and commerce, the corporate workplace, the faith 
community, media, the banking industry, neighborhoods, youth, 
and families. The Coalition, which was founded by Dade County’s 
corporate and civic leadership in 1988, spent much of its founding 
year in a strategic planning process that resulted in a detailed 
analysis of community needs and resources related to the local 
drug problem and the formation of task forces assigned to address 
specific goals. This same process of analysis and response has 
been continued and refined each year since then. 
For more information: Join Together, Boston, MA, 617/437-1500, 
www.jointogether.org; Community Anti-Drug Coalitions of America, 
Alexandria, VA, 703/706-0560, www.cadca.org; The Miami Coalition, 
Coral Gables, FL, 305/284-6848, www.miamicoalition.org. More 
information on primary drug prevention can also be obtained from 
National Families in Action, a national drug education, prevention, 
and policy center founded in 1977. NFIA, Atlanta, GA, 404/248-9676, 
www.emory.edu/NFIA. 
Community Coalitions Are Powerful Agents for Change 
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anti-HIV medication and opport u n i s t i c 
i n fection pro p hylaxis as recommended. In 
addition, a full range of c o m p l e m e n t a ry, 
a ffo rd a ble, and accessible services should 
be made available, including substance abuse 
t reatment services, mental health servi c e s , 
and help with other basic needs such as 
food, housing, child care, and job training. 
P R I M A RY D R U G 
P R E V E N T I O N 
P r i m a ry drug prevention is a key strategy 
in a compre h e n s ive appro a ch to preve n t i n g 
blo o d - b o rne diseases among IDUs and 
reducing the spread to others. By helping 
individuals avoid drug use and drug injection 
altogether, these programs help eliminate the 
risk of i n j e c t i o n - related blo o d - b o rne virus 
transmission. Primary drug prevention pro-
grams, which are conducted in a variety of 
settings, including schools, families, and 
community-based organizations and through 
a variety of channels, such as the media, are 
largely aimed at youth to encourage them 
to avoid or delay the age of first use of 
alcohol, tobacco, marijuana, inhalants, and 
other drugs. Avoiding or delaying substance 
use can help youth prevent many problems 
associated with it, including truancy, aca­
demic failure, violence, thefts, motor vehicle 
crashes, homicides, injuries, suicides, and 
risky sexual behaviors (Ary et al., 1999; 
Berger and Levin, 1993; Cohen et al., 1997; 
Donovan et al., 1988; Farrell et al., 1992; 
Osgood et al., 1988). 
Next Steps for Communities 
This chapter has described the elements of 
a comprehensive approach to preventing the 
continued transmission of blo o d - b o rn e 
p a t h o gens among IDUs — eight strategi e s 
s u p p o rted by four essential principles. 
Health departments, community planning 
groups, community-based organ i z a t i o n s , 
health care and social service prov i d e r s , 
correctional facilities, policy makers, and 
others who work with IDUs are already 
carrying out many of these elements and 
working in creative ways to enhance the 
impact and reach of their efforts. 
At the same time, communities and com­
munity planning groups must deal with 
various realities that hamper their ability to 
bring individual efforts together into a truly 
comprehensive approach. These realities ca n 
include limited funding; restrictive laws and 
regulations; community opposition; a lack of 
trained staff; insufficient knowledge about 
the extent and nature of the community’s 
HIV, hepatitis, and injection drug use 
problems; a limited understanding of the 
community’s IDU populations; or polarized 
political and philosophical viewpoints 
among different organizations and providers. 
What can communities do to adjust their 
programs to overcome these realities? 
One important step that communities can 
take is to assess existing IDU-related pre­
vention needs, services, interventions, and 
b a rriers in light of the compre h e n s ive 
a p p ro a ch. The process of gathering this 
information does not have to involve a 
formal or lengthy needs assessment. Health 
d ep a rtment staff, service providers, and 
other interested local groups may already 
know much of this information or have 
ongoing working relationships with those 
who do. An important group to include in 
this process is IDUs themselves, for they 
have a unique perspective on the programs 
and services that are designed for them. 
Various reports have been written that also 
p rovide val u a ble back ground information 
and exp e rt consensus on effe c t ive interve n­
tions (NIH, 1997b). 
The fol l owing questions, organized aro u n d 
the four principles that guide the compre-
A number of primary drug prevention programs have been rigorously 
evaluated and are recommended. They fall into several categories: 
Universal programs, which are designed to reach a general 
population, such as all students in school — 
• Project Star (Pentz, 1995; Pentz et al., 1989) • Life Skills Training 
Program (Botvin et al., 1990; Botvin et al., 1995a; Botvin et al., 
1995b) • Adolescent Alcohol Prevention Trial (Donaldson et al., 
1994) • Seattle Social Development Project (Hawkins et al., 1992) 
• Adolescents Training and Learning to Avoid Steroids (Goldberg et 
al., 1996a; Goldberg et al., 1996b) • Project Family (Spoth, 1998) 
Selective programs, which target groups at risk or other subsets 
of the general population — 
• Strengthening Families Program (Kumpfer et al., 1996) 
• Focus on Families (Bry et al., 1998) 
Indicated programs, which target people who are already experi­
menting with drugs or who exhibit other risk-related behaviors — 
• Reconnecting Youth Program (Eggert et al., 1994; Eggert 
et al., 1995) 
Comprehensive programs, which include several interventions 
to reach the general population, groups at risk, or those already 
using drugs — 
• Adolescent Transitions Program (Dishion et al., 1998) 
For more information: Drug Strategies, 1999; NIDA, 1997. 
Learning What Makes A Program Effective 
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h e n s ive appro a ch, provide a framework for 
communities to generate the info rm a t i o n 
n e c e s s a ry for this assessment. 
E N S U R E  C O  O R D I N A T  I  O  N 
A N D  C O L  L A B O R A  T I O N 
Successfully reaching IDUs must involve 
a range of services and inter ventions. By 
definition, this means that different agencies, 
health and social services providers, health 
professionals, and others active in the 
community must work together to plan, 
carry out, manage, and monitor these efforts. 
Understanding ongoing efforts as well as 
the attitudes of key players toward coordi­
nation is an essential first step to building 
and maintaining effective collaborations. 
• What kinds of collaborations and coor­
dination curre n t ly exist among health 
d ep a rtment staff, community planning 
groups, community organizations, health 
and social services providers, corre c t i o n a l 
institutions, policy makers, and others 
who work with IDUs? 
• How might these collaborations be 
strengthened or new ones created? 
• What barriers to coordination and 
collaboration exist (e.g., philosophical 
d i ffe rences, organizational cha r a c t e r i s t i c s 
o f se rvice delivery systems, funding limi­
tations, legal or reg u l a t o ry barriers, lack 
o f communication)? 
• How might these barriers be overcome? 
• Do the various providers who work 
with IDUs (such as those in substance 
abuse treatment, public health, primary 
care, criminal justice, mental health, and 
social services) have opportunities to 
learn about each others’ issues and treat­
ment approaches and philosophies (e.g., 
through cross-training, site visits, formal 
or informal networking)? 
• Are IDUs involved in planning, 
designing, and car rying out services 
and interventions? 
E N  S U R E  C O  V  E  R  AG  E  , 
A C  C  E  S  S , A N D  Q U  A L I T Y  
Assessing services and programs from 
these three perspectives will provide valuable 
insight into the strengths of existing pro-
grams and services and the ways in which 
communities can build on these stre n g t h s . 
This exercise can also shed light on the 
barriers that individuals face as they attempt 
to obtain or participate in them and reveal 
gaps or weaknesses in programs that must 
be addressed. 
Coverage 
• Which of the eight key strategies are 
being carried out at present? At whom 
are they directed and how are they 
being implemented? 
• H ow many IDUs rec e ive whi ch serv i c e s 
and interventions (e.g., are there multiple 
outreach teams to cover the multiple 
neighborhoods that have injection drug 
use problems)? 
Access 
• Do IDUs know which prevention and 
c a re services and interventions are 
available to them? 
• Whe re are services and interve n t i o n s 
located (e.g., in a central location only, in 
multiple “storefront” locations across the 
community)? 
• What must IDUs do to obtain the services 
or interventions (e.g., get a referral, fill 
out forms, be on a waiting list, pay a fee, 
attend wee k ly sessions)? 
• What sort of barriers to these requir e­
ments exist and how can they be 
ameliorated? 
Quality 
• Do IDUs obtain services and medica­
tions in appropriate and recommended 
quantities (e.g., sufficient daily doses 
of methadone, psychosocial support 
services in tandem with substance 
abuse treatment)? 
• Are IDUs able to obtain services or 
participate in inter ventions for a suffi­
cient length of time (e.g., substance 
abuse treatment that extends beyond 
initial detoxification)? 
• Do the services obtained by IDUs com­
plement and reinforce each other (e.g., 
assistance with basic living needs provided 
along with substance abuse treatment, risk 
reduction counseling that covers sexual risk 
behaviors as well as drug use behaviors)? 
R E C O G N I Z E  A N D  
O V  E  RC O M E S T  I G M A  
In addition to collecting facts about services, 
programs, and interventions, it will be 
i m p o rtant for those participating in the 
assessment to examine the community’s atti­
tudes toward IDUs, including the attitudes 
of the general public, providers, and policy 
makers. An important element of this task 
will be to ex p l o re the community’s lega l , 
p o l i cy, and social env i ronment and how it 
affects the services and programs available 
to IDUs. For example, one community may 
have laws that penalize IDUs for carrying 
syringes and an outspoken citizen group that 
opposes syringe exch a n ge pro grams. The s e 
clearly are barriers to IDUs in their attempts 
to obtain sterile syringes and reduce trans-
mission risks. Another community may have 
laws allowing possession of a certain number 
of sterile syringes and a strong outreach 
init i a t ive with active peer-led education 
groups that are successful in helping IDUs 
cha n ge their behaviors. Learning about 
attitudes and environments and how they 
inhibit or encourage successful implemen­
tation of programs and services is critical. 
• How has the community responded to 
e ffo rts to establish and expand serv i c e s 
and programs for IDUs (e.g., substance 
a buse treatment pro grams or dro p - i n 
clinics for IDUs)? 
• Is the current concept of addiction as a 
brain disease known and understood by 
providers and the public? 
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• How have current attitudes about 
IDUs and resulting laws and policies 
helped or hindered prevention and 
treatment initiatives? 
• What are the current laws and regulations 
regarding sale, distribution, and possession 
o f sterile syringes? 
• Do syringe exch a n ge pro grams operate 
in the community? Under what legal and 
organizational auspices do they operate? 
T A  I  LO R  S E RV I C E S  
A N D  P  RO G R A M S  
To effectively plan and deliver prevention 
and care services, providers and organizations 
need to understand the particular character­
istics and risk profiles of the various IDU 
populations in the community. Generating 
this information will help providers to more 
effectively reach those at highest risk. 
• What are the demographic, language, 
and cultural characteristics of the IDUs 
in the community? 
• A re there specific groups at parti c u l a rly 
high risk of acquiring or transmitting 
blo o d - b o rne pathogens? 
• If so, what are their particular patterns of 
drug use and sexual behavior and how do 
these behaviors increase transmission risk? 
• What perc e n t a ge of the IDUs in the 
community are homeless? Mentally ill? 
Have other serious medical conditions? 
In what demographic, racial, or ethnic 
groups do they belong? 
• Do providers and service agencies have 
s u fficient staff who are culturally and 
l i n g u i s t i c a l ly capable of working with the 
c o m m u n i t y ’s IDU populations? 
• Are IDUs involved in planning, designing, 
and carrying out services or interventions? 
Because it may not be financially possible or 
organizationally feasible for a community 
to implement all eight of the strategies 
described in this chapter, agencies, organi­
zations, and providers will need to mak e 
choices and trade-offs. The information that 
emerges from answering the questions listed 
above can help communities, community 
planning groups, and health departments 
set priorities and plan programs because 
it will reveal gaps in services, needs for 
expanded or new services, and existing 
duplication of services and interventions. 
The assessment also can be useful in helping 
organizations match high priority needs 
with potential areas of collaboration as 
they plan activities and determine how 
funding, staff, and other resources are to 
be allocated. 
Conclusion 
Preventing Blood-Borne Infections Among 
Injection Drug Users: A Compre h e n s ive Approach 
has described a critically important public 
health problem now facing our nation. The 
intersecting epidemics of injection drug use 
and blood-borne pathogen infection present 
multiple, long-term challenges that demand 
immediate action. If this problem is to be 
effectively addressed, many different groups, 
o rganizations, and individuals must wor k 
singly and together to focus on both 
epidemics. We hope that the comprehensive 
a p p ro a ch presented here provides some 
new ways of thinking about the problem 
and about IDUs, some starting points 
for dialogue and collaboration, and some 
avenues for constru c t ive action. Injection 
drug users, their sex partners, and their 
children have much to gain from this 
new thinking, collaboration, and action. 
Neighborhoods, communities, and the 
nation also have a major stake in the 
success of these efforts, for reduced drug 
use and reduced HIV and viral hepatitis 
transmission have concrete and long-lasting 
benefits — safer streets, healthier people, 
and a more productive society. 
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This Appendix details the eight key strate­
gies of the compreh e n s ive appro a ch. Each 
section describes the service or intervention 
and explains its importance, provides findings 
from research and programs, and describes 
the issues and barriers facing providers and 
agencies in that area. 
Substance Abuse Treatment 
For injection drug users, substance abuse 
treatment is a powerful disease prevention 
s t r a t egy. Drug injectors who do not enter 
treatment are up to six times more likely to 
become infected with HIV than are injectors 
who enter and remain in treatment (NIDA, 
1999). Substance abuse treatment helps 
users reduce the number of drug injections 
and, thus, lower the risk of infection with 
HIV or hepatitis that might occur through 
unsafe injection practices, such as multi-
person use of syringes or sharing of drug 
injection equipment. It also prevents or 
reduces other harmful consequences of 
d rug use, such as abscesses or endocard i t i s . 
F u rt h e r, because drug use impedes rational 
decision making, which can lead to high-
risk behavi o r, substance abuse tre a t m e n t 
can reduce the risk of HIV and hep a t i t i s 
transmission through high-risk, unprotected 
s ex. Substance abuse treatment has bro a d e r 
social benefits as well because it can lead 
to reduced health care costs, reduced drug-
related crime and associated criminal justice 
costs, reduced interpersonal conflicts and 
d ru g - related injuries, and improved work-
place pro d u c t ivity (NIDA, 1999). 
Drug addiction is a complex and chronic, 
but tre a t a ble, illness characterized by com­
pulsive, uncontrollable drug craving, seeking, 
and use, even in the face of enormous neg­
ative consequences. Though nearly all addicts 
believe initially that they can stop on their 
own, most of their attempts result in failure 
to ach i eve long-term abstinence (NIDA , 
1999). Substance abuse treatment provides 
the medical, psychological, and behav i o r a l 
support necessary for an individual to stop 
using drugs and for their brain processes to 
ret u rn to pre-addiction functioning. Often, 
because of the complexity of the disease 
and the fre q u e n cy of relapse to drug use, 
t reatment re q u i res multiple episodes over a 
long period of time. Successful treatment 
can have a major impact on many areas of a 
person’s life, helping him or her improve 
family life, employment and health, and 
decrease involvement with crime. 
Treatment services differ in their approaches 
and components. They are generally divided 
into five major kinds of programs (AED, 
1997; NIDA, 1999): 
• detoxification; 
• inpatient; 
• therapeutic communities; 
• outpatient; and 
• methadone maintenance. 
In addition, many drug users also partici­
pate in self-help or 12-Step pro gr a m s , 
s u ch as Narcotics Anonymous, Cocaine 
Anonymous, or Smart Rec ove ry. By provi d­
ing a crucial support network of peers 
who are going through similar experiences, 
these programs can reinforce and extend 
more formal types of treatment services 
(NIDA, 1999). 
In the last decade, the overall effec t ive n e s s 
of substance abuse treatment has been 
demonstrated (Gerstein and Harwo o d , 
1990; Hubbard et al., 1989; NIDA, 1999; 
NIH, 1997; Pickens et al., 1991). A number 
of studies have shown that persons who 
receive treatment reduce their alcohol and 
drug use and improve their legal, employ­
ment, family, social, psychiatric, and medical 
situations (Anglin et al., 1989; Ball et al., 
1988; DeLeon, 1984; Hubbard et al., 1989; 
McLellan et al., 1994; Moos, 1974; Moos 
et al., 1990; Simpson and Savage, 1980). 
Overall, treatment for addiction is as 
successful as treatment of other chronic 
conditions, such as asthma, diabetes, and 
hypertension (NIDA, 1999; O’Brien and 
McLellan, 1996). Studies of m e t h a d o n e 
maintenance treatment have shown that 
participation in treatment is associated 
with lower HIV risk behaviors as well as 
l ower rates of HIV sero p revalence and 
seroincidence (Abdul-Quader et al., 1987; 
Avins et al., 1997; Ball et al., 1988; Blix 
and Gronbladh, 1991; Booth et al., 1996; 
Brown et al., 1988; Caplehorn and Ross, 
1995; CDC, 1984; Friedman et al., 1995; 
Meandzija et al., 1994; Metzger et al., 
1998; Metzger et al., 1993; Moss et al., 
1994; Novick et al., 1990; Orr et al., 
1996; Serpelloni et al., 1994; Shoptaw et 
al., 1997; Williams et al., 1992). 
Methadone is the medication most frequently 
provided to IDUs in substance abuse treat­
ment because it is the most widely available 
and because many IDUs inject heroin or a 
combination of heroin and cocaine (Battjes 
et al., 1991; Hahn et al., 1989; Haverkos, 
1998; NIH, 1997). Methadone red u c e s 
p a t i e n t s ’c r avings for heroin and blocks its 
e ffects, thereby enabling patients to red u c e 
h e roin use and live more pro d u c t ive lives . 
The effec t iveness of methadone tre a t m e n t 
is dependent on many factors, incl u d i n g 
adequate dosing, a sufficient duration and 
continuity of treatment, and the presence of 
complementary services, such as psychosocial 
and medical support, counseling, and voca­
tional training (NIH, 1997). Some patients 
s t ay on methadone indefi n i t e ly; others 
progress to abstinence with decreasing doses 
of methadone. Several other medications can 
be used to treat opiate addiction, including 
levo-alpha-acetylmethadol (LAAM) and 
naltrexone, but they have not been in exis­
tence as long as methadone and are not as 
w i d e ly used (NIDA, 1999; NIH, 1997). 
Substance abuse treatment makes financial 
sense as well. Every $1 invested in substance 
abuse treatment reduces the costs of drug-
related crime, criminal justice costs, and 
theft by $4 to $7. The average cost of 1 
year of methadone maintenance treatment 
is $4,700 per person. The cost of 1 year 
of imprisonment per person is about 
$18,400. When health care savings are 
added in, total savings can exceed costs by 
a ratio of 12 to 1 (NIDA, 1999). 
A3A P P E N D I X A 
Another compelling reason for provi d i n g 
substance abuse treatment is that these 
programs are a good way to reach drug 
users and their partners with other HIV 
p revention messages and interve n t i o n s . 
Participation in these interventions offered 
in the treatment setting is associated with 
reduced drug- and sex-related risk behaviors 
(Calsyn et al., 1992; El-Bassel and Schilling, 
1992; Malow et al., 1994; McCusker et al., 
1992). One of the most consistent findings 
of both behavioral and serologic studies is 
that early entry and longer duration of treat­
ment are associated with protection from 
HIV infection (Metzger et al., 1998). 
For example, twenty years of data collected 
in the Bronx, New York, show that longer 
time in treatment is associated with a lower 
likelihood of HIV infection (Hartel and 
Schoenbaum, 1998). The strongest protective 
associations against HIV in this popula­
tion were early entry and continuous stay in 
methadone treatment plus higher methadone 
doses (80 milligrams or higher per day). 
Despite clear evidence regarding the utility 
and effec t iveness of substance abuse tre a t­
ment in helping users reduce or eliminate 
their drug use and helping them address 
a host of other problems, significant bar­
riers remain for IDUs to fully obtain 
these services. For example, data from the 
Substance Abuse and Mental Health 
Services Administration’s (SAMHSA) 
National Household Survey on Drug 
Abuse (NHSDA) show that in 1996, 
more than 5.3 million people with severe 
substance abuse problems needed treatment 
s e rvices. However, only 37 percent rec e ive d 
such treatment (Epstein and Gfroerer, 1998). 
Less than 20 percent of o p i a t e - d ep e n d e n t 
individuals are in methadone maintenance 
(NIH, 1997). Many IDUs cannot afford 
p r iva t e ly-funded services, and limitations 
in funding restrict the number of publicly 
funded slots. Even for those IDUs who are 
in treatment, the processes and pro c e d u re s 
associated with participation may be daunt­
ing. For example, waiting lists, delays in 
admissions and lengthy and cumbersome 
intake processes can discourage drug users 
from seeking treatment. Many communities 
s t re n u o u s ly resist the introduction of drug 
treatment facilities in their neighborhoods, 
and this limits the availability of treatment 
for many IDUs. State and federal funding of 
substance abuse treatment is insufficient to 
make treatment avai l a ble to all who need it. 
The effec t iveness of substance abuse tre a t­
ment depends on many factors, including its 
goals, the length of time treatment lasts, the 
doses of medications that may be prescribed, 
links to other services, and the characteristics 
of the user. Limitations in all of these areas 
m ay pose significant barriers. For exa m p l e , 
an IDU in a methadone maintenance pro-
gram may rec e ive adequate medication but 
not the behavioral counseling or the case 
m a n a gement and referral to other medical, 
psychological, and social services that are 
necessary for full and effective treatment. Or, 
he or she may receive lower methadone doses, 
which compared to doses of 80-100 mil­
ligrams, are less effective (Strain et al., 1999). 
Community Outreach 
Many IDUs do not participate in conven­
tional service systems that provide treatment 
and prevention services or medical, mental 
health, or social welfare services. This is due 
partly to funding and capacity limitations 
on the part of the service systems and partly 
to barriers that limit IDUs’ ability to use 
these systems. IDUs’ own attitudes and life 
circumstances also determine the extent to 
which they use or are reached by conven­
tional service systems. The overwhelming 
priorities of obtaining and using the drugs 
they are addicted to often preven t ID U s 
from seeking services, such as HIV preven­
tion, that may seem abstract or unimportant 
in comparison. In addition, the stigma and 
n ega t ive attitudes of s e rvice providers that 
are experienced by many IDUs leads them 
to mistrust government agencies and con­
ventional service systems and be reluctant to 
obtain services. Thus, to effectively provide 
prevention, treatment, and care services to 
IDUs, it is essential to bring the services 
to IDUs in the settings in which they live 
and socialize. 
Community outreach programs can make a 
val u a ble contribution to HIV preven t i o n 
(Wiebel et al., 1996). These practical and 
rel a t ive ly low-cost appro a ches are designed 
to reach IDUs at high risk of HIV and 
other blo o d - b o rn infections who are not 
in conventional service systems. They can 
be the first step in developing an ongoing 
relationship with these drug users and ulti­
mately linking them with services. For those 
users who are linked to conventional serv­
ice systems, outreach is an important way 
to reinforce educational and preve n t i o n 
m e s s a ges and strategies. Because they are 
an individual- and community-level inter­
vention, they help create a community 
culture of risk reduction among drug users, 
their families, friends, and neighbors. This 
culture of risk reduction also helps to sup-
port recovering drug users returning from 
substance abuse treatment and those return­
ing to the community from prison or jail. 
Community outreach is typically carried out 
in areas where drug users congregate — on 
the street, in shooting galleries and crack 
houses, and in housing projects, emergency 
rooms, laundromats, and parks. The mes­
sages and services are delivered by people 
with whom the drug user is familiar and 
likely to trust, such as peers who live in the 
c o m m u n i t y. This personal contact betwe e n 
outreach worker and IDU is an important 
reason why community outreach can be 
influential in helping IDUs. Many commu­
nity outreach wor kers are rec overing IDUs 
t h e m s e l ves. A typical outrea ch encounter 
i nvo l ves fa c e - t o - face communication that is 
intended to assist IDUs in changing their 
high-risk drug use and sexual behaviors. 
O u t re a ch wor kers may give out literature 
on drug use, substance abuse treatment, 
and HIV and how to prevent it, and provide 
information on available services. They a l s o 
d i s t r i bute condoms and ble a ch kits for 
decontaminating injection equipment and 
help IDUs obtain services in the community, 
A4 A P P E N D I X A 
such as housing assistance or mental health 
t reatment. Outre a ch also invol ves wor k i n g 
with drug users’ social and drug-using 
networks to extend and reinforce prevention 
m e s s a ges and build risk reduction skills. 
Outreach can also be used to recruit drug 
users to other activities, such as confidential 
risk assessments, HIV testing and counsel­
ing, and substance abuse treatment, and to 
distribute sharps containers for safe disposal 
o f used syringe s . 
O u t re a ch interventions were one of t h e 
earliest HIV prevention strategies designed 
to reach high-risk IDUs. Results of a num­
ber o f studies and pro grams have shown 
that this approach, in fact, works. It can be 
used to identify and contact IDUs and it 
creates an atmosphere in which IDUs are 
c o m fo rt a ble talking about HIV preve n t i o n . 
Community outre a ch is effec t ive in get t i n g 
IDUs to accept HIV-prevention literature, 
risk reduction materials, and referral serv­
ices, and outreach workers have played an 
important role in providing condoms to 
high-risk populations (Anderson et al., 
1996; Anderson et al., 1998). Follow-up 
assessments have shown that IDUs have 
regularly reported reductions in five major 
risk behaviors after participating in com­
munity outreach interventions (APA, 1996; 
CDC/ACDP, 1999; Coyle et al., 1998; 
Semaan et al., 1998; Sumartojo et al., 
1997). These incl u d e : 
• stopping drug injection; 
• reducing fre q u e n cy of i n j e c t i o n ; 
• reducing multi-person reuse of s y r i n ges; 
• reducing multi-person reuse of o t h e r 
equipment, such as cookers, cotton, and 
rinse wat e r; and 
• reducing crack use. 
They also have reported increases in 
three protective behaviors (APA, 1996; 
CDC/ACDP, 1999; Coyle et al., 1998; 
Semaan et al., 1998; Sumartojo et al., 1996): 
• needle disinfe c t i o n ; 
• entry into substance abuse treatment; and 
• condom use. 
A number of researchers have demonstrated 
the effectiveness of peer-delivered inter­
ventions conducted by community health 
outreach workers who were formerly active 
drug users, and peer-d r iven interve n t i o n s , 
whi ch are conducted by out-of-tre a t m e n t 
IDUs who are provided with guidance 
and stru c t u red incentives and play an active 
role in their social networks in HIV pre­
vention. Overall, these studies suggest 
that peers, whether former or active drug 
users, can be ef fective in reaching large and 
diverse communities of out-of-treatment 
users (Broadhead et al., 1998; Carlson and 
Needle, 1989; Cottler et al., 1998; Friedman 
et al., 1993; Jose et al., 1996; Latkin et al., 
1998; Neaigus, 1998; Sufian et al., 1991). 
They also suggest that peers are ef fective 
role models for promoting reductions in 
d ru g - related HIV risk behaviors with active 
drug users, but less effective in changing 
sexual risk behaviors (Coyle et al., 1998). 
Although community outre a ch is cl e a rly an 
important element in any overall strategy to 
reach IDUs, it has its challenges. By its very 
n a t u re, it is cli e n t - c e n t e red and less formal 
and struc t u red and therefore can be more 
difficult to supervise and monitor. Outreach 
work is demanding and workers must con-
tend with fre q u e n t ly difficult conditions, 
i n cluding unsafe neighborhoods, incl e m e n t 
wea t h e r, and, for those wor kers who have 
had drug problems, situations that may 
challenge their own recovery. Outreach staff 
need reinforcement, training, and support 
to avoid burnout and the risk of relapse to 
drug use and to help them understand the 
l i festyles or cultures of p a rticular IDUs 
(AED, 1999). Another issue in community 
outreach strategies that use peers is defining 
who a “ p e e r ” re a l ly is. Some current IDUs 
may not consider a former user to be their 
p e e r. Demographic diffe rences between the 
IDUs and the peer outreach workers may 
a ffect how messages are rec e ived. The s e 
differences may also make it more difficult 
for the workers to establish trusting rela­
tionships with IDUs. 
Environmental and structural factors also 
may hamper the effectiveness of community 
outreach efforts. For example, community 
outreach can face active opposition in the 
community from powerful individuals such 
as neighborhood political leaders or local 
drug dealers. The limited capacity of many 
substance abuse treatment programs means 
that IDUs may not be able to enter treat­
ment even if they are referred by an outreach 
worker. Further, existing laws and regula­
tions, such as restrictions on the sale of 
sterile syringes in pharmacies or prohibitions 
against syringe exchange programs or criminal 
penalties for possession of syringes, make 
it hard for outre a ch wor kers to disseminate 
crucial prevention messages, such as the need 
to consistently use sterile syringes and make 
it hard for IDUs to follow such advice. 
F i n a l ly, the re l a t ive ly unstru c t u red and 
u n s t a n d a rdized nature of community 
outreach work may make it difficult for 
p roviders to identify consistently effec t ive 
strategies. It also may be hard to measure 
the outreach process and control for extra­
neous factors, and attrition can skew research 
results. Cohort effects may promote socially 
desirable responses among those who return 
for follow-up, making self-reports less 
valid measures of i n t e rvention effec t s . 
Interventions to Increase IDUs’ 
Access to Sterile Syringes 
Clearly, the best way for injecting drug 
users to avoid the problems of drug use 
and blood-borne infection is to stop 
injecting and enter substance abuse treat­
ment. However, many drug users either 
cannot get into substance abuse treatment 
programs or will not stop injecting drugs. 
Even those injectors who stop drug use 
through substance abuse treatment may 
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relapse to injecting drugs. Given these 
realities, several governmental bodies and 
i n s t i t u t i o n s1 have recommended consistent, 
one-time-only use of sterile syringes to 
prepare and inject drugs as a central strategy 
in a comprehensive effort to reduce the 
transmission of HIV and other blood-
borne pathogens among those individuals 
who continue to inject drugs. 
Currently, IDUs obtain syringes in 
several ways: 
• t h rough illegal or “black marke t ”s o u rc e s , 
such as street drug dealers (individuals who 
sell drugs and syringes to IDUs), needle 
dealers (individuals who sell syringes to 
IDUs), “shooting galleries,” or friends, 
injection partners, or diabetics — these 
s y r i n ges may have been used and contam­
inated with blood; some dealers “reseal” 
used syringes in their packaging to make 
them appear to be new (Des Jarlais et al., 
1985; Gleg h o rn et al., 1995; Gro s e cl o s e 
et al., 1995); 
• by purchase from pharm a c i es — th i s 
ensures that the syringes are sterile; and 
• t h rough syringe excha n ge programs 
( S E P s)— this ensures that the syringe s 
a re sterile. 
Most states have legal and regulatory 
restrictions on the sale and distribution 
of sterile syringes: 47 states have drug para­
phernalia statutes, 8 states have syringe 
prescription statutes, and 23 states have 
pharmacy regulations or practice guidelines. 
These restrictions present a significant 
barrier to the sale of sterile syringes to 
IDUs by pharmacists, the prescription of 
sterile syringes to IDUs by physicians, the 
operation of syringe exchange programs, 
the safe disposal of blood-contaminated 
used syringes, and ultimately, to the efforts 
by IDUs to reduce their injection-related 
risks of acquiring or transmitting blood-
borne pathogens (Gostin, 1998). 
In essence, IDUs are in a Catch-22 situation. 
They are advised to enter substance abuse 
treatment and, if they continue to inject, to 
use only sterile syringes, but major structural 
and environmental factors—insufficient sub-
stance abuse treatment capacity and syringe 
laws that make it illegal to obtain or possess 
sterile injection equipment—effectively 
reduce IDUs’ ability to carry out this advice. 
Three types of i n t e rventions are now being 
pursued in the U.S. to ameliorate the second 
of these two structural barriers and increase 
IDUs’ access to sterile syringes. Several states 
and municipalities are engaged in policy efforts 
to change existing syringe laws and regulations to 
allow increased pharmacy sales of syringes, 
remove criminal penalties for syringe pos­
session, and include language in laws stating 
that preventing HIV and other blood-borne 
pathogens is a “legitimate medical purpose” 
for prescribing sterile syringes. Many juris­
dictions are carrying out efforts to sustain 
and expand syringe exchange programs, which 
provide IDUs with free sterile syringes and a 
way to safely dispose of blood-contaminated 
used syringes. Initiatives with pharmacists also 
are underway to provide education about 
the role of sterile syringes in reducing the 
transmission of blood-borne pathogens, 
address pharmacist concerns and questions 
about syringe sales and disposal, and encour­
age changes in pharmacy policy and practice. 
All of these interventions are closely 
interrelated and the success of one partly 
depends on the success of the others. The 
effectiveness of interventions that encourage 
pharmacists to sell syringes to IDUs, for 
example, is enhanced when laws and regu­
lations that limit pharm a cy sale of s y r i n ge s 
and that prohibit possession of syringes 
are repealed. Similarly, for IDUs to openly 
participate in syringe exchange programs, 
the public health implications of laws that 
m a ke possession of s y r i n ges a crime should 
be reviewed. An individual IDU makes 
approximately 1,000 injections each year, 
which even in a moderate-size city adds up 
to millions of injections a year (Lurie et 
al., 1998). Therefore, achieving the recom­
mendation of the one-time-only use of 
sterile syringes will require the coordination 
of all of these interventions so that IDUs 
who continue to inject will be able to obtain 
and safely dispose of a sufficient number of 
sterile syringes to prevent the acquisition or 
transmission of blood-borne pathogens. 
The magnitude of this challenge to adequate 
coverage is illustrated by Montreal, a city 
that has made major strides in ensuring that 
IDUs can obtain sterile syringes (it does not 
p rohibit the sales of s y r i n ges without pre­
scription, it encourages pharmacy sales, 
and it has active and well-supported syringe 
exchange programs). An analysis estimated 
that in 1994 Montreal’s 10,000 IDUs 
injected 10,683,000 times (Remis et al., 
1998). About 338,000 sterile syringes 
were distributed through pharmacy sales 
and syringe exchange programs. This 
meant that only 3.2 percent of the need 
for sterile syringes was being met. Based on 
these results, the Montreal Regional Public 
Health Department removed the quota of 
15 syringes that could be exchanged at one 
time and drafted an action plan to expand 
the number of sites for syringe distribution 
t h rough community organizations, health 
centers, and pharmacies, with a target of 
more than 1 million syringes distributed 
by 1997. In 1996, 500,000 syringes were 
d i stributed. Though this represented signifi­
cant progress, the number distributed in 
1996 was still far short of the number of 
sterile syringes needed. 
In October 1999, the American 
Medical Association (AMA), the American 
P h a rmaceutical Association (APhA), 
the Association of State and Terr i t o r i a l 
Health Officials (ASTHO), the National 
Association of Boards of Pharmacy (NABP), 
1This includes the U.S. Public Health Service, the Institute of Medicine of the National Academy of Sciences, and the U.S. Prevention Services Task Force. 
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and the National Alliance of State and 
Territorial AIDS Directors (NASTAD) 
issued a joint letter urging state leaders in 
medicine, pharmac y, and public health to 
coordinate action to improve IDUs’ access 
to sterile syringes through pharmacy sales. 
They encouraged public health leaders to 
work to reduce state-level legal and regula­
tory barriers that restrict access, expand 
availability of substance abuse treatment, 
and improve options for safe disposal of 
syringes (NASTAD, 1999). This statement 
builds on previous similar policies adopted 
by the APhA in 1999, the AMA and 
NASTAD in 1997, and ASTHO in 1995. 
P O L I C Y  E  F F O  R T S  T O 
I N C R E  A S  E I D U S ’  A C  C  E  S  S 
T O  S T E R  I L E  S Y R I N G E S  
As described above, most states prohibit 
IDUs from possessing or carrying sterile 
syringes and many states bar their sale 
without a valid medical prescription. The 
result of these restrictions is that even if 
IDUs are legally able to acquire sterile 
syringes, they often do not want to carry 
and are unable to safely dispose of them 
because of the potential for arrest and 
criminal prosecution (Bluthenthal, Kral et 
al., 1999; Bluthenthal, Lorvick et al., 1999; 
Koester, 1994; Springer et al., 1999). This 
environment serves to increase transmission 
risk because IDUs who are concerned about 
being arrested for obtaining or car rying 
syringes are more likely than other IDUs 
to share syringes and injection supplies 
(Bluthenthal, Kral et al., 1999; Bluthenthal, 
Lorvick et al., 1999). 
Although widespread negative opinions 
of drug users and a reluctance to appear 
s u p p o rt ive of d rug use make it difficult to 
cha n ge syringe laws and regulations, sever a l 
states have done so. In 1992, Connecticut 
partially repealed its laws and regulations 
that limited pharmacy sales of syringes 
and made possession of syringes a crime. 
This allowed pharmacy sales of up to 10 
syringes without a prescription and legalized 
the possession of up to 10 clean syringes 
(Groseclose et al., 1995; Valleroy et al., 
1995). In 1993, Maine changed its laws 
so as to allow anyone aged 18 or older to 
purchase from a pharmacy any quantity of 
syringes (Beckett et al., 1998). In January 
1997, the Maine state legislature adopted 
rules to permit legal syringe exchange and 
to remove the criminal penalties for pos­
sessing 10 or fewer syringes. Other states 
have tried other approaches. For example, 
some state legislatures have given health 
departments the power to establish SEPs 
and to exempt them from drug parapher­
nalia and syringe prescription statutes. Five 
states (Hawaii, Maryland, Massachusetts, 
New York, and Rhode Island) and the 
District of Columbia have carved out 
an exemption in their drug paraphernalia 
laws for SEP staff and participants. Three 
states have specifically exempted SEPs 
from their prescription laws (Connecticut, 
Massachusetts, Rhode Island). In California, 
legislation went into effect in January 2000 
that permits the use of public funds for 
SEPs after a local agency has declared a 
health emergency for hepatitis C and AIDS. 
However, the city or county must renew the 
state of emergency every 14 days to keep the 
new law in effect. New legislation exempts 
cities and public employees from criminal 
prosecution if the SEP is operating under a 
declared public health emergency. 
Results from states that have changed their 
laws have been positive. For example, after 
Connecticut part i a l ly repealed its syringe 
laws, most pharmacies in the state (about 
87 percent) began to sell nonpre s c r i p t i o n 
syringes, though in limited numbers (Valleroy 
et al., 1995; Wright-De Agüero et al., 1998). 
As a result, fewer IDUs bought syringes on 
the street, syringe sharing decreased, and 
police rep o rted fewer needlestick injuries 
(Groseclose et al., 1995). 
Those in Maine who worked for success­
ful policy changes to improve access to 
sterile syringes attribute their success to 
the following actions, which were focused on 
building an environment of collaboration 
and a sense of common purpose among the 
various stakeholders (Beckett et al., 1998): 
• surveying pharmacies to identify current 
syringe sale policies, practices and barriers; 
• building coalitions to work for legislative 
action to modify or repeal criminal penal-
ties for possession of s y r i n ges; and 
• conducting conferences and other aware­
ness-building events among a wide variety 
of interest groups (pharmacists, substance 
abuse specialists, law enforcement officers, 
legislators, HIV prevention providers, 
drug users, and advocates of drug users) 
to discuss relevant issues and necessar y 
action steps. 
S Y R I N G E E X C H A N G E 
P RO G R A M S 
Syringe exchange programs (SEPs) are a 
second important strategy for increasing 
IDUs’ access to sterile syringes. SEPs 
allow IDUs to exchange their used needles 
and syringes for new, sterile injection equip­
ment at no cost. By collecting used injection 
equipment, SEPs remove blood-contaminated 
syringes from circulation and allow for safe 
disposal of equipment that may have been 
contaminated with HIV or hepatitis. SEPs 
were first introduced in the United States 
in the late 1980s. By 1997, there were 123 
programs in 33 states, the District of 
Columbia, Puerto Rico and Guam (CDC, 
1998a). These programs exchanged over 
17 million syringes in 1997, but two-
thirds of these were exchanged by the 10 
largest programs. One-half of the SEPs 
distribute fewer than 50,000 per program 
per year. SEPs in the U.S. are able to cover 
only a small percentage of the need for 
sterile syringes. 
IDUs are drawn to SEPs because they get 
f ree syringes. This “ p a s s ive outreach” st r a t­
egy has an added benefit because it gives 
programs an efficient way to reach IDUs 
with additional services and interve n t i o n s . 
These services include HIV/AIDS educa­
tion and counseling; condom distribution 
to prevent sexual transmission of HIV; 
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primary medical services; referrals to sub-
stance abuse treatment and other medical 
and social services; bleach distribution for 
disinfecting injection equipment; distribution 
of alcohol swabs to help prevent abscesses 
and other bacterial infections; on-site HIV 
testing and counseling; crisis intervention; 
and screening for tuberculosis, hepatitis B, 
hepatitis C, and other infections. SEPs vary 
widely in their locations (fixed versus rov­
ing sites), hours of operation, the number 
of syringes allowed for exchange, and 
other policies. 
Because of the controversy associated with 
SEPs, a great deal of research has been con­
ducted on their effects and outcomes. This 
work has shown that SEPs have significant 
positive effects on preventing adverse health 
consequences associated with injection drug 
use and that SEPs do not increase drug use 
or promote the initiation of injection drug 
use (Des Jarlais et al., 1996; Hagan et al., 
1995; Heimer, 1998; Heimer et al., 1994; 
Kaplan and Heimer, 1992; Lurie et al., 
1993; Vlahov and Junge, 1998; Vlahov et al., 
1997; Watters et al., 1994). Other benefits 
of SEPs are that they can facilitate the entry 
o f IDUs into substance abuse tre a t m e n t 
and other services that can reduce the 
risk of HIV infection (Heimer, 1998). 
SEPs have also been shown to successfully 
engage IDUs as peer outreach workers 
to create new exchangers and increase the 
number of syringes exchanged (Whiticar 
and Smetka, 1999). 
Results showing higher HIV incidence 
among IDUs using SEPs in Vancouver 
(Strathdee et al., 1997) and Montreal 
(Bruneau et al., 1997) have been interpreted 
by some to suggest that SEPs may contribute 
to the spread of HIV. However, investigators 
in these cities have shown that SEPs are not 
c a u s a l ly associated with HIV transmission 
and that this association was confo u n d e d 
by the fact that SEPs attract higher-risk 
users (Archibald et al., 1996; Schechter et 
al., 1999). th Canadian cities have con­
tinued to expand their SEP services. 
Despite their success, syringe excha n ge 
programs face continuing cha l l e n ges. The s e 
i n clude legal and reg u l a t o ry res t r i c t i o n s , 
precarious funding, and, in some locations, 
community opposition. While some com­
munities welcome SEPs, others stren u o u s ly 
reject them. This opposition comes from 
local leaders, the general public, or residents 
o f the neighborhoods in whi ch they wou l d 
be located. Some objections relate to beliefs 
that SEPs will increase drug use among 
participants and attract youth or new indi­
viduals to drug use. Other objections are 
that SEPs will threaten the safety of the 
community because they will foster an 
increase in illicit drug sales in the area and 
result in people discarding contaminated 
syringes in the community. However, a recent 
study examining the potential effect of SEPs 
on the formation of drug-using social net-
works found that this was unlikely to occur 
(Junge et al., 2000). 
I  N  I  T  I  A T I V E S  W  I  T  H 
P H A R M AC I S T S 
The Public Health Service recommenda­
tion that IDUs who cannot or will not 
stop injecting should consistently use 
sterile syringes to prevent transmission of 
blood-borne infections provides a legitimate 
medical foundation for the sale of s t e r i l e 
syringes to IDUs. Pharmacies, therefore, can 
play a crucial role because they are a reliable 
source of sterile syringes.  Pharmacies are 
conveniently located in most neighborhoods, 
and often have extended hours of operation. 
Many are open 24 hours a day. In addition, 
they are staffed by trained, licensed pro­
fessionals who are able to provide sound 
medical advice and to make referrals for a 
variety of related services, including HIV 
testing and counseling, substance abuse 
treatment, health care, and other community 
services. They also provide a safe environ­
ment for IDUs to make their purchases and 
some degree of anonymity for those IDUs 
who do not want to self-identify by going 
to an SEP. Some pharmacies accept used 
syringes for disposal. 
E ven in states that have parti a l ly or com­
pletely repealed laws and regulations banning 
the sale of sterile syringes, however, sales may 
be hampered by specific pharmacy store 
policies restricting the sale of s y r i n ges to 
IDUs, the personal reluctance of individual 
p h a rm a cy managers or pharmacists to sell 
syringes to IDUs, or other factors that create 
b a rriers to buying syringes. For exa m p l e , 
p h a rm a cy practice regulations that require 
purchasers to show identification, sign a 
register of s y r i n ge purchasers, and confirm 
that the syringes sale is for a “ l eg i t i m a t e ” 
purpose, reduce IDUs’ ability or willingness 
to come into the pharmacy and buy syringes. 
These policies and attitudes are partly due 
to store managers’ and pharmacists’concerns 
that IDUs will discard contaminated syringes 
around their businesses and in the commu­
nity (Case et al., 1998; Gleghorn et al., 1998; 
Singer et al., 1998; Wright-De Agüero et 
al., 1998). Another reason may be the 
limited amount of training and academic 
material on addiction and the rel a t i o n s h i p 
b e t ween injection drug use and blo o d -
borne pathogens provided by schools of 
p h a rm a cy to their students. 
Some states are carrying out interve n t i o n s 
with pharmacy managers and pharmacists in 
conjunction with efforts to repeal restrictive 
laws and regulations that limit pharmacy 
sales of s y r i n ges. For example, several state 
health departments are working with state 
pharmacy associations, medical societies, and 
b o a rds of p h a rmacies to raise awa re n e s s 
about the barriers to the purchase of sterile 
s y r i n ges and to review current laws and 
regulations. In Connecticut, Minnesota, and 
Maine, where laws prohibiting the purchase 
or possession of syringes have been partially 
repealed, partnerships between health 
d ep a rtments and pharmacies have been 
formed, education has been conducted to 
a d d ress pharm a c i s t s ’ co n c e rns, and phar­
macists have been encouraged to sell syringes 
to IDUs. Results from one peer education 
program for pharmacists in Connecticut 
demonstrate that pharmacists can become 
a c t ive participants in AIDS preve n t i o n 
Bo
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a c t ivities; pharmacies, schools of p h a rm a cy 
and local health dep a rtments can deve l o p 
c o l l a b o r a t ive linkages to carry out HIV 
prevention for IDUs; and professional peer 
education for pharmacists can be effective 
in expanding prevention services for IDUs 
(Weinstein et al., 1998). 
Despite this pro gress, states and organ i z a­
tions face a number of s i g n i ficant cha l­
lenges as they work with pharmacists to 
change policies related to selling sterile 
s y r i n ges to IDUs. One important cha l l e n ge 
is attitudinal. Pharmacists are trained to 
distrust IDUs and drug users, who may try 
to use bogus prescriptions or rob the phar­
macy. They may also fear that an increase 
in sales of s y r i n ges to IDUs might attract 
d rug users to the neighborhood and cre a t e 
s a fety and littering problems. 
Sales of sterile syringes also raise issues 
related to safe disposal of used syringes. 
Community options for safe disposal of used 
syringes are often limited. The public worries 
that IDUs will discard syringes in their 
neighborhoods without recognizing that 
diabetics who use insulin contribute a sub­
stantial number of used syringes (Macalino 
et al., 1998). Further, pharmacists may 
mistakenly equate the pharmacy sale of 
s y r i n ges to IDUs with syringe exch a n ge in 
the pharm a cy. 
Interventions in the Criminal 
Justice System 
Because the possession and sale of i l l i c i t 
drugs and syringes are crimes and drug users 
are often involved in crimes to support their 
drug addiction, IDUs are frequently arrested 
or in prison or jail. A recent study on sub-
stance abuse and prisoners found that 81 
percent of state inmates, 80 percent of 
federal inmates, and 77 percent of local jail 
inmates had used an illegal drug regularly; 
been incarcerated for drug selling or pos­
session, driving under the influence of 
alcohol (DUI) or another alcohol abuse 
violation; were under the influence of alco­
hol or drugs when they committed the 
crime for whi ch they were in corre c t i o n s ; 
committed their offense to get money for 
drugs; had a history of alcohol abuse, or 
s h a red some combination of these cha r a c­
teristics (Belenko, 1998). In 1996, an esti­
mated 250,000 state prison inmates had 
injected drugs, including 120,000 who had 
s h a red needles. Some 14,000 federal prison 
inmates had injected drugs, including 6,000 
who shared needles (Be l e n ko, 1998). 
At the same time, inmates in prisons and 
jails have dispro p o rt i o n a t e ly high rates of 
HIV infection and other STDs, hep a t i t i s , 
and other health problems. At the end of 
1996, 2.3 percent of male and 3.5 percent 
of female state and federal prison inmates 
were known to be infected with HIV 
(Hammett et al., 1999). Confirmed AIDS 
cases were found in 0.5 percent of all 
inmates, a rate six times higher than that 
of the total U.S. population. The high-risk 
b e h aviors re s p o n s i ble for the transmission 
o f HIV and other blo o d - b o rne illnesses 
among inmates include high-risk sexual 
activity, sharing of needles and other drug 
injection equipment, and tattooing with 
i m p rovised tools and materials (Calzavar a 
et al., 1997; Dolan et al., 1996; Mahon, 
1996; Struck m a n - Johnson et al., 1996). 
Given the large numbers of IDUs involved 
with the criminal justice system and the large 
numbers of at-risk and infected individuals, 
this setting is a crucial venue for HIV- and 
h ep a t i t i s - related interventions and servi c e s . 
Providing a range of health and prevention 
education interventions to inmates not only 
benefits them and their overall health, but 
can improve the health of the communities 
to which the vast majority of inmates return 
(Hammett et al., 1999). 
P revention services curren t ly offered to 
i n c a rcerated populations vary widely acro s s 
state, county, and city jails and prisons. They 
include instructor-led and/or peer-led HIV 
education, pre- and post-test counseling, 
multi-session prevention counseling, the use 
of audiovisual materials, and the distribution 
of printed materials (Hammett et al., 1999). 
Risk reduction strategies have not been 
widely adopted in U.S. correctional systems. 
For example, only two state prison systems 
and four city/county jail systems make con­
doms avai l a ble to inmates. Howeve r, most 
correctional systems provide HIV antibody 
testing, although testing policies differ widely. 
Few systems rou t i n e ly screen inmates for 
STDs and only limited viral hepatitis pre­
vention and treatment services are available. 
The few systems that provide an inte­
grated continuum of care for at-risk 
and HIV-infected inmates provide the 
fol l owing services: 
• s c reening and identification of m e d i c a l 
and psychosocial problems; 
• case management, including the use of a 
medical treatment plan; 
• substance abuse tre a t m e n t ; 
• provision of antiretroviral medications and 
prophylaxis of opportunistic infections; 
• mental health serv i c e s ; 
• hospice care; 
• discharge planning; and 
• continuity of care and community linkages 
when prisoners are rel e a s e d . 
Although few HIV prevention programs in 
correctional settings have been rigorously 
evaluated, limited evidence suggests that 
they can be successful in reaching this high-
risk population with practical risk-reduction 
messages (Hammett et al., 1999). For 
example, several innovative models of prison-
based substance abuse treatment programs 
that use a therapeutic community approach 
have resulted in reduced rates of return to 
the correctional system and sustained drug 
abstinence and condom use at follow-up 
(Field, 1989; Inciardi, 1996; Wexler et al., 
1994). These innovative programs include 
New York State’s Stay’n Out, Oregon’s 
Cornerstones program, and Delaware’s 
Crest Outreach Center program. Jail-based 
methadone maintenance has shown positive 
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results among participants, including low­
ered rates of drug use and criminality 
after release (Magura et al., 1993). 
One of the most important types of inter­
ventions in prisons and jails is education and 
prevention efforts led by inmates themselves. 
These pro grams can be cost-effe c t ive and 
flexible, and they have an added cre d i b i l i t y 
that programs led by outsiders cannot match. 
Pee r-led pro grams also provide signifi­
cant benefits to peer educators themselves. 
Through participating in the pro gr a m s , 
these inmates can develop a positive focus 
in their lives, regain a sense of purpose and 
empowerment, and realize that they are 
able to influence others in ways they never 
believed po s s i ble (Hammett et al., 1999). 
The careful selection of peer trainers and 
open support of corrections staff are among 
the factors contributing to the success of 
such innovative programs as the peer pro-
gram at Louisiana State Pen i t e n t i a ry in 
A n gola, the AIDS Counseling and Tru s t 
program at Louisiana’s Avoyelles Correctional 
C e n t e r, the peer pro grams in California’s 
state prisons at San Quentin, Frontera, and 
Vacaville, and the AIDS Video Project and 
Peer HIV Education Project in the Los 
A n geles County Juvenile System. Sever a l 
i n n ova t ive models of i n s t ru c t o r-led HIV/ 
AIDS education and prevention programs 
also have evolved in correctional systems. 
These include the Forensic AIDS Pro j e c t 
conducted in the San Francisco jails and the 
Corrections AIDS Prevention Program con­
ducted at Rikers Island in New York City 
(Hammett et al., 1999). 
Although many correctional systems in the 
U.S. have instituted HIV prevention serv­
ices, numerous gaps in cover a ge still exi s t 
for IDUs, both for those in the system and 
those leaving jail or prison to return to their 
home communities. Gaps for those in the 
system can be found in insufficient num­
bers of i n s t ru c t o r-led and peer-based HIV 
education and prevention programs. For all 
inmates, there is a lack of c o m p re h e n s ive 
substance abuse treatment and mental health 
services. Supervised medical care services are 
also lacking for HIV-infected IDU inmates. 
M a ny HIV seron ega t ive and serop o s i t ive 
inmates leaving the system, including those 
using antiretroviral drug therapy for HIV 
infection, still do not receive appropriate dis­
charge planning or continuity of s u b s t a n c e 
abuse treatment and medical services after 
release. Without planning and support, many 
ex-prisoners are arrested and jailed again. 
These gaps occur for a variety of reasons. A 
primary reason is financial. HIV prevention 
and treatment services, particularly treatment 
services, can be costly and the issue of 
who should pay has not been adequately 
addressed. Because inmates are legally wards 
of the government correctional system, 
health and substance abuse agencies (for 
example, Medicaid) do not pay for services 
inside prisons and jails. At the same time, 
most correctional systems have limited 
budgets to address issues related to preventing 
and treating substance abuse, blood-borne 
diseases, and mental health issues. 
A second major reason relates to differences 
between the philosophies, perspectives, and 
priorities of p u blic health and corre c t i o n a l 
agencies. When these differences are not 
s e n s i t ive ly addressed, they can make collab­
oration difficult because they undermine 
respect by public health staff for the skills 
and expertise of correctional medical staff 
and other cor rectional staff and they pro-
mote obstruction and lack of cooperation 
on the part of correctional staff 
(Hammett, 1998). 
A third ch a l l e n ge facing efforts to red u c e 
HIV and other blood-borne illnesses among 
IDUs in prisons and jails is the primary need 
for correctional systems to maintain security 
and to control inmates. Administrators of 
correctional systems often do not want to 
acknowledge that HIV risk behaviors, such 
as men having sex with men or injection drug 
use, are occurring in their facilities. Prisoners 
also may not want to acknowledge these 
behaviors for fear of sanctions. In addition, 
s p e c i fic security measures limit the effec­
t iveness of p revention efforts. For exa m p l e , 
the frequent movement of inmates within 
and between facilities disrupts the continuity 
o f educational pro gr a m m i n g, counseling, 
and care. Req u i rements that prisoners be 
escorted by guards to meetings with health 
and HIV prevention staff may res t r i c t 
i n m a t e s ’ pa rticipation in counseling and 
education initiatives and significantly threaten 
confidentiality protections. The prohibition 
against condom distribution because they 
are considered contraband closes off a major 
risk reduction interven t i o n . 
Finally, HIV education programs face 
challenges in working with diverse inmate 
populations having different cultures, lan­
guages, and literacy levels or who may be 
incarcerated for only a short time. 
Strategies to Prevent Sexual 
Transmission 
S exual transmission of HIV and hep a t i t i s 
involving IDUs is an important factor in the 
spread of these diseases in the U.S. In 1999, 
13 percent of the new AIDS cases rep o rt e d 
that year were among men and women whose 
s ex partners were IDUs. Th i rteen perce n t 
were among male IDUs who also reported 
having sex with other men (CDC, 1999a). 
High-risk sexual behavior is also strongly 
associated with hepatitis B transmission 
(CDC, 1999b). High-risk drug behaviors 
and high-risk sexual behaviors are often 
linked (Chu et al., 1998). For example, a 
large portion of IDUs use alcohol and/or 
c r a ck cocaine, whi ch are often associated 
with increased frequencies of unsafe sexual 
behavior (Edlin et al., 1994). Some IDUs 
s u p p o rt their drug habits by excha n g i n g 
s ex for money or drugs. For these rea s o n s , 
the extent to which IDUs change their sexual 
behaviors in response to these diseases is 
critical. This is part i c u l a rly true in light of 
evidence showing that although IDUs will 
m a ke large cha n ges in their injection risk 
behavior in response to concerns about 
A I D S, cha n ges in sexual behavior are gen­
erally more modest. All studies that have 
compared changes in injection risk behavior 
with changes in sexual risk behavior found 
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greater cha n ges in injection risk behav i o r 
(Friedman et al., 1993). In addition, it 
appears that IDUs are more likely to change 
sexual risk behaviors (reduce number of 
partners, increase use of condoms) with 
casual sexual partners than with their pri­
mary sexual partners (CDC/ACDP, 1999; 
Friedman et al., 1994; Friedman et al., 
1999) or with sexual partners who do not 
inject illicit drugs (Friedman et al., 1994; 
Friedman et al., 1999; Vanichseni et al., 
1993). The reluctance to use condoms 
with main partners may be partly due to 
concerns that such action violates the inti­
macy and trust developed in the relationship. 
D i s t r i buting condoms and information 
h ave been an important means of h e l p i n g 
IDUs reduce their risk of sexual transmis­
sion. These materials are given out for free 
by most outreach workers, syringe exchange 
and other risk reduction programs, drug 
users’ organizations, and some substance 
abuse treatment programs. One-on-one 
sexual risk reduction counseling and group 
interventions are also conducted by peers to 
address skills building and rehearsal, inter-
personal communication, problem-solving, 
situational analysis, and self-managem e n t 
s t r a t egies. Intervention strategies for fem a l e 
drug users and sexual partners of drug users 
h ave stressed the importance of bui l d i n g 
self-esteem, social supports, and sex u a l 
negotiation skills to encourage safer sex 
practices with partners. 
S everal approa ches to sexual risk red u c t i o n 
i n t e rventions have had parti c u l a rly goo d 
results. For example, skills-building interven­
tions that target sexual risk reduction have 
s h own more positive effects in improvi n g 
drug users sexual risk reduction than have 
interventions that try to target risk reduction 
in general (Beardsley et al., 1996; El-Bassel 
and Sch i l l i n g, 1992; Schilling et al., 1991). 
Other interventions that have been effec­
tive in sexual risk reduction with drug 
users have included the AIDS Community 
Demonstration Projects in five U.S. cities 
(CDC/ACDP, 1999), the use of a problem-
solving therapy model in a male detention 
center (Magura et al., 1994), and a condom 
giveaway program at an outpatient sub-
stance abuse treatment program (Calsyn 
et al., 1992). 
In developing strategies to reduce sexual 
transmission, agencies and organ i z a t i o n s 
should tailor them to specific high-risk 
groups (for example, in-treatment as well as 
out-of-treatment drug users) and to specific 
goals (for example, preventing acquisition of 
infection in uninfected IDUs and preventing 
transmission from infected IDUs to others). 
These strategies should also take into 
consideration the determinants of sexual 
transmission, including the consistency of 
condom use, the presence of c o n c u rre n t 
STDs, the presence of concurrent injection 
drug and crack use, and the extent of sexual 
activity while high. Interventions designed 
for the sexual partners of IDUs are an 
i m p o rtant element of these strateg i e s . 
HIV Counseling and Testing, Partner 
Counseling and Referral Services, 
and Prevention Case Management 
A compre h e n s ive appro a ch to preve n t i n g 
HIV and other blo o d - b o rne infec t i o n s 
among IDUs must include the capacity 
to allow individuals to discover whether 
they are infected, and if they are, to help 
them inform their partners. If they are not 
infected but engage in high-risk practices, 
the approach can also help IDUs begin or 
sustain behavior cha n ges that will red u c e 
their risk of acquiring or transmitting the 
i n fection. Three services are designed to 
meet these objectives: 
• HIV prevention counseling and 
testing (C&T); 
• partner counseling and referral serv i c e s 
(PCRS); and 
• prevention case management (PCM). 
HIV counseling and testing services are 
gen e r a l ly the first step. The HIV antibody 
test results and the person’s history of risk 
behavior and other factors determine whether 
he or she is referred to the other servi c e s . 
Because these three types of services are 
cli e n t - c e n t e red and one-on-one, they have 
the potential to address the complex lives 
and circumstances of some IDUs and more 
effectively influence their risk behaviors 
than can more limited and diffuse inter­
ventions. In addition, these services have 
the potential to provide the continuity of 
care that is so important to successful out-
comes. Each of these services is discussed 
in greater detail below. 
H I  V  P R E  V E N T I O  N 
C O U N S E L I  N G  A N D  
T E S T  I N G  ( C &  T ) 
HIV C&T is a prevention intervention 
that provides HIV antibody testing and 
individual, client-centered risk reduction 
counseling. It provides a private and confi­
dential way for individuals to learn their HIV 
serostatus and get further help, whatever 
the results of the testing. 
HIV antibody testing is provided to individ­
uals who seek, either through private care 
providers or publicly funded programs, to 
determine if they are living with the HIV 
virus. If the results of the test are positive, 
they can be referred to clinical care and 
case management. If the results are negative, 
they can receive counseling and suppor t 
for risk reduction ef forts and referrals for 
needed services. 
The counseling element, a short - t e rm 
i n t e rvention involving two brief se s s i o n s 
(one before and one after the antibody 
test), has several functions, including: 
• offering information on HIV testing and 
helping a client make a decision about 
being tested; 
• helping clients understand their res p o n s i­
bility, if their HIV test results are positive, 
for ensuring that sex and drug-use partners 
a re info rmed of their possible exposure, 
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and for referring their partners to HIV 
prevention counseling, testing, and other 
s u p p o rt services; 
• reviewing all ava i l a ble options for partn e r 
counseling and referral services (PCRS); 
• helping assess a cli e n t ’s risk of a c q u i r i n g 
or transmitting HIV; 
• helping clients develop a realistic and incre­
mental plan for reducing their risk; and 
• offering referrals to clients for substance 
abuse treatment or other interventions, such 
as prevention case management (PCM), 
for more intensive risk reduction services 
if needed. 
Given that many IDUs mistrust conven­
tional health service systems or are unable 
to obtain services, agencies and providers 
must offer C&T services in settings where 
IDUs are already found (such as substance 
abuse treatment or criminal justice) and 
deliver them in ways that are tailored to the 
specific circumstances of the IDUs who will 
receive them. For example, in November 
1987, the City of Boston’s Department of 
Health and Hospitals, the Division of 
Drug Rehabilitation of the Massachusetts 
Department of Public Health, and the 
Massachusetts Center for Disease Control 
established Project TRUST (Teaching, 
Referral, Understanding, Support, and 
Testing) at Boston City Hospital. The project 
offered anonymous HIV testing in conjunc­
tion with a range of related prevention, 
education, referral, and social s u p p o rt 
services. A number of factors helped attract 
IDUs and increase the numbers of p e o p l e 
o ffe red counseling and testing, incl u d i n g 
the range of f ree services ava i l a ble without 
a need for appointments, staff who included 
recovering IDUs, location in a neighbor-
hood with a visible drug-user presence, and 
anonymity (CDC, 1989). New, rapid HIV 
a n t i b o dy tests are being developed that will 
allow a person to be tested and receive their 
results in one visit (CDC, 1998b). This may 
be attractive to many IDUs, for whom a 
second visit to receive results can be difficult 
to manage. Another possibility that could 
be used effe c t ive ly with IDUs is oral flu i d 
testing kits, which allow antibody testing 
without the need for a blood sample. This 
permits HIV testing to be carried out in out-
reach settings, making it much easier to reach 
a larger number of IDUs with this service. 
Research conducted among IDUs and other 
drug users has shown that HIV C&T has 
resulted in some beneficial behavior changes, 
including positive impacts on both drug-
related and sexual practices (Gibson et al., 
1999). As with general at-risk populations, 
C&T has produced a more positive effect 
with HIV-infected drug users than with 
HIV-negative or untested IDUs (Weinhardt 
et al., 1999; Wolitski et al., 1997). Studies 
with general at-risk populations and IDUs 
have shown that both standard, 2-session 
and enhanced, 4-session counseling inter­
ventions significantly increased participants’ 
condom use (Kamb et al., 1998). Compared 
to standard interventions, enhanced HIV 
C&T has had a greater effect on IDUs’ 
needle risk behaviors (Siegal et al., 1995) 
than on their sexual risk behaviors 
( M c C u s ker et al., 1993). 
A number of cha l l e n ges limit the potential 
impact and benefits of counseling and testing 
services. Perhaps the most important issue 
is that C&T is a short - t e rm interven t i o n 
and therefore would be expected to have 
a relatively limited impact on risk behav­
iors. Individuals frequently go through a 
relatively long cognitive and behavioral 
process, including several cycles of attempted 
change and relapse, before achieving lasting 
behavioral change (Prochaska, 1989). In 
many cases, individuals must come to a 
testing site twice, once to have the test 
performed and once to receive their results 
a week later. Many persons who are tested 
do not return to receive their HIV antibody 
test results, especially those who are tested 
in STD clinics. Further, some individuals 
who test positive have difficulty being inte­
grated into more intensive services, such as 
HIV medical care, case management, and 
support services. Finally, and most impor -
tant for IDUs, publicly funded HIV C&T 
does not now include counseling, testing, 
and treatment for other blood-borne 
infections that have a significant impact 
on IDUs, particularly viral hepatitis. 
P A  RT N E R  C O U N S  E L I N G  
A N D  R E  F E R R  A L  S E RV  I  C  E  S 
( P C R S ) 
P C R S, also known as partner notific a t i o n , 
is a public health activity that evolved from 
“contact tracing” a c t ivities developed earli­
er in the 20th century for the control of 
sexually transmitted diseases, part i c u l a rly 
syphilis. Public health workers conduct 
confidential interviews with newly identified 
infected persons to find out the names of 
and tracing information for recent sexual 
or drug contacts who are at high risk of 
also being infected and to make confidential 
efforts to locate them, recruit them for 
diagnostic tests, and provide treatment as 
needed (Bayer and Too m e y, 1992; Cates 
and Too m e y, 1990). 
PCRS can have important benefits for indi­
vidual IDUs and their communities. PCRS 
provides an opportunity for agencies to 
notify the sexual and drug-use partners of 
i n fected individuals of their exp o s u re to 
HIV and, potentially to viral hepatitis also, 
to counsel them, and potentially to offer 
longer-term follow-up. If already infe c t e d , 
the part n e r s ’ prognosis can be improve d 
through earlier diagnosis and treatment. If 
not infected, the partners can be assisted in 
changing their risk behav i o r, thus red u c i n g 
the likelihood of acquiring the virus. From 
an epidemiological standpoint, following 
the chain of transmission from one HIV-
infected individual to another within and 
across social networks permits public health 
investigators to chart the course of the 
epidemic and conduct more effective pre­
vention planning. Epidemiologists suspect 
that recently infected persons account for a 
substantial pro p o rtion of t r a n s m i s s i o n , 
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either because they have higher viral loads 
than those who have been infected longer 
and are therefore more infectious, or because 
they have more sex partners, or both (West 
and Stark, 1997). Identifying and tre a t i n g 
infected partners early may reduce HIV 
transmission by reducing the number of 
p o t e n t i a l ly infectious contacts (Fenton and 
Pet e rman, 1997). 
PCRS also can yield important eva l u a t i o n 
information for HIV prevention programs. 
If conducted in conjunction with social 
n e t work methods, it can aid in identifying 
networks with priority prevention and treat­
ment needs and insight on how to access 
them. In addition, partners can be inter-
viewed about their past experience with 
p rev i o u s ly used prevention services and the 
e ffe c t iveness of those services in helping 
them reduce risk. 
PCRS begins when an IDU seeks HIV 
prevention C&T. If the HIV test is posi­
tive, he or she is given the opportunity to 
receive PCRS at the earliest appropriate 
time. During the initial PCRS interview, 
the counselor will discuss with the client 
his or her responsibilities to sexual and 
drug-use partners and available options for 
notifying them of the client’s infection sta­
tus. The HIV-infected client is encouraged 
to voluntarily and confidentially disclose 
the identifying, locating, and exposure 
information for each partner. The PCRS 
provider and client together formulate a 
plan and set priorities for notifying part­
ners. Partner referral options include: 
• client referral in wh i ch the HIV-infected 
person agrees to personally inform part­
ners about possible exp o s u re and refer 
them to serv i c e s ; 
• provider referral in whi ch the provi d e r, 
u s u a l ly health dep a rtment staff, with the 
consent of the client, takes res p o n s i b i l i t y 
for contacting/referring partners; 
• dual-referral in which the HIV-infected 
person info rms the partner of h i s / h e r 
HIV infection in the presence of the 
p rov i d e r; and 
• contract-referral in whi ch the provi d e r 
informs the partner only if the client 
does not notify the partner within a 
negotiated time period. 
During the notification process each 
partner is: 
• informed of p o s s i ble exp o s u re to HIV 
and other STDs or blo o d - b o rn e 
p a t h o gens; 
• p rovided with accurate info rm a t i o n 
about HIV transmission and prevention; 
• informed of the benefits of knowing 
o n e ’s serostatus; 
• assisted in obtaining counseling, testing, 
and other support services; and 
• cautioned about the possible negative 
consequences of revealing their own or 
o t h e r s ’ se rostatus to anyone else. 
M a ny HIV-i n fected drug users are critical 
o f pa rtner referral interventions exp e r i­
enced in the past (Rogers et al., 1998). 
These opinions are based on a mistrust 
o f gove rnment age n cy invo l vement and 
concerns about confidentiality and potential 
discrimination in disclosing inform a t i o n 
related to their behaviors and their partners. 
However, the few studies on HIV partner 
referral with drug users provide some insights 
into the kind of intervention that may work 
best with them (Levy and Fox, 1998; Rogers 
et al., 1998). One innovative approach to 
p a rtner referral with drug users builds on 
the success of community outreach methods 
by adding contact tracing and partner refer­
ral to the role of o u t re a ch staff. With the 
understanding that IDUs often can be more 
rea d i ly rea ched using community-based 
i n d i genous staff members, the Outreach-
Assisted Model of Partner Referral uses 
indigenous outreach workers in a more active 
role delivering street-based HIV counseling, 
t e s t i n g, and partner referral (Levy and Fox, 
1998). The expanded outreach model offers 
testing to IDUs in an environment that is 
more comfo rt a ble and community oriented 
than those IDUs generally experience in 
using public health HIV testing services. 
To date, no research has been conducted 
on the effec t iveness of p a rtner notifi c a t i o n 
in helping partners adopt safer behav i o r s 
or preventing new infections. Res e a rch has 
focused on the process and its effe c t ive n e s s 
in reaching partners, testing them, and 
identifying serop o s i t ivity rates (Macke et 
al., 1999). Most HIV- i n fected indiv i d u a l s 
who take part in HIV C&T willingly par­
ticipate in PCRS (West and Stark, 1997), 
although the rates of participation have been 
found to vary considerably across existing 
state programs (Crystal et al., 1990; Landis 
et al., 1992; Pavia et al., 1993; Spencer et 
al., 1993; Wykoff et al., 1991). One study, 
conducted with IDUs in Utah, showed a 
participation rate of 93 percent (Pavia et 
al., 1993). Further research is needed to 
improve partner notification procedures and 
tailor them to specific populations, to under-
stand the impact of new testing technologies 
on partner notification, and to understand 
the consequences of p a rtner notifi c a t i o n 
for individuals and their partners (Macke 
et al., 1999). 
HIV-infected individuals who take part in 
PCRS name approxi m a t e ly three partn e r s , 
although this has also varied considerably 
a c ross state pro grams. Of the part n e r s 
named, the majority are sex rather than drug-
use partners. Of those partners named, state 
program records indicate that 60 to 80 
percent are located (Crystal et al., 1990; 
Landis et al., 1992; Pavia et al., 1993; 
Spencer et al., 1993; Wykoff et al., 1991). 
P rovider referral has resulted in the notifi­
cation of more partners than has patient 
referral (Jones et al., 1990; Landis et al., 
1992). Those index clients with the most 
past sex partners are least likely to attempt 
to notify any partner (Marks et al., 1992). 
If located, sex partners are generally receptive 
to confidential notification of their potential 
exposure to HIV by the client or the health 
department and usually seek HIV testing 
(West and Stark, 1997). 
PCRS also has been effe c t ive in uncover i n g 
p rev i o u s ly undiagnosed HIV infec t i o n s . 
IDU partners who are tested have shown 
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higher rates of HIV infection than have 
p a rtners with other known routes of t r a n s-
mission (Waldron et al., 1995). 
Partner referral faces several challenges, 
p a rt i c u l a rly when agencies attempt to fin d 
partners of IDUs. One reason is that the 
success of p a rtner refe rral depends heav i ly 
on the discl o s u re of names of contacts by 
the HIV-infected client. IDUs may be par­
ticularly unwilling to reveal the names of or 
other information about partners partially 
because the drug culture discourages reveal­
ing information about others. Other barriers 
to discl o s u re can include fear of losing a 
p a rt n e r, of losing support and, especially 
for women, fear of violence (North and 
Rot h e n b e rg, 1993; Norwood, 1995; 
Rothenberg et al., 1995). However, studies 
have found that when an infected individual 
reveals his or her infection to a main partner, 
the discl o s u re does not result in sep a r a t i o n 
or disruption of the relationship (Nabais 
et al., 1996; Padian et al., 1993). 
Even when a client discloses drug-use part­
ners’ names, it is often difficult to locate 
these IDUs because the client may know 
them only by a nickname or street name 
(Rogers et al.,1998). The long incubation 
period of HIV and anonymous partn e r s 
of clients are other reasons why it may be 
difficult to locate IDU partners. 
Because PCRS activities often require the 
n o t i fication of m a ny partners, they can be 
labor intensive and costly. The cost to 
counsel and refer one sex partner to needed 
services ranges from $100 to $2,260 and 
from $810 to $3,205 to identify one HIV-
infected partner through provider referral 
(Pavia et al., 1993; Peterman et al., 1996). 
Although partner notification for STDs is 
gen e r a l ly regarded as ethically accep t a bl e , 
ethical concerns about the role of HIV 
partner notification as a prevention strategy 
h ave been voiced (Fenton and Pet e rm a n , 
1997). Community representatives often 
perceive HIV PCRS to be an intrusive 
activity that is unlikely to protect the confi­
dentiality of the HIV-i n fected person or 
his or her partners (West and Stark, 1997). 
Health departments are often viewed with 
suspicion, and their ability to keep personally 
identifying information confidential is fre­
q u e n t ly questioned. Efforts are needed to 
e n s u re that community HIV preve n t i o n 
needs are met, misconceptions about PCRS 
practices and policies are corrected, and 
l egitimate concerns about confi d e n t i a l i t y 
and discrimination are addressed. 
P R E V E  N T  I O N  C A S E  
M  A  N A G E M E N T  ( P C M )  
PCM is an intensive, ongoing, client-
centered HIV prevention activity with the 
fundamental goal of helping indiv i d u a l s 
with complex lives and circumstances adopt 
and maintain HIV risk-reduction behaviors. 
For those who are living with HIV, preven­
tion case management helps in obtaining 
and adhering to treatment for HIV. It 
provides counseling, support, and service 
assistance to address the relationship between 
HIV risk and other issues such as substance 
abuse, STDs, mental health problems, and 
social and cultural factors. PCM staff closely 
collaborate with Ryan White CARE Act 
case managers to provide information and 
referrals for secondary prevention needs of 
persons living with HIV or AIDS. PCM is 
also useful for HIV seronegative persons, or 
those of unknown HIV serostatus who are 
either engaging in high-risk behavior within 
communities with moderate to high sero­
prevalence rates of HIV infection or are 
otherwise at heightened risk of infection. 
Because it has the potential to address a wide 
r a n ge of social pro blems for persons with 
multiple and complex HIV risk-re d u c t i o n 
situations, PCM is parti c u l a rly suited for 
individuals like IDUs, who have or are likely 
to have difficulty initiating or sustaining 
practices that reduce or prevent HIV trans-
mission and acquisition. PCM strives to 
develop an ongoing relationship with each 
client to provide an environment of trust 
and understanding within which prevention 
counseling can take place. 
PCM includes the fol l owing seven 
components: 
• client recruitment and engagement; 
• s c reening and compre h e n s ive assessment 
of HIV and STD risks, medical and 
psychosocial service needs, including STD 
evaluation and treatment, and parti c i p a­
tion in substance abuse treatment; 
• d evelopment of a cli e n t - c e n t e red 
p revention plan; 
• HIV risk-reduction counseling over 
multiple sessions; 
• a c t ive coordination of s e rvices with 
fol l ow-up; 
• monitoring and reassessment of cli e n t s ’ 
needs, risks, and progress; and 
• discharge from PCM when the client 
attains and maintains his or her risk-
reduction goals. 
Case management is often offered as part 
of a larger care system and this makes it 
difficult to assess its effects apart from other 
s e rvices. In parti c u l a r, it has been diffi c u l t 
to assess prevention case management with 
HIV seronegative drug users and determine 
the most effe c t ive appro a ches to use with 
IDUs because of the high drop-out rate of 
participants even when the required number 
of sessions with a prevention case manager 
is reduced (Falck et al., 1994). Other diffi­
culties in evaluating PCM have been small 
sample size; the lack of ability to control 
for disease progression, which can cause a 
d e c rease in sexual activity; the fai l u re to 
collect behavioral data in the time between 
HIV testing and the first case management 
appointment; and the fai l u re to collect 
data on the serostatus of program parti c i-
p a n t s ’p a rtners. 
At present, five CDC-funded demonstra­
tion projects are being carried out to test 
the effectiveness of PCM on reducing the 
transmission of HIV from HIV-infected 
persons. One intervention in California is 
being conducted within early interve n t i o n 
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program (EIP) sites and employs a risk 
reduction specialist who uses behavior 
cha n ge theory in the context of cli e n t -
c e n t e red counseling and/or short - t e rm , 
s o l u t i o n - focused counseling tech n i q u e s . 
Another cha l l e n ge for PCM services is 
their greater cost compared to other HIV 
p revention activities, whi ch can employ 
peers or parapro fessionals to rea ch large r 
numbers of people with less time-intensive, 
s t a ff - i n t e n s ive risk reduction strateg i e s . 
Coordinated Services for IDUs 
Living with HIV/AIDS 
Because HIV disease is a complex chronic 
condition, infected IDUs and their fam i l i e s 
req u i re a changing arr ay of s e rvices in their 
homes, in the hospital or health care facility, 
and in the community (Keenan, 1990). In 
addition, anti-HIV medication reg i m e n s 
i nvo l ve multiple medications with diffe r i n g 
s chedules and re q u i rements. Fai l u re to fol­
low recommendations can lead the virus to 
develop resistance to anti-HIV medications. 
However, with appropriate and high-quality 
services and medications, IDUs living with 
HIV can lead healthy, pro d u c t ive lives . 
Many IDUs continue to engage in high-risk 
b e h aviors after they learn they are infe c t e d 
with HIV and, thus, place others at risk 
of HIV infection and themselves at risk 
for collateral health problems (CDC, 1996; 
HRSA, 1994; Kwi a t kowski and Booth, 
1998; Metsch et al., 1998). When HIV-
infected IDUs are actively engaged in health 
care, however, they can be followed to 
identify renewed high-risk sex or drug use 
and counseled about the effects of these 
behaviors on themselves and others. HIV-
infected drug users who are in substance 
abuse treatment and are receiving other 
health services are more likely to comply 
with HIV/AIDS drug treatment regimens 
and to reduce their sex and drug risk-related 
behaviors (Booth et al., 1999). 
IDUs living with HIV/AIDS need a full 
complement of services, delivered in a setting 
geared to attract IDUs from the community 
and retain them. Case managers and preven­
tion case managers need training in issues 
s p e c i fic to IDUs, wh i ch should help them 
offer risk reduction counseling and preven­
tion services to these individuals and assist 
them with managing their chronic and acute 
health care needs, including taking anti-HIV 
medication and opportunistic infection pro­
phylaxis as recommended. In addition, a 
full range of complementary affordable and 
accessible services should be made available, 
including substance abuse treatment services, 
mental health services and assistance with 
other basic needs such as food, housing, 
chi l d c a re, and job training. 
A major barrier to providing comprehensive 
s e rvices for HIV- i n fected IDUs is inade­
quate funding. HIV-infected IDUs have 
high levels of need that are only partially 
being addressed by the current service system 
(HRSA, 1994). While acute medical services 
are generally accessible, other health serv­
ices (dental, home care, hospice, long-term 
residential drug treatment) and ancillary 
services (shelter, food, stable living condi­
tions, vocational training, long-term therapy) 
often are not adequately provided. 
As a marginalized population, IDUs can be 
less connected to the AIDS-related service 
delivery system than are other infected indi­
viduals. For example, HIV- i n fected IDUs, 
i n cluding those rec e n t ly incarcerated, with-
out clinical disease who have less contact 
with health care providers, have not been 
receiving optimal care (Celentano et al., 
1998). Like non-IDU consumers, many 
IDUs do not know where to go to obtain 
services or what services are appropriate 
for different people at different stages of 
the disease. The service delivery system is 
too complex and fragmented for them to 
navigate and often too remote geographi­
cally, socially, and culturally. Some programs 
prohibit services to active drug users and 
those who are HIV-infected and this 
presents formidable barriers for IDUs. 
Negative attitudes by staf f toward IDUs’ 
behaviors and life circumstances exacerbate 
the situation. 
Women living with HIV disease face 
particular educational, cultural, economic, 
p s ychological, physical, and social barr i e r s 
in accessing and using care (Weissman et al., 
1995; Weissman and Brown, 1995). Most 
are either active or recovering injection drug 
or crack users who have a history of sexual/ 
physical abuse, psychological distress and 
d ep ression, and lack of social support. 
I n c reased funding for services will help to 
address these barriers, but other changes 
are also needed, including: 
• expanded outreach to women with HIV; 
• cha n ges in substance abuse tre a t m e n t 
policies and procedures that do not favor 
women (for example, those that do not 
a d e q u a t e ly address issues of p reg n a n t 
women and women with children); 
• efforts to build peer networks and 
o n going support stru c t u res; 
• i m p rovements in HIV counseling and 
testing pro c e d u res to ensure that wom e n 
understand the testing and services needed; 
• c ross-training of p roviders in wom e n’s 
issues; and 
• enhanced advoc a cy for women liv i n g 
with drug abuse and HIV disease 
(Weissman and Brown, 1995). 
Primary Drug Prevention 
Primary drug prevention is a centrally 
important strategy in a comprehensive 
approach to preventing blood-borne diseases 
among IDUs and reducing the spread to 
others. By helping individuals avoid drug 
use and drug injection altogether, these 
programs help to eliminate the risk of 
i n j e c t i o n - related blo o d - b o rne virus trans-
mission. Primary drug prevention programs, 
which are conducted in a variety of settings, 
including schools, families, and community-
based organizations and through a variety 
of channels, such as the media, are largely 
aimed at youth to encourage them to avoid 
or delay the first use of alcohol, tobacco, 
marijuana, inhalants, and other drugs. 
Avoiding or delaying substance abuse can 
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help youth prevent many problems associ­
ated with it, including truancy, academic 
failure, violence, thefts, motor vehicle 
crashes, homicides, injuries, suicides, and 
risky sexual behaviors (Ary et al., 1999; 
Berger and Levin, 1993; Cohen et al., 1997; 
Donovan et al., 1988; Far rell et al., 1992; 
Osgood et al., 1988). 
Res e a rch has identified effe c t ive primary 
prevention programs that target all forms of 
substance abuse and reach all populations 
(Drug Strategies, 1999; NIDA, 1997; 
ONDCP, 1998). Successful programs 
incorporate messages and strategies that 
are tailored to respond to the specific nature 
of drug use in the community and the level 
of risk in the audience. In addition, they are 
age-specific, developmentally appropriate, 
and culturally sensitive. 
Successful programs also are designed to 
enhance “protective fa c t o r s ” and red u c e 
“risk fac t o r s ” by: 
• raising awa reness of ext e rnal pre s s u re s , 
s u ch as peer pre s s u re and media effe c t s , 
and internal pre s s u res, such as gro u p 
identity; 
• developing personal social and refusal skills; 
• teaching that drug use is not the norm 
among young people; 
• promoting bonding to schools and to 
c o n s t ru c t ive role models; and 
• using interactive methods of d e l ive ry. 
Successful primary prevention pro gr a m s 
also include a variety of components and 
characteristics, such as: 
• media campaigns; 
• consistent anti-drug messages across 
components and settings; 
• environmental and policy initiatives, such 
as raising the minimum age to buy alcohol; 
• a paren t / c a reg ivers component; 
• training and support to ensure that inter­
ventions are delivered as intended; and 
• “booster sessions” over the long term to 
reinforce original prevention goa l s . 
Although primary drug prevention has 
been shown to have clear benefits — many 
professionals feel that the primary prevention 
movement within communities has been 
instrumental in reducing regular drug use 
among adolescents and young adults by 
two-thirds between 1979 and 1992 (Rusche, 
personal communication, September 3, 
1 9 9 9) — th e re are still some limitations 
that must be addressed. Many of the tested 
p r i m a ry drug prevention pro grams are 
s chool-based and their effec t iveness with 
o u t - o f - s chool youth, who may be at higher 
risk, is not clear. Some school-based pro-
grams whose effectiveness has not been 
c o n cl u s ive ly demonstrated continue to be 
p o p u l a r. Furt h e rm o re, school-based inter­
ventions have been designed and tested 
m a i n ly with middle school students; pro­
gramming for younger students and older 
teens is limited. Pro gress in eva l u a t i o n 
research in this area has also been hampered 
by methodological limitations, such as lim­
ited curriculum assessment that does not 
consider the multiple requirements teachers 
must address in the classroom, and a paucity 
of medium- and long-term follow-up 
studies of i n t e rve n t i o n s . 
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